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Abstract
Cytoplasmic dynein is a molecular motor that moves cargoes along microtubules.
Dynein, together with its large co-factor dynactin, is responsible for the vast majority
of traffic towards the centre of the cell. The largest subunit of the dynein complex
is called the dynein heavy chain (DHC). The DHC includes a C-terminal motor
domain, which converts ATP hydrolysis into mechanical force, an N-terminal tail
domain, and a flexible linker domain to join the two together. An intermediate chain
(DIC) and light intermediate chain (DLIC) bind directly to the DHC tail, while light
chains (DLCs) bind to the DIC. This tail complex is important for both cargo binding
as well as homodimerisation of the DHC, which is necessary for processive movement.
Previous studies suggest that the DLCs play an important role in homodimerisation,
but it remains unclear how else the DHCs are held together.
Using S. cerevisiae as a model system, I co-expressed all four dynein subunits
and purified functional dynein motors. In this background, I found that truncating
the DHC to include only the first 1004 residues (out of the total 4092) eliminates
the motor domain as well as the flexible linker domain, while preserving binding to
the DIC, DLIC and DLC. However, truncating just another 50 residues off of the C-
terminus led to a loss of all accessory subunits. I developed a protocol for expressing
and purifying large quantities of the 1004 residue construct, thus I provide the first
description of a recombinant dynein tail domain. Using negative stain electron
microscopy (EM), I also present the first 3D structural information for the tail
region of the cytoplasmic dynein motor.
I then describe a construct including only the first 557 residues of the DHC,
which dimerises despite not being able to bind any of the other subunits. I present
a crystal structure of this smaller DHC fragment, which shows that the N-terminal
180 residues of the DHC constitute an intricate dimerisation domain made up of a β-
sheet sandwiched between α-helices. Not only is this the first crystal structure of any
part of the DHC N-terminus, but it reveals a previously undocumented dimerisation
domain within the DHC itself. Furthermore, information garnered from this crystal
structure allowed for interpretation of a recent cryo-EM structure of a triple complex
containing the dynein tail, dynactin and the cargo adaptor BICD2 (TDB) that was
solved by my colleagues in the Carter group. Only by docking the DHC N-terminus
crystal structure within the TDB EM density did it become clear that the N-terminus
of the DHC is responsible for the majority of the contacts the dynein tail makes with
both dynactin and BICD2.
Therefore the work that I present here sheds new light on the unexpected im-
portance of the DHC N-terminus and allows two important conclusions to be made.
First, the N-terminal 180 residues of the DHC constitute a dimerisation domain of
its own. Second, the next ∼ 400 residues of the DHC form a domain that plays a
key role in the complex interface between dynein, dynactin and BICD2.
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Chapter 1
General Introduction
1.1 An overview of the cytoskeleton
All living cells contain a dynamic and complex intracellular matrix known as the
cytoskeleton. The cytoskeleton plays an essential role in processes as diverse as
chromosomal segregation, cytokinesis, endocytosis, signal transduction, intracellu-
lar transport and locomotion of the entire cell (Wittmann et al. 2001, Noguchi &
Mabuchi 2001, Qualmann et al. 2000, Liu et al. 2013, J. Howard 1996 and T. H.
Howard & Meyer 1984). The foundation of the cytoskeleton is a network of long
protein filaments, but these filaments interact with a variety of other proteins, such
as cross-linkers, capping proteins, regulators and motor proteins in order to achieve
their myriad functions. The focus of this thesis is one of these motors, called dynein.
Therefore, this brief overview of the cytoskeleton provides a general introduction to
the context in which dynein is found.
1.1.1 Cytoskeletal filaments
The general eukaryotic cytoskeleton contains two fundamental types of cytoskeletal
filaments: microfilaments and microtubules. There is a third type of cytoskele-
tal filaments present in many animal species, called intermediate filaments. These
diverse filaments are essential for many cells’ function and survival. The roles of
intermediate filaments include providing mechanical support and integrating other
cytoskeletal components (Granger & Lazarides 1979). However, as they are often
specific to cell type (Lazarides 1980), they are beyond the scope of this general
introduction and will not be discussed further.
Microfilaments
Microfilaments (also known as actin filaments) are the narrowest of the cytoskeletal
filaments, measuring only ∼ 7nm in diameter (Kishino & Yanagida 1988). They
are long polymers of a single protein, which is known as F-actin (filamentous actin)
when it is found within a microfilament or G-actin (globular actin) when it is in its
free monomeric form (Korn 1982). Each microfilament contains two helical strands
wrapped around each other and is formed when G-actin monomers polymerise in
an ATP-dependent manner (Fig. 1.1A). The actin monomers within both strands
are oriented in the same way, which gives the microfilament an overall polarity.
The two ends, which were named for their appearance in electron micrographs, are
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Figure 1.1: Formation of microfilaments and their role in muscle contrac-
tion. A) Polymerisation of microfilaments begins when ATP–G-actin monomers
(pink) form stable trimers (purple). The filament then extends in both directions,
but it extends more rapidly from the barbed (+) end. The ends of the filament
reach a steady state where ATP-G-monomers are added and released at the same
rate. After incorporation into the filament, subunits hydrolyse ATP and become the
more stable ADP–F-actin (white). Figure reproduced from Lodish et al. 2004 with
permission of the author. B) A model of skeletal muscle sarcomeres. The sarcom-
ere is made up of thin filaments (microfilaments), thick filaments, and titin. When
the myosin heads of the thick filament move along the anchored microfilaments, the
entire sarcomere contracts. It is the coordinated contraction of several thousand
sarcomeres in series that results in the contraction of skeletal muscle fibres. Figure
reproduced from Ottenheijm et al. 2008 with permission of the author.
the barbed (or plus) end and the pointed (or minus) end. Upon nucleation of a
microfilament, G-actin associates with the barbed end at a much higher rate than
at the pointed end (Korn 1982). Migrating cells exploit the resulting directional
bias of microfilament growth by orienting the barbed ends toward the cell’s leading
edge. The rapid polymerisation of microfilaments exerts sufficient force on the cell
membrane to create protrusions such as lamellipodia and filopodia, which allow the
cell to creep forward along a substrate (Westphal et al. 1997).
Microfilaments are essential for many fundamental cellular processes, including
cytokinesis, chemotaxis and signal transduction (Noguchi & Mabuchi 2001, T. H.
Howard & Meyer 1984 and Liu et al. 2013). One well-known role of microfilaments
is within sarcomeres, the basic contractile unit of skeletal muscle. In this con-
text, microfilaments are ”thin filaments” that the thick filaments slide in relation
to (Fig. 1.1B). As the myosin heads of the thick filaments undergo coordinated,
ATP-dependent power strokes, the interlaced thin and thick filaments slide with re-
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lation to one another, increasing the overlap between them and therefore decreasing
the overall length of the sarcomere (Huxley & Hanson 1954). Each skeletal muscle
fibre contains thousands of sarcomeres arranged in series. When these microscopic
units contract in unison, the muscle fibre shortens, resulting in the macroscopic
movements observed at the organismal level.
Microtubules
Microtubules (MTs) are the thickest of the cytoskeletal filaments, measuring∼ 24nm
in diameter (Olmsted & Borisy 1973), and their structure is very different from
that of microfilaments (Stephens & Edds 1976). The basic subunit of MTs is a
heterodimer of two related, yet distinct, globular proteins called α-tubulin and β-
tubulin. The GTP-bound form of these heterodimers polymerise head-to-tail and
form linear protofilaments (Bergen et al. 1980). The α- and β-tubulins alternate
down the length of each protofilament. Therefore, the protofilament, like a microfil-
ament, has a plus end and a minus end (Bergen et al. 1980). In vivo, a ring-shaped
template ensures that exactly 13 protofilaments associate with one another later-
ally to form a hollow tube (Moritz et al. 2000). All the protofilaments in a MT
are oriented in the same direction, meaning the MT as a whole is polar as well.
Once the tube has been formed, GTP-α/β-tubulin dimers may continue to add to
the plus end, extending the length of the MT further (Akhmanova & Steinmetz
2008)(Fig. 1.2). GTP-α/β-tubulin dimers that have already been incorporated into
a MT slowly hydrolyse their GTP into GDP. GTP-α/β-tubulin favours a straight
protofilament conformation and maintains a protective cap at the plus end of grow-
ing MTs. If all of the GTP-α/β-tubulin at the plus end hydrolyses the GTP to GDP,
a curved protofilament is favoured. This introduces strain within the MT, causing it
to spontaneously fray into individual protofilaments, which then depolymerise back
into GDP-α/β-tubulin dimers (Akhmanova & Steinmetz 2008)(Fig. 1.2).
MTs play a central role in various cellular processes, including intracellular trans-
port and chromosomal segregation during nuclear division (J. Howard 1996). The
MT network in most cells is formed by the radiation of MTs outward from the mi-
crotubule organising centre (MTOC). The minus ends are anchored at the MTOC,
whereas the plus ends are oriented outward (Bergen et al. 1980). This highly po-
larised organisation supports a system whereby one set of unidirectional motors
carries cargoes out to the cell periphery and a different set of unidirectional motors
carries cargoes back toward the cell centre (Vale 1987). This polarity is partic-
ularly crucial for efficient transport in neuronal axons, which can span distances
several magnitudes of order longer than the diameter of the cell body (Goldstein &
Z. Yang 2000). MTs also play a key role in nuclear division, as they form the mi-
totic spindle. This MT-based apparatus aligns and segregates chromosomes into two
daughter nuclei, ensuring an equal division of genetic material is distributed to each
one (Wittmann et al. 2001). Finally, MTs comprise the core structure of axonemes,
the highly specialised structures that power both cilia and flagella (Stephens & Edds
1976). A more detailed discussion of the axoneme follows in Section 1.2.2.
1.1.2 Cytoskeletal motors
In order for the cytoskeleton to carry out the majority of its functions, it relies not
just on the filaments described above, but also on the molecular motors that move
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Figure 1.2: Microtubule polymerisation. A) Polymerisation of microtubules
(MTs) begins when GTP-α/β-tubulin dimers join end-to-end and form polar
protofilaments. B) A hollow MT is formed when protofilaments interact with each
other laterally in a helical pattern. The closing of the MT results in a lattice seam
(red dashed line). C) An overview of MT turnover. Once a MT is formed as de-
scribed in A and B, GTP-α/β-tubulin dimers may continue to add to the plus end,
extending the MT length. Over time, GTP-α/β-tubulin that has been incorporated
into the MT hydrolyses its GTP and becomes GDP-α/β-tubulin, which favoured
a curved protofilament rather than a straight one. If all theGTP-α/β-tubulin at
the growing end hydrolyses, this strain overwhelms the lateral interactions between
protofilaments and the MT separates into individual protofilaments, which are ulti-
mately depolymerised back into GDP-α/β-tubulin dimers. Figure reproduced from
Akhmanova & Steinmetz 2008 with permission of the author.
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processively along them. Cytoskeletal motors can be divided into three families:
myosins, kinesins and dyneins. Each motor includes at least one heavy chain, which
contains a motor domain that converts the chemical energy of ATP into mechanical
work as well as binding sites for various accessory chains. Despite these similarities
in overall structure and function, each family has unique characteristics that relate
to its members’ specific functions. The focus of this section is to give a broad
structural and functional overview of each of the three families, while making use of
relevant examples to compare and contrast them.
Myosins
Myosins are cytoskeletal motors that move along microfilaments. Although myosins
were first studied in the context of muscle contraction, there are many other types
of myosin with a host of functions outside of skeletal muscle cells. There are
even myosins present in unicellular organisms. For example, S. cerevisiae has five
myosins, which play roles in processes ranging from endocytosis to the generation
of asymmetry between mother and daughter cells (S. S. Brown 1997).
There are at least 17 known classes of myosins, each being structurally and/or
functionally distinct from the others (Hodge et al. 2000). Myosin II includes the
motors that assemble into the thick filaments of sarcomeres (Fig. 1.1B) and are
responsible for muscle contraction (Reggiani & Bottinelli 2008). Myosin VI includes
motors that move toward the pointed end of microfilaments, whereas all other char-
acterised myosins move toward the barbed end (Wells et al. 1999). Myosin V will
be described in greater detail as it appears to be present in nearly all non-plant
eukaryotes and is well characterised as a processive motor involved in long-range
cellular transport (Reck-Peterson et al. 2000).
Structurally, myosin V is a homodimer of two heavy chains, which bind each
other via an extended coiled-coil called the stalk (Fig. 1.3). At the N-terminus
of the myosin heavy chain is a globular motor domain, which is the site of ATP
hydrolysis and actin binding. Immediately C-terminal to the motor domain is a
neck domain, which consists of six IQ motifs. Five of the IQ motifs bind calmodulin,
and the last binds an essential light chain. The stalk connects the neck domain to
the C-terminal tail domain. The tail domain mediates cargo binding via adaptor
proteins (Vale 2003).
Compared to conventional myosin II, which is characterised by high-speed, en-
semble based motility, myosin V’s high duty ratio and 36nm step size make it highly
processive (Enrique et al. 1999). Thus, it is uniquely suited for membrane trafficking
and long-range cargo transport along microfilaments (Mehta et al. 1999). Myosin
V has also been shown to walk using a ”hand-over-hand” mechanism (Yildiz et al.
2003). This means that one motor is always attached to the microfilament and that
the two motors alternate between leading and trailing, as opposed to an ”inchworm”
mechanism whereby one motor always leads.
Kinesins
Kinesins move along MTs rather than microfilaments. The kinesin family is large,
with at least 14 distinct families (Lawrence et al. 2004), and 45 known kinesin genes
in the human genome (Miki et al. 2001). Of these, conventional kinesin, or kinesin I,
is the best characterised. Kinesin I is processive (Vale et al. 1985a) and moves toward
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Figure 1.3: A model of myosin V. Myosin V consists primarily of two myosin
heavy chains, which dimerise via a long coiled-coil stalk. At the heavy chain N-
terminus there is a motor domain, which is connected to the stalk by a neck do-
main. The neck domain contains six IQ motifs, which provide binding sites for five
calmodulin molecules and one essential light chain. The globular tail domain at the
heavy chain C-terminus binds cargo adaptors, which link the motor to its various
cargoes. Figure adapted with permission of the author from a model illustrated by
Janet Iwasa.
Figure 1.4: A model of conventional kinesin (kinesin I). Kinesin I consists
primarily of two heavy chains, which dimerise via a long coiled-coil stalk. At the
heavy N-terminus there is a motor domain, which is connected to the stalk by a
neck linker. At the heavy chain C-terminus is the tail domain, which binds to the
light chains (KLCs). The heavy chain’s globular tail domain and KLCs bind cargo
adaptors, which link the motor to its various cargoes. The stalk is interrupted in the
middle by a hinge, which allows kinesin to fold in half and adopt an autoinhibited
conformation where the tail is bound to the motor. Figure adapted with permission
of the author from a model illustrated by Janet Iwasa.
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the plus end of MTs (Vale et al. 1985b). Other kinesin variants include some that are
non-processive (Rogers et al. 2001), some that are monomeric (Okada et al. 1995),
and some that move toward MT minus ends (McDonald et al. 1990). There are
even kinesins that are not motors, but rather MT polymerases and depolymerases
(Hunter et al. 2003, Varga et al. 2009 and Grava & Philippsen 2010).
Structurally, kinesin I is a homodimer of two heavy chains, bound together via
an extended coiled-coil called the stalk (Fig. 1.4). The N-terminal motor domain,
which is connected to the stalk by a neck linker, is the site of ATP hydrolysis and
MT binding. The C-terminal tail of the heavy chain binds to kinesin light chains
(KLCs), which are important for cargo binding (Pernigo et al. 2013). The coiled-coil
of the stalk is interrupted halfway through by a hinge region, which allows kinesin
I to fold in half. When folded, the motor domain and tail domain can interact to
adopt an autoinhibited state (Kaan et al. 2011), the advantage of which is to prevent
idle motors from wasting precious ATP (Vale 2003).
Kinesin I functions via a ”hand-over-hand” mechanism, like myosin V (Yildiz
et al. 2004). However, the step-size of kinesin I is only 8nm (N. J. Carter & Cross
2005), in contrast to the 36nm steps that myosin V takes. This results from the
kinesin I neck linker being much shorter than the myosin V neck, and corresponds to
the spacing between available binding sites on MTs compared to microfilaments. As
a processive cytoskeletal motor, kinesin I is also involved with long-range transport
of cargoes. For example, kinesin I transports organelles such as mitochondria and
lysosomes, as well as anterograde-directed vesicles in axons (Hirokawa 1998). In
light of all the structural, mechanistic and functional similarities between kinesins
and myosins, it has been proposed that the kinesins and myosins share a common
ancestor (Kull et al. 1998 and Vale & Milligan 2000).
Dyneins
All known dyneins are motors that drive movement toward the minus end of MTs.
In many ways, dyneins are the odd ones out of the three cytoskeletal motor families.
At over 500kDa, dynein heavy chains (DHCs) are much larger than those of kinesin
(∼ 70− 170kDa) and myosin (∼ 120− 250kda). In addition to their massive size, in
DHCs, the N-terminus forms the tail domain and the C-terminus forms the motor
domain, while in the heavy chains of most myosins and kinesins, the orientation is
reversed. This disparity in both size and domain organisation reflects the difference
in evolutionary origin between dynein and the other two motor families. This differ-
ence is further highlighted by the fact that the highly conserved nucleotide binding
pockets of kinesin and myosin are homologous to the active site of G proteins (Kull
et al. 1998), whereas dynein’s hydrolytic activity relies on AAA+ domains (Neuwald
et al. 1999).
The overall structure of dyneins (Fig. 1.5) is also quite different from myosins
and kinesins. For example, in myosins and kinesins, the motor domain itself binds
directly to the filament. On the other hand, dynein’s microtubule binding domain
(MTBD) is located at the end of a stalk, which extends ∼ 15nm away from the
motor domain. Furthermore, the dimer interface of both myosin and kinesin are
simple coiled-coils. Although dynein’s mechanisms for oligomerisation are not well
understood, there is evidence that the homodimerisation of cytoplasmic dynein-1
involves accessory subunits as well as the DHCs (see Section 1.3.2 for a more detailed
discussion). Dyneins also tend to have many stably bound accessory subunits. The
7
Figure 1.5: A model of cytoplasmic dynein-1. Cytoplasmic dynein-1 consists
primarily of two dynein heavy chains (DHCs). The C-terminal two thirds of the
DHC (blue and grey) form the motor domain, while the N-terminal one-third and
various accessory chains (shades of green) form the tail domain. The ATPase ac-
tivity of the motor domain occurs within a hexameric ring of AAA+ domains, and
results in mechanical motion that is communicated through the linker domain. The
motor domain binds microtubules through a globular microtubule binding domain
(MTBD), which is located at the end of stalk, a 15nm coiled-coil that projects out
of AAA+ domain 4. Far less is known about the organisation of the tail domain
than the motor domain, which is the site of oligomerisation, cargo binding and reg-
ulation of the dynein motor. In mammals, the tail domain consists of the two DHC
N-termini as well as two copies each of the dynein intermediate chain (DIC), dynein
light intermediate chain (DLIC), and three dynein light chains (DLCs), called LC8,
Tctex-1 and Roadblock/LC7. The DLCs bind to the DICs, rather than the DHCs
directly. The DLICs and DICs both contact the DHCs directly. Figure adapted
with permission of the author from a model illustrated by Janet Iwasa.
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specific subunits vary depending on species and dynein type, but the tail domain
typically includes intermediate chains (DICs), light intermediate chains (DLICs) and
light chains (DLCs) in addition to the DHCs (Fig. 1.5).
Dynein functions are diverse, but generally related to either long-range transport
of various cargoes or axonemal bending, the latter being a mechanism for translating
dynein’s movements on the molecular scale into locomotion of the entire cell. The
following section provides a more detailed description of dynein’s functions while
discussing the various members of the dynein family.
1.2 Dynein family classification
Some text and the figures in this section have been adapted from the following
article. Figures that have already been published are indicated by citing Diamant
& A. P. Carter 2013 in the figure legends.
Diamant, A. G. & Carter, A. P. Dynein Family Classification in Encyclopedia of
Biophysics. (ed. Roberts, G. C. K.) 552-558. (Springer Heidelberg, 2013).
1.2.1 Overview of dynein families
The dynein family is divided into axonemal and cytoplasmic dyneins. Axonemal
dyneins reside within cilia and flagella and are responsible for the rhythmic and
coordinated bending of these organelles. Cytoplasmic dynein-1 is found across the
cellular MT network and is responsible for retrograde transport of various cargoes
toward the minus ends of MTs, while cytoplasmic dynein-2 predominantly transports
cargoes along MTs within the axoneme. The axonemal dyneins consist of one known
outer dynein arm (ODA) and at least seven distinct inner dynein arms (IDAs), with
the exact number varying between species. The ODA can contain either two or
three heavy chains, which are further defined as the α, β and γ DHCs. Each IDA
contains a single DHC except for one known as inner arm I1 or f (hereafter referred
to as I1/f), which is a heterodimer. Both cytoplasmic dyneins are homodimers of
their respective DHCs (Fig. 1.6).
Structurally, the dyneins differ not only in the number and sequences of their
DHCs, but also in the composition and organisation of the smaller subunits. These
differences are described below, but first there are some key characteristics that all
dyneins share. Every dynein complex contains at least one DHC. The C-terminal
two-thirds of the DHC is known as the motor domain. It consists of six AAA+
domains that form a ring. The stalk, a 15nm antiparallel coiled-coil, projects out
of the fourth AAA+ domain and bears the globular microtubule-binding domain
(MTBD) at its tip (Fig. 1.7). A shorter coiled-coil, known as the buttress or the
strut, extends from the fifth AAA+ domain to the middle of the stalk. N-terminal
to the hexameric ring is an element known as the linker, which plays a pivotal
role in translating the ATPase action of the motor domain into mechanical motion
(Burgess et al. 2003). The N-terminal one-third of the DHC is known as the tail
domain and serves as a major site of protein-protein interactions. It contains the
site of DHC oligomerisation (homo and heterodimerisation, as well as trimerisation)
and binds accessory proteins, such as dynein intermediate chains (DICs) and dynein
light chains (DLCs). The resulting tail subcomplex is responsible for attachment of
9
Figure 1.6: Classification of dynein. A phylogenetic tree of ∼ 60 distinct dynein
heavy chains. Sequences cover all known types of dynein heavy chains from several
species, including A. gossypii, C. elegans, C. reinhardtii, D. rerio, D. melanogaster,
G. gallus, H. sapiens, K. lactis, N. crassa, S. cerevisiae, T. thermophila. Surrounding
the phylogenetic tree are schematic representations of the heavy chains that make
up each type of dynein motor. Figure adapted from Diamant & A. P. Carter 2013
with permission of the author.
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Figure 1.7: Overview of dynein heavy chain structure. Starting at its N-
terminus, the heavy chain includes a cargo-binding tail domain (red), a mechanical
linker (purple), and a motor domain (blue), which consists of a hexameric ring of
AAA+ domains. A 15 nm coiled-coil known as the stalk (yellow) projects out of
the ring from the fourth AAA+ domain and bears the globular microtubule-binding
domain (green) at its tip. A shorter coiled-coil known as the buttress or strut (pink)
similarly extends out from the fifth AAA+ domain and interacts with the middle
of the stalk, possibly playing a role in the mechanochemical cycle. Figure adapted
from Diamant & A. P. Carter 2013 with permission of the author.
cytoplasmic dynein to cargoes and anchors the motor to doublet MTs in axonemal
dyneins.
1.2.2 Axonemal dyneins
The axoneme is a highly conserved structure found in cilia and eukaryotic flagella.
In motile cilia and flagella, each axoneme is made up of a bundle of nine peripheral
doublet MTs and two central singlet MTs that run longitudinally throughout the or-
ganelle. Each doublet MT has several arms projecting toward neighbouring doublet
MTs as well as radial spokes that span the gap between the peripheral and central
MTs (Fig. 1.8). In 1963, Ian Gibbons set out to identify the protein responsible for
axonemal bending. He dissolved the membrane of Tetrahymena cilia and treated
the exposed axonemes with various solutions. He found that after treatment with
EDTA, the axonemes lost their ATPase activity, while the supernatant gained it.
Using an electron microscope, Gibbons noticed that the arms that extend between
adjacent peripheral MTs were missing from these inactive axonemes and named the
large protein purified from the supernatant “dynein” after the dyne, a unit of force
(S. M. King 2011).
The unicellular green alga Chlamydomonas has served as an important model
organism for the study of axonemal dyneins. Several dynein deficient mutants that
exhibit reduced flagellar motility or are completely paralysed have been described.
By comparing their physiology, subcellular anatomy and genotypes, it was demon-
strated that there are several types of inner dynein arms (IDAs), which are struc-
turally and functionally distinct from the single outer dynein arm (ODA). The IDAs
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Figure 1.8: Arrangement of various dyneins within the axoneme. Cross-
sectional view of an axoneme showing the 9 + 2 arrangement of microtubules and
the location of various dyneins. The outer dynein arms are heterotrimers of three
distinct heavy chains (two in some species). The inner dynein arms are monomers
aside from the heterodimeric I1/f dynein. Colours correspond to Fig. 1.6. The red
box outlines the doublet microtubule that is viewed in Fig. 1.9. Figure reproduced
from Diamant & A. P. Carter 2013 with permission of the author.
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Figure 1.9: Longitudinal view of the spacing and orientation of dyneins
along a doublet microtubule within the axoneme. Longitudinal view of a
single doublet microtubule (enclosed in a red box in Fig. 1.8) demonstrating the
spacing of outer dynein arms (ODAs) and inner dynein arms (IDAs) along the
axoneme. There is one outer dynein arm every 24 nm, while a complex pattern
of several inner dynein arms repeats every 96 nm. Colours correspond to Fig. 1.6.
Figure reproduced from Diamant & A. P. Carter 2013 with permission of the author.
can be further resolved into seven distinct dyneins by using high-pressure liquid chro-
matography to fractionate high salt extracts of Chlamydomonas axonemes. The
seven resulting peaks have been named a–g (Kagami & Kamiya 1992). Full genome
sequencing predicted at least three more axonemal DHCs, which have only recently
been purified due to a lower level of expression. These minor IDAs were shown to
localise specifically to either the proximal or distal region of the axoneme, demon-
strating yet another level of complexity in the coordination between the various
IDAs (Yagi et al. 2009).
The outer dynein arm
The ODA can be found on the side of the doublet MT farthest from the central pair
of MTs (Fig. 1.8). Each doublet MT is made of one complete MT, known as the
A-tubule, and one incomplete MT, known as the B-tubule. The ODA is situated
such that its tail subcomplex associates with the A-tubule of one doublet MT, and
its stalk stretches across to the B-tubule of the neighbouring doublet MT. The link
between the ODA and A-tubule remains intact throughout the mechanochemical
cycle, while the MTBD at the tip of the stalk dissociates and reassociates with the
B-tubule each step. Looking down the length of the axoneme, there is one ODA
every 24 nm (Nicastro et al. 2006 and Bui et al. 2010)(Fig. 1.9).
Depending on the species, each ODA can contain either two or three DHCs.
Electron tomography of Chlamydomonas axonemes shows the planes of the AAA+
rings of three DHCs (α, β and γ) stack parallel to the A-tubule they are attached
to (Nicastro et al. 2005 and Takazaki et al. 2010). Phylogenetically, the α and β
chains are very similar and probably result from gene duplication, while the γ chain
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is more distantly related. Animal ODAs contain only two DHCs, which are most
similar to the β and γ chains of Chlamydomonas (Fig. 1.6).
Each ODA also contains two DICs and eight DLCs, which associate with the tail
portion of the DHC to form the tail subcomplex. Several of the DLCs are homologues
of well-known proteins and these relationships have been used to suggest potential
mechanisms for regulation of the ODA by these DLCs. For example, LC3 and LC5
are closely related to thioredoxin, and allow control of activity in response to changes
in redox potential (Kamiya 2002).
There are associated complexes that are not considered part of the ODA, but are
found adjacent to it and are thought to play a role in its regulation. One subcomplex
of three proteins, known as the ODA docking complex (ODA-DC) is made primarily
of coiled-coils that are roughly 24 nm in length (Casey et al. 2003). The ODA-DCs
lay end-to-end along the A-tubule, which suggests that its primary function is to
measure out the appropriate distance between adjacent ODAs (Bui et al. 2009).
There are also two linkers, which are thought to contribute to the tight inter-dynein
regulation necessary for axonemal beating. The first, known as the outer-outer-
dynein linker (OOD) connects adjacent (down the length of the axoneme) ODA
HCs, and is thought to help propagate ODA activity necessary for the production
of the observed waveform. The second is the outer-inner-dynein linker (OID), which
connects two out of every 4 ODAs to the IDAs and is thought to help coordinate
activity between the ODAs and IDAs (Nicastro et al. 2006). In summary, although
there is only one type of ODA, it is a highly complex molecular machine made up of
several individual polypeptides and forming direct interactions with at least a dozen
others.
The inner dynein arms
In contrast to the ODA, each IDA is much simpler in structure, but the interplay
of the different types of IDAs results in complexity. The IDAs are found on the side
of the doublet MT closest to the central pair. They are oriented in the same way as
the ODAs, with their tail attached to the A-tubule of one doublet MT and the stalk
attached to the B-tubule of its neighbour. Rather than repeating every 24 nm like
the ODA, a complex pattern consisting of several IDAs repeats every 96 nm (Fig.
1.9).
IDA I1/f is phylogenetically, structurally and functionally distinct from the rest
of the IDAs. It is a heterodimer of two DHCs, also referred to as α and β (not to be
confused with the α and β DHCs of the ODA), which form distinct clusters in Fig
1.6. I1/f contains three ICs (140, 138, and 97 kDa). The 140-kDa IC anchors IDA
I1/f to the doublet MT, while the 138-kDa either promotes or inhibits the activity
of this dynein depending on its state of phosphorylation. The monomeric IDAs do
appear to form some phylogenetic clusters, but these groups do not correlate well
with groups that are based on structural, biochemical, and physiological properties
(Hom et al. 2011). Structurally, each monomeric IDA has a single DHC, the tail of
which interacts with an actin monomer. The actin subunit in turn interacts with a
centrin DLC in IDAs b, e, and g and a p28 DLC in IDAs a, c, and d (Kamiya 2002).
Therefore actin may provide a scaffold for DLCs to bind to the DHC tail in these
dyneins.
Each 96 nm repeat of IDAs also contains a crescent-shaped complex called the
dynein regulatory complex (DRC). This complex is situated directly on the doublet
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MT and interacts with the radial spokes, the OID mentioned above and nexin, an
elastic protein that ties together the bundle of nine peripheral doublet MTs. Because
of its central location and interaction with both the radial spokes and the OID, the
DRC plays a key role in coordinating the activity of the axoneme (Barber et al.
2012). The OIDs themselves promote communication between the ODAs and IDAs.
Since there are two OIDs for every 96 nm unit in the IDA pattern, the two OIDs
must interact with different parts of the inner arm. One OID forms a connection
from an ODA to the DRC, while the other links an ODA to IDA I1/f (Nicastro et al.
2006). The discovery of these OID connections underscored the critical roles that
the DRC and IDA I1/f have in regulating axonemal activity.
Functional characteristics of axonemal dyneins
Functional studies of various Chlamydomonas mutants revealed that not all axone-
mal dyneins are necessary for motility and helped to define a minimum combination
of dyneins that must be present for axonemal beating to take place. The first, some-
what unexpected finding was that mutants lacking ODAs altogether still swim, but
at less than half the speed of the wild type. Mutants lacking certain combinations
of IDAs were also able to swim at a reduced velocity, but other combinations were
paralysed. Specifically, if a mutant lacked two of the following three items, it was
paralysed completely: (1) The entire ODA, (2) IDA I1/f, (3) IDAs a, c, and d.
Analysis of these same mutants also helped characterise the types of motion each
type of dynein is responsible for. For example, ODAs produce a high beat frequency,
while IDAs promote the large amplitude of each beat.
In vitro motility assays performed with isolated dyneins provided further insights
into the velocity and force produced by each specific dynein. For example, IDA I1/f,
which appears to be very important to the function of the axoneme in vivo, moves
MTs 95–99% slower than the other isolated dyneins (E. F. Smith & Sale 1991).
Additionally, IDAs a, c, d, e, and g rotate MTs in addition to translocating them
(Kagami & Kamiya 1992), which suggests that one of the key roles of these dyneins
is to produce torque. Furthermore, IDA c has been reported to be a processive motor
(Sakakibara et al. 1999), which was surprising both because it is a monomer, and
because there is no immediately obvious benefit for such a motor in the axoneme.
The current model for reconciling all of these structural and functional obser-
vations describes two independent systems working in parallel within the axoneme.
The relationship between the two remains unclear, but it appears that the IDA
system is responsible for initiating axonemal beating, while the ODA amplifies the
power. This would account for the fact that mutants completely lacking ODAs can
still swim, while those lacking all IDAs cannot. It is also supported by the layout
of the regulatory network, which seems to suggest that the signal originates in the
central pair MTs and radial spokes, and moves outward through the IDAs, before
arriving at the ODAs through the DRC and OIDs (Movassagh et al. 2010). An-
other perplexing observation is the large discrepancy in velocity between individual
dyneins. One possibility is that some may only be involved in beat initiation while
others are required for propagation, similar to how one shifts gears on a bicycle when
accelerating from a complete stop. It has also been shown that different dyneins are
active on each side of the axoneme (Hayashi & Shingyoji 2008). This combination of
temporal and spatial coordination of the various axonemal dyneins is likely to play
a critical role in producing the beating pattern of the motile cilium or flagellum.
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1.2.3 Cytoplasmic dynein-1
Whereas all other dyneins are found in the axoneme, a single dynein, cytoplasmic
dynein-1 (hereafter, dynein-1) carries out all dynein functions in the cytoplasm. In
contrast to the axonemal dyneins, which collectively promote cellular locomotion
(Milisav 1998), dynein-1’s many functions involve transport within the cell. Like
certain myosins and kinesins, dynein-1 transports vesicles, organelles (e.g., mito-
chondria and nuclei), RNAs, and proteins to specific locations in the cell (Caviston
et al. 2007, Varadi et al. 2004, Xiang et al. 1994, Dienstbier et al. 2009 and Z. Y.
Yang et al. 2003). It is also responsible for the collection of misfolded and aggregated
proteins (Ravikumar et al. 2005). Furthermore, due to its retrograde direction of
motility, dynein-1 has been co-opted for a parasitic function. Through an example
of co-evolution, many different viruses are capable of hijacking dynein-1 and taking
advantage of its retrograde motion to increase their chances of infecting the cell
nucleus (Do¨hner et al. 2002). These functions lead to dynein-1 playing a key role in
processes as diverse as fast axonal transport, golgi dynamics, protein recycling, viral
infection and several distinct stages of mitosis including spindle orientation, nuclear
migration, spindle assembly, and chromosomal segregation during anaphase (Karki
& Holzbaur 1999).
Dynein-1 forms a homodimer made up of DHCs, DICs, DLCs, and light inter-
mediate chains (DLICs) (Fig. 1.5). Each motor contains a dimer of DHCs, which
binds directly to a pair of one of two DLIC homologues (either DLIC1 or DLIC2).
The DHCs also bind a dimer of DICs, which provide a scaffold for dimers of one to
three different DLCs depending on the species. The role of the DLCs has been con-
troversial, and is still not entirely clear. As the purpose of this section is to briefly
introduce all the various dyneins, a more in-depth discussion of this controversy,
and many other aspects of dynein-1 is provided in Section 1.3.
1.2.4 Cytoplasmic dynein-2
Even though cytoplasmic dynein-2 (hereafter, dynein-2) is most closely related to
dynein-1 in phylogeny, general function, and structure, it is primarily found within
or near cilia and flagella where it carries out its primary function of axoneme main-
tenance. Fig. 1.6 shows that the two cytoplasmic dyneins cluster together and are
more closely related than either is to the axonemal dyneins. Functionally, dynein-2
is also similar to dynein-1 in that it participates in long-range transport. Dynein-2’s
main function is to bring intraflagellar transport (IFT) particles back to the cell
body where they can be recycled (Rosenbaum & Witman 2002). The mechanism
is thought to be similar to that used by dynein-1 to carry cargoes across the cell,
except in this case the cargo is a form of proteinaceous raft (IFT particle) and the
track is the axoneme (Mikami et al. 2002). When dynein-2 is defective, flagella are
extremely short and IFT particles accumulate in their tips (Pazour et al. 1999).
Dynein-2 also plays a role in signal transduction by relaying signals from the tip of
a nonmotile cilium back toward the cell body. For example, mouse embryos lacking
dynein-2 are not responsive to the Hedgehog signalling pathway and are therefore
unable to specify ventral neural cell types in the neural tube (Scholey & Anderson
2006).
Structurally, dynein-2 is similar to dynein-1 in that it also contains a dimer of
DHCs and two DLICs; however, it is only known to bind one type of DLIC called
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DLIC3 (Tan et al. 2011). A recent study demonstrated that two DICs called WDR34
and WDR60 bind to dynein-2’s DHC (Asante et al. 2014). Interestingly, WDR60
is larger than both WDR34 and the DIC that binds dynein-1, which suggests that
dynein-2 may be asymmetrical. Furthermore, the same study also confirmed that the
DLCs Tctex-1, Tctex-3, Roadblock-1, Roadblock-2, LC8-1 and LC8-2 all interact
with dynein-2, in addition to dynein-1. Finally, they identified a new DLC called
Tctex-2, which is unique to dynein-2 (Asante et al. 2014). Much less is known about
the regulation of dynein-2 than that of dynein-1, but some likely adaptors that are
necessary for proper function include IFT complex A (Jonassen et al. 2012), IFT
complex B (Follit et al. 2009), and a subunit of kinesin-2 (which is required for
anterograde IFT) called FLA10 (Kozminski et al. 1995).
1.3 The state of cytoplasmic dynein-1 research
Because of the central role that cytoplasmic dynein-1 (hereafter ”dynein”, unless
otherwise specified) plays in so many essential cellular processes, it has been the
subject of intense study ever since its discovery in 1987 (Paschal et al. 1987). How-
ever, dynein proved a much more elusive subject of scientific investigation than
kinesin I or myosin V and progress in understanding dynein lagged far behind the
other cytoskeletal motors for years. This was largely due to dynein’s large size and
the fact that it is a complex consisting of two copies of each of four to six protein
subunits. Both of these characteristics made every step of expressing recombinant
dynein a formidable challenge. Cloning, sequencing, expressing and purifying large
protein complexes only became much more feasible in the last ten to fifteen years
thanks to advances in molecular biology. Before these advances, most dynein studies
were carried out either in vivo, or using protein purified from endogenous sources.
Much was learnt about dynein despite these obstacles, but the eventual ability to
design and create recombinant constructs accelerated dynein research.
1.3.1 Dynein motor domain
Early work on the motility of dynein was done using samples purified from endoge-
nous sources. The first cytoplasmic dynein was purified from cow brains. Its in
vitro motility was confirmed by observing that it could translocate MTs after being
adsorbed onto glass slides (Paschal et al. 1987). Another early study discovered
a large protein that was responsible for transporting vesicles in squid axons. This
molecule’s dynein-like structure was confirmed by negative stain EM (Gilbert &
Sloboda 1989). A more detailed analysis of dynein’s motility was made possible
using latex beads coated with dynein purified from chick embryo brains. This study
was precise enough to see that dynein sometimes moved across MT protofilaments
and often took backward steps when doing so (Wang et al. 1995). Furthermore,
native cow dynein was used to show that the addition of a co-factor called dynactin
improves motor processivity (S. J. King & Schroer 2000).
A critical step toward understanding dynein’s mechanochemical cycle came after
a series of studies where groups introduced specific mutations into the various AAA+
sites of recombinant motor domains. This allowed them to measure the relative
importance of each AAA+ site for ATPase activity, MT binding and MT gliding
ability (Silvanovich et al. 2003, Kon et al. 2004, Reck-Peterson & Vale 2004 and
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Figure 1.10: The 3.3A˚ crystal structure of the S. cerevisiae dynein motor
domain. A) The 3.3A˚ crystal structure of the S. cerevisiae dynein motor domain
(PDB accession code 4AKI). The construct began at residue 1364 of the S. cerevisiae
DHC and eliminated the majority of the stalk and the MTBD. In this crystal, the
motor domain is in an open conformation and the only AAA+ domain with ATP
bound is AAA2. The linker is in the post-powerstroke position. B) A schematic
summary of all the information gained from the crystal structure in A. The linker
was discovered to have a cleft, which allows it to bend between the AAA5 docking
site where it binds in the post-powerstroke state and the AAA2 β-hairpins, where
it was predicted to bind during the pre-powerstroke state. A summary of what
was learnt about ATP binding in each AAA+ site was included as well. Figures
reproduced from Schmidt et al. 2012 with permission of the author.
Kon et al. 2005). Another major step resulted from the creation of a minimal
motor domain that could be chemically induced to artificially dimerise and was
fluorescently labelled. This degree of control during in vitro assays was essential in
determining the effect of dimerisation on motility. It also provided a means for a
much more precise characterisation of dynein’s stepping behaviour than was possible
with latex beads (Reck-Peterson et al. 2006).
Over the same time period, there was much work being done to elucidate the
dynein motor domain’s structure. Genetic analysis of the dynein gene first pro-
vided evidence that is made up of four or five AAA+ domains, although the actual
number was not settled until much later (Gibbons et al. 1991 and Ogawa 1991).
Recombinant fragments of dynein from R. norvegicus were used to define the C-
terminal two-thirds of the DHC as the motor domain. This study also first provided
evidence of the MTBD and stalk structures using sequence-based predictions and
rotary shadowing EM (Gee et al. 1997). The first low-resolution model of the dynein
motor AAA+ domains was proposed using a recombinant motor domain structure
from D. discoideum. Using negative stain EM, it was possible to see a ring-like
structure, with a central cavity (Samso´ et al. 1998). This provided clear evidence
that dynein was structurally distinct from myosin and kinesin.
One study that revealed much about both the structure and function of dynein
made use of the axonemal IDA c from C. reinhardtii. By performing negative stain
EM on this intact, endogenous dynein in various nucleotide conditions, it was possi-
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ble to directly observe the movement of the linker relative to the tail domain (Burgess
et al. 2003). Finally, the ability to fine-tune and overexpress recombinant dynein
motors in large quantities culminated in crystal structures of the entire dynein mo-
tor domain (A. P. Carter et al. 2011, Kon et al. 2011, Kon et al. 2012, Schmidt et al.
2012 and Schmidt et al. 2014). These crystal structures provided unprecedented
levels of detail about dynein motility, such as the mechanism by which the linker
domain bends during different stages of the mechanochemical cycle.
One theme that is clearly visible throughout the history of dynein motor domain
research is that many of the biggest turning points came from the freedom intro-
duced by new recombinant expression techniques. Many of the questions that were
answered using recombinant dyneins, through site-directed mutagenesis and pro-
tein engineering, would have been much more difficult to probe using endogenous
samples only.
1.3.2 Tail domain
Recombinant studies of the dynein tail domain lagged far behind those of the motor
because in addition to being larger than a single motor domain, the tail domain
is also a multi-subunit complex. This makes recombinant overexpression and pu-
rification, which would be necessary for many potential biochemical and structural
experiments, even more challenging. When I began my PhD in October, 2011,
the first crystal structures of the minimal dynein motor domain crystal had just
been published (A. P. Carter et al. 2011 and Kon et al. 2011), but there were still
no reports of a purified minimal tail complex. One group had successfully puri-
fied endogenous levels of recombinant full-length dynein for in vitro motility assays
(Kardon et al. 2009), and another had expressed tail complexes in vivo to observe
the effects by fluorescence microscopy (Markus et al. 2009). Relative to the progress
being made on the motor domain, there was little known about the structure and
functions of the dynein tail domain, and one of the primary obstacles was the lack
of a recombinant minimal tail sample.
Nevertheless, a basic knowledge of the components of the dynein tail, with some
hints to its organisation were already available. As the work presented in this
thesis was done using the S. cerevisiae (yeast) model system, the differences between
yeast and mammalian dynein will be highlighted when applicable. Both yeast and
mammalian dynein consist of a homodimer of DHCs, which binds two DICs and
two DLICs (Fig. 1.5). However, in yeast, each DIC binds to two copies of the same
DLC, called Dyn2, while in mammalian dynein, each DIC binds to three different
DLCs, called light chain 8 (LC8), light chain 7 (LC7 or roadblock) and t-complex
testis specific protein 1 (Tctex-1) (Kardon & Vale 2009). Furthermore, in yeast,
there is just one gene for each dynein subunit, whereas in mammalian cells, there
are often multiple genes for each dynein subunit, which are expressed as various
isoforms. The resulting combinatorial possibilities give rise to a large number of
potential dynein complexes of differing compositions (Pfister et al. 2006 and Palmer
et al. 2009).
Functionally, there is a large difference between yeast dynein and mammalian
dynein. Yeast dynein has only one known function, which is to position the mitotic
spindle to ensure proper nuclear segregation (Eshel et al. 1993). Furthermore, it
is not essential for this role as there is a redundant pathway for this function. On
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the contrary, dynein is absolutely essential for mammalian cells, and it has multiple
roles (listed above in Section 1.2.3). Despite this apparent difference between yeast
dynein and mammalian dynein as a whole, the tail domain is thought to have at
least three key functions common to all species: dynein homodimerisation, dynein
cargo binding and dynein regulation. Indeed, the simplicity of the yeast system
could be seen as a benefit of using it as a model system as there is only one known
cargo and consequently less regulation required, compared to the dozens of proposed
cargoes and extremely convoluted regulation present in mammalian cells.
The remainder of this introduction addresses each of the three general functions
of the dynein tail in turn. In each section, the focus is on what was known at the
beginning of my PhD, in October 2011, with an emphasis on the controversies and
gaps in understanding that existed at the time. This is in order to provide the
context and motivation for the work that I carried out during my PhD. However,
at the end of each section, any major developments that occurred over the course
of my PhD will also be summarised.
Dynein homodimerisation
One of the characteristics that processive motors have in common is that they are
dimeric. This is expected as a dimeric motor is able to keep one head bound to
the track at all times, preventing the motor from diffusing away (Vale & Milligan
2000). While it was known that dynein forms a homodimer, the exact mechanism
of dimerisation had remained elusive. The first study to map a site for homod-
imerisation looked for a region within the DHC that was necessary and sufficient for
co-immunoprecipitating another DHC out of solution (Habura et al. 1999). They
concluded that the region between residues 627-780 in the D. discoideum DHC was
the site of dynein homodimerisation.
That same year, the first crystal structure of any dynein component was pub-
lished: the structure of LC8, one of the DLC (Liang et al. 1999). This paper
suggested that LC8 forms a homodimer in solution, and the crystal structure con-
firmed the presence of an intricate dimer interface that includes domain swapping of
a β-strand. Several years later, the structure of Tctex-1, another DLC, was solved
(Williams et al. 2005). Despite having no sequence identity to LC8, the Tctex-1
structure adopted a similar fold and also formed a homodimer. Finally, just two
years later, a crystal structure was solved of the ternary complex formed by mixing
LC8, Tctex-1 and a peptide fragment of the DIC that included both of their binding
sites (Williams et al. 2007)(Fig. 1.11A,B).
All three structures suggest that DLCs form homodimers, even in the context of
the DIC. In fact, the consensus model suggested that one of the primary functions
of the DLCs is to drive the homodimerisation of the entire dynein complex. A di-
rected evolution study determined what the LC8 binding motif preference is, and
then searched the human proteome for novel LC8 interactors (Rapali et al. 2011).
This list included several proteins that homodimerise, so it was suggested that LC8
actually serves as a ”dimerisation engine” and it’s primary function is to bind other
proteins and dimerise them. The specific case of dynein homodimerisation was fur-
ther addressed by Nyarko & Barbar 2011 and Stuchell-Brereton et al. 2011. Nyarko
& Barbar 2011 used NMR and fluorescence quenching to establish that the DIC
N-terminus dimerises only in the presence of the DLCs. Using yeast as a model,
Stuchell-Brereton et al. 2011 determined that the two DLCs that bind the DIC sta-
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Figure 1.11: Homodimerisation of a LC8/Tctex-1/DIC complex. A) Above
is a schematic diagram of the DIC. It shows various binding sites including the two
DLCs bound in the crystal structure. Below are the sequences of two different DIC
variant peptides, as well as splice isoforms of each one. IC2 was the peptide used
in the crystal structure. The DLC binding sites are highlighted in cyan and wheat.
B) The crystal structure (PDB accession code 2PG1) of Tctex-1 (cyan) and LC8
(wheat) homodimers bound to two DIC peptides (residues 104–138; magenta). Each
DIC peptide binds to one side of each LC dimer producing a 2:2:2 complex. Residues
112–124 of the IC contact Tctex-1, and residues 129–137 contact LC8. Two views
are shown, rotated by 90° about the vertical axis. C) Two crystal structures of
LC8 (red surface representation) bound to different peptide fragments (green stick
representation). The view of both structures is similar to the view of LC8 in the red
box in B. Above is LC8 bound to a DIC peptide (PDB accession code 2P2P) and
below is LC8 bound to a potential cargo (Swallow) peptide (PDB accession code
2P1K). The two structures show that both DIC and Swallow occupy the same cleft
of the LC8 dimer. A and B adapted from Williams et al. 2007 with permission of
the journal and C adapted from Benison et al. 2007 with permission of the authors.
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bilise the DIC dimer, and in doing so support the DIC’s interaction with dynactin,
an important co-factor of dynein.
Evidence that the DLCs drive dimerisation of the DICs does not exclude the pos-
sibility that the DHCs also homodimerise within the region determined by Habura
et al. 1999. Nevertheless, this was the current state of knowledge about dynein
homodimerisation as I began my PhD, and so one obvious question we hoped to
explore with a minimal tail complex was how the tail dimerises.
During my PhD, at least two more publications came out, both reinforcing the
model that the DLCs are promiscuous proteins that drive the dimerisation of various
other proteins, of which dynein is just one example (Romes et al. 2012 and Rao et al.
2013).
Dynein cargo binding
An early model for how dynein binds cargoes was suggested by the fact that LC8
is known to bind both dynein, and many other proteins, which suggests that it
could be a cargo adaptor. When two possible LC8 binding motifs, KXTQTX or
XGIQVD, were identified using a pepscan technique (Rodr´ıguez-Crespo et al. 2001),
the number of LC8 binding partners (and therefore potential dynein cargoes) in-
creased greatly. Some proteins that were thought to be dynein cargoes based on
LC8 binding or the pepscan results include neuronal nitric oxide synthase (nNOS)
(Jaffrey & Snyder 1996), inhibitor of NF-κB transcription factor (IκBα) (Cre´pieux
et al. 1997), p53 binding protein 1 (Lo et al. 2005), oestrogen receptor (Rayala et al.
2005), and even the microfilament-based motor described above, myosin V (Espin-
dola et al. 2000 and Ho´di et al. 2006 ). Furthermore, most of these proteins were
somehow inhibited upon LC8 binding, suggesting that dynein may inhibit the cargo
as it is being transported.
However, in light of structural information that revealed how LC8 binds the DIC,
serious doubts were cast on the role of LC8 as a dynein cargo adaptor. Another study
presented two crystal structures similar to the one shown in Fig. 1.11B (Benison
et al. 2007). The first of these new structures showed a LC8 dimer bound to a DIC
peptide (Fig. 1.11C, top). The second showed a LC8 dimer bound to a peptide
from Swallow, a potential dynein cargo that contains the same KXTQTX motif as
the DIC (Fig. 1.11C, bottom). A comparison of these two structures revealed that
Swallow and the DIC bind in the same cleft of the LC8 dimer. Therefore, LC8
cannot bind both dynein and swallow at the same time. This finding lent further
credence to the idea that LC8 is only associated with dynein due to its capacity to
drive dimerisation, and that it might drive dimerisation for many other proteins as
well.
Many other mechanisms for cargo binding in mammalian cells were proposed.
One example involves a cargo adaptor discovered in D. melanogaster called Bicau-
dal D, (BICD), which interacts with dynein (Bullock & Ish-Horowicz 2001). Its
mammalian homologues, BICD1 and BICD2, were shown to colocalise with both
dynein and its activator, dynactin (Hoogenraad et al. 2001). Finally, it was shown
that BICD1 and BICD2 also co-localise with Rab6 on the trans-Golgi network
(TGN)(Matanis et al. 2002). With this, a complete connection could finally be
traced between dynein and one of its known cargoes.
In yeast, there is only one known cargo, called Num1. Num1 is a large cortical
protein that interacts with the DIC and the MT network (Farkasovsky & Ku¨ntzel
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2001). An oﬄoading model was proposed to explain how dynein achieves its role
in nuclear migration with yeast cells. Inactive dynein is targeted to the growing
plus end of a MT, which it tracks until it reaches the cell cortex. At the cortex,
it becomes anchored to the cortical Num1 and is activated. It then pulls the MT
toward itself as if it were walking toward the minus end of the MT. Since dynein is
anchored in place, the MT moves toward it, bringing the nucleus with it, which is
attached via the centrosome at the minus MT minus end (Lee et al. 2005).
Concerning dynein’s mechanisms for binding cargoes, one extremely important
advance took place during my PhD. Two different groups found that dynein only
binds its activator, dynactin, in the presence of a cargo adaptor, such as BICD2
(Schlager et al. 2014 and McKenney et al. 2014). Furthermore, mammalian dynein
on its own in vitro never displayed the processivity observed in vivo. But upon form-
ing a dynein-dynactin-adaptor triple complex, the dynein became super processive
and displayed motility characteristics similar to in vivo motors. This is discussed
further in the context of dynein regulation in the following section.
Dynein regulation
The dynein tail is the primary site of regulation for dynein. Regulation of dynein
can be divided into two important aspects. The first applies to all dyneins, and
is concerned with if and how dynein is switched from an active state to an inac-
tive one. As described above, kinesin-1 is capable of autoinhibition via a dramatic
conformational change, and so it is at least plausible that dynein may have a sim-
ilar mechanism. The second aspect, which only applies to dyneins with multiple
functions (and therefore not yeast dynein) is concerned with cargo specificity. In
humans, there are at least 29 different cytoplasmic kinesins, each specialised for its
role as an anterograde MT motor within the cytoskeleton. However, there is only
one cytoplasmic dynein to perform most of the retrograde MT-associated motility
within the cytoskeleton. Therefore, the question arises of how dynein is controlled
to ensure that it always functions with the correct cargo, at the correct place and
at the correct time.
One proposed mechanism for the complete activation/inactivation of dynein is
through differential phosphorylation of specific sites within the dynein tail. An early
study separated two distinct pools of dynein from cow brains and determined their
phosphorylation states. The total cellular pool had a higher degree of phosphoryla-
tion on the DHC than a pool consisting of only anterograde moving dyneins (i.e.,
inactive dyneins being transported by kinesin), suggesting that phosphorylation of
the DHC may be correlated with activation (Dillman & Pfister 1994). Another
study found that Casein Kinase II, which is a highly conserved serine/threonine
kinase, binds to and phosphorylates dynein (Karki et al. 1997). Over the course of
my PhD, three more studies were published, all suggesting regulation of dynein by
differential phosphorylation of the DIC, although some of these proposed changes in
the specific behaviour of dynein rather than a simple activation/deactivation switch
(D. J. Mitchell et al. 2012, Pullikuth et al. 2013 and Blasier et al. 2014).
Another way that dynein may be activated and deactivated is through the pres-
ence of its most important co-factor, dynactin. Dynactin is a 1 MDa, multi-subunit
complex (Fig. 1.12) (Schroer 2004). It has been shown that for in vitro transport
of vesicles, dynein requires dynactin (S. R. Gill et al. 1991). Furthermore, in vivo
experiments suggested that dynactin is required for all of dynein’s cellular functions
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Figure 1.12: Schematic model of the dynactin complex. An overview of the
structure of dynactin, as it was understood when I began my PhD. An Arp1 filament
is capped on either end by two different capping subcomplexes. The shoulder (blue
and purple) contains the largest dynactin subunit, p150Glued, which was thought to
be the primary site of dynein interactions. p150Glued also contains a MTBD at its
tip. Figure reproduced from Schroer 2004 with permission of the author. See Fig.
4.18 for the cryoEM structure of dynactin published in 2015.
(Schroer 1996). Both of these results provide evidence for dynactin as a dynein acti-
vator (in fact this is the origin of its name: dynein act ivator, S. R. Gill et al. 1991).
However, further experiments complicated the matter. For example, recombinant
mammalian dyneins were generally not processive on their own when tested in vitro
and mixing dynactin and dynein together in vitro failed to produce processive mo-
tors, as they did not form a stable complex. As described above, it was only upon
the inclusion of a cargo adaptor, such as BICD2, that a stable complex formed, and a
processive motor could be observed (Schlager et al. 2014 and McKenney et al. 2014).
It is therefore possible that the S. J. King & Schroer 2000 study may have only seen
processive movement because the beads had both dynein and dynactin bound di-
rectly to them and that in reality they were not interacting directly. In contrast
to mammalian dynein, it has long been thought that yeast dynein does not require
dynactin to be processive, although it also displays an increase in processivity when
dynactin is present (Kardon et al. 2009).
There are also many possible mechanisms by which mammalian dynein might
achieve cargo specificity. As mentioned above, in mammalian cells, there are multiple
genes expressed as various isoforms for all but one dynein subunit. So one idea is that
the heterogeneity required for dynein to perform so many different roles comes from
mixing and matching gene products to create different variants of dynein (Pfister et
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al. 2006). Some preliminary work has been done to explore this possibility. Dyneins
that were formed with different DLICs seemed to show some different characteristics;
DLIC1 was important for ER-to-Golgi transport, whereas DLIC2 was important for
recycling endosome distribution and cytokinesis (Palmer et al. 2009). However, the
different DICs seem to be more tissue-specific rather than having separate pools of
distinct dyneins within a single cell (Ha et al. 2008).
Another way that one dynein might be adapted into functionally distinct motors
would be through the binding of different cofactors. In addition to dynactin, dynein
requires various adaptors in order to recruit cargoes, such as BICD and the Rod-
ZW10-Zwilch (RZZ) complex (Kardon & Vale 2009). Therefore, depending on the
adaptor present, dynein might only bind specific types of cargoes. Another impor-
tant complex, made of LIS1 and NUDE or LIS1 and NUDEL, was known to bind
dynein in at least two different places and to have multiple regulatory effects on
the motor (Kardon & Vale 2009). During my PhD, a lot of exciting work has been
published on LIS1. It was first shown that LIS1 acts as a clutch, disengaging the
ATPase activity of the AAA+ ring from the MTBD (Huang et al. 2012). Then, a
cryo-EM structure of LIS1 bound to the motor domain shed light on the mechanism,
which is essentially due to LIS1 binding to the AAA+ ring and sterically blocking
the linker domain from completing its powerstroke (Toropova et al. 2014).
Finally, some results suggest an interesting interplay between different cofactors.
When I began my PhD, the consensus model was that dynactin binds to the N-
terminus of the DIC through its own p150Glued subunit (Schroer 2004). This same
region of the DIC was also thought to bind to the LIS1/NUDE complex. One study
suggested that the dynactin and LIS1/NUDE bind to the DIC in a mutually exclu-
sive way, resulting in a reciprocal regulation between the two co-factors (McKenney
et al. 2011). While we have no evidence to exclude the possibility that the DIC
also binds to dynactin, some of the work I describe in Chapter 4 suggests that there
is another, very prominent dynein/dynactin interface between the Arp1 filament of
dynactin and the DHC N-terminus of dynein (Urnavicius et al. 2015).
Clearly, even at the time that this thesis is being written, the functions of the
dynein tail domain remain poorly understood. Some previously controversial issues
have been resolved, but as is often the case, this only led to more questions. However,
many of the tools that were not available just a few years ago are finally in hand
and ready to be put to use. Therefore it is an exciting time in this important field
as many of the longstanding questions about dynein function are set to be resolved
in the near future.
1.4 Experimental aims of this thesis
The last section of this introduction has provided just a glimpse of the compli-
cated body of knowledge about the dynein tail, resulting from efforts made using a
combination of genetics, biochemistry, structural biology and cell biology. Having
witnessed first-hand how using a recombinant construct of the dynein motor domain
brought such clarity, and ultimately a structure, to a field that had been clouded
by contradictory results, I was inspired to help accelerate the same process in the
dynein tail.
When I began my PhD, there were still no reports of the expression of a re-
combinant minimal dynein tail complex. So my first aim was to develop a strategy
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for the expression and purification of such a complex. My next aim was to char-
acterise this minimal tail complex biochemically, as having an in vitro sample of a
minimal dynein tail would make certain experiments possible that had never been
done before. For example characterising its native phosphorylation state, testing its
stabilty in different buffer conditions and understanding the function of the different
subunits. My final aim was to characterise the minimal tail complex structurally,
using whatever methods would be most suitable. In practice, after trying crystal-
lography on the entire tail complex, I shifted to a negative stain EM approach for
that particular construct. However, I managed to solve the crystal structure of a
smaller piece of the dynein tail. This was the first structure of any part of the DHC
tail, and it played an important role in understanding how dynein binds dynactin.
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Chapter 2
The expression of a minimal
dynein tail complex
2.1 Introduction
The dynein tail is the site of cargo binding and is involved in regulation (Kardon
& Vale 2009). Previously, there was no high-resolution structural information on
the dynein tail. In order to shed light on dynein regulation and cargo binding, my
initial goal was to solve this structure using X-ray crystallography. The primary
prerequisite for this techniques is a large amount of a homogeneous, stable sample
without intrinsic flexibility. This chapter describes my efforts to establish a protocol
for producing such a sample.
Before I began, there were no published methods for purifying the dynein tail
complex separate from the motor domains. Therefore, my first goal was to purify
a minimal dynein tail complex from S. cerevisiae (yeast). I chose yeast because it
had already been established as a useful model system for dynein for the following
reasons. First, genomic modification via homologous recombination is both simple
to execute and extremely reliable. Furthermore, yeast dynein is simpler than mam-
malian dynein both structurally and functionally. In fact, yeast dynein only has one
function, for which it is not essential (Eshel et al. 1993). Therefore, the endoge-
nous dynein genes of yeast are free to be modified using homologous recombination
without causing a deleterious phenotype.
The first tail truncation construct I attempted was unsuccessful, so I took a
step back and first tried to overexpress the full-length dynein complex. Once I
accomplished this, I began truncating the dynein heavy chain (DHC) in search of
a minimal tail complex that would still bind all accessory chains while eliminating
the flexible linker and the motor domains. After finding a suitable truncation of
the DHC, I explored different expression systems, in hopes of increasing yield and
purity. Finally, I screened crystallisation conditions and determined a low-resolution
initial 3D model of the tail complex using negative stain EM.
Some of the initial work on expressing and purifying the dynein complex from
yeast was done in collaboration with Max Schlager (Section 2.2.2). Andrew Carter
constructed the plasmid that expresses the NH truncation in four separate cassettes
(Section 2.2.6). EM data were collected and processed with the help of Linas Ur-
navicius, Andrew Carter helped with manual particle picking (Section 2.2.8) The
remainder of the experiments described in this chapter are my own work.
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2.2 Results
2.2.1 Expression of the dynein tail complex as a polyprotein
I first attempted to express the dynein tail complex using a polyprotein approach
since this technique had proved advantageous for the recombinant expression of
several other complexes (de Felipe et al. 2006, Vijayachandran et al. 2011). The
defining feature of this approach is that the genes coding for all the components of a
complex are fused together to create a single open reading frame (ORF). Individual
genes are separated by short sequences that code for a flexible linker containing the
recognition site for a highly specific protease. Including the gene for the protease
itself at the 5′ end of the ORF ensures that that protease levels are high enough
to cleave the subunits apart either during, or shortly after polyprotein expression.
The primary benefit of using a polyprotein, which was my motivation for using
it to express the dynein tail, is that the stoichiometric expression of all subunits
prevents one subunit from becoming limiting (Chaplin et al. 1999, Lorens et al.
2004). Furthermore, the subunits are translated consecutively by a single ribosome.
I speculated that the resulting temporal and spacial proximity might aid in proper
complex formation, especially when subunits contain inherently disordered regions
that require a binding partner to fold properly.
As this was my first attempt to express the dynein tail recombinantly, I had little
information about where to truncate the DHC. I decided to include the N-terminal
1363 residues since the construct used in the crystal structure of the motor domain
began at residue 1364 (A. P. Carter et al. 2011). Furthermore, an in vivo study had
previously shown that this truncation was viable in yeast cells (Markus et al. 2009).
For the other three subunits, I included the full-length proteins.
I amplified the first 4089bp of DYN1 (which codes for the first 1363aa of the
DHC) and the full-length genes of PAC11, DYN3 and DYN2 (which code for the
DIC, DLIC and DLC, respectively) from genomic DNA of the wild type W303 yeast
strain (CY176, Fig. A.4). As DYN2 contains two introns, I designed primers to
amplify each exon and then stitched them together using a PCR-based approach to
create my own intron-free version of this gene. I also amplified the TEV protease
gene from the Carter lab plasmid p107 (Fig. A.5) and a ZZ-tag from Carter lab
plasmid p61 (Fig. A.5). I then used PCR stitching to link together all of these genes
in frame, with the appropriate linkers, in order to create an 8kb insert. The insert
began with the TEV protease, linked to the ZZ-tag by a TEV cleavage site. The
ZZ-tag was linked to the first 4089bp of DYN1 by a PreScission cleavage site and
then the following three genes were all linked by additional TEV cleavage sites. This
insert was cloned into the pYES2 yeast expression vector (Thermo Fisher Scientific),
which places the inserted cassette under control of the GAL1 promoter (Fig. 2.1).
The polyprotein plasmid was transformed into two yeast strains for expression:
DSY-5 (MoBiTec, CY223 in Fig. A.4) and BCY123 (Nagai lab, MRC-LMB, CY282
in Fig. A.4) and 12L of each strain was grown. The DSY-5 strain grew much slower
than the BCY123 one, taking 48 hours longer to reach the density required for har-
vesting. Furthermore, both resulting pellets were much smaller than expected from
12L of yeast. The DSY-5 pellet weighed ∼ 60g and the BCY123 pellet weighed
∼ 30g, compared to a typical yield of ∼ 150g of yeast from 12L of culture. The
combination of slow growth rates and small pellets suggest that overexpression of
this dynein tail construct may limit cell growth. Nonetheless, a test purification
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Figure 2.1: Schematic diagram of the dynein tail polyprotein plasmid.
The four subunits of the dynein complex were expressed from a single open read-
ing frame and then cleaved apart by the TEV protease that was expressed from
the same mRNA transcript. The open reading frame was preceded by the GAL1
promoter (pGAL1 ) for high level inducible expression and followed by the CYC1
transcriptional terminator (T) for efficient termination of mRNA. The genes were
separated by linker peptides containing TEV cleavage cites (TCS). An N-terminal
ZZ-tag was fused to the DHC by a PreScission cleavage site (PCS).
was performed on each pellet to test whether the complex actually expressed and
if so, whether it could be purified successfully. For this test purification, I followed
a protocol similar to the one used for purification of the yeast dynein motor do-
main (Reck-Peterson et al. 2006). Cell lysate was incubated with IgG beads (GE
Healthcare), which are designed to bind with high affinity to the N-terminal ZZ-tag
of the DHC. After washing away unbound protein, bound protein was released by
PreScission cleavage and the supernatant was collected.
When the samples were concentrated and analysed by SDS-PAGE (Fig. 2.2)
it appeared that the expression and purification were at least partially successful.
Both strains produced a protein that ran at the expected height of the truncated
DHC, but in BCY123 it appears to have remained bound to the IgG beads even
after PreScission cleavage. While there were some very faint bands near where the
DIC and DLIC were expected to run on the gel, there were also several other bands
of similar heights present. Therefore, the identities of these lower-MW bands were
not clear.
From this experiment it wasn’t possible to determine whether the limited, slow
cell growth and low protein yield were due to the polyprotein approach or the some-
what arbitrarily chosen DHC truncation at residue 1363. So I decided to take a
step back and attempt to purify full-length dynein complex before testing DHC
truncations. However, making the polyprotein with a full-length DHC would have
required making the already unwieldy 15kb polyprotein plasmid 8kb larger. So for
the expression of the full-length dynein complex and identification of a suitable DHC
truncation I turned to a different strategy, which avoids the problem of making a
polyprotein on a plasmid altogether by overexpressing the genomic copies of all four
dynein genes.
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Figure 2.2: Gels showing the dynein tail polyprotein purified from both
DSY-5 and BCY123. A) A polyprotein dynein tail was expressed in two yeast
strains, DSY-5 and BCY123. 12L of each strain was grown and the protein was
purified using affinity chromatography and then concentrated and analysed by SDS-
PAGE. The predicted heights for the truncated DHC, DIC and DLIC are indicated
to the right of the gel. The DSY-5 contains a band at the correct height for the
truncated DHC, but its level was low. B) A slurry of the IgG sepharose beads used
in the purification described in A was boiled and the supernatant was analysed
by SDS-PAGE. In addition to the predicted heights for the dynein subunits, the
expected heights for the two IgG subunits are indicated to the right of the gel. Both
samples contain bands at the correct height for the truncated DHC.
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2.2.2 Overexpression of endogenous dynein genes using mul-
tiple GAL1 promoters
Using the commercial yeast expression strain, DSY-5 (MoBiTec, CY223 in Fig.
A.4), as a background strain we replaced the endogenous promoter at the 5′ end
of each dynein gene with a copy of the strong, inducible GAL1 promoter. The
GAL1 promoter is convenient because it is inhibited by glucose, and induced by
galactose, both of which support the growth of yeast. DSY-5 was selected as the
background strain because it lacks two major vacuolar proteases, Pep4 and Prb1,
which increases yield and limits non-specific degradation. It also contains mutations
in four different biosynthetic pathways, leu2, trp1, ura3-52 and his3. This allowed
us to perform homologous recombination in four consecutive steps, using a different
selectable marker for each one. While inserting a GAL1 promoter at the 5’ end of
each dynein gene, we simultaneously reverted one of the biosynthetic pathways back
to wildtype. This provided the selection pressure necessary for picking colonies with
the desired genotype. The GAL1 promoter inserted in front of DYN1 (the DHC
gene) was followed by ZZ-tag, so that it was fused to the DHC N-terminus by a
TEV cleavage site. Each intermediate strain was verified by colony PCR and the
final strain was verified using colony PCR and Sanger sequencing. The resulting
strain is referred to as CY286 (Fig. A.4)(Fig. 2.3).
Figure 2.3: Schematic diagram of CY286, a yeast strain engineered to
overexpress the full-length dynein complex using the multiple Gal1 pro-
moter approach. Using homologous recombination, the promoter for each of the
four dynein subunit genes was replaced by the GAL1 promoter (pGAL1 ) for high
level inducible expression. An N-terminal ZZ-tag was fused to the DHC by a TEV
cleavage site (TCS).
We performed an initial test expression and purification from 2L of culture fol-
lowing the same protocol used above for the dynein tail polyprotein, except we used
TEV instead of PreScission to cleave the protein off of the IgG sepharose beads. I
analysed the purified CY286 sample and a boiled slurry of the IgG sepharose beads
using SDS-PAGE and found that the full length DHC was present in both, but the
other subunits were not clearly visible in this first experiment (Fig. 2.4). The low
level of full-length DHC suggested that even if the other subunits were present in
the sample, they would not be visible since their MWs are several-fold less than
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Figure 2.4: Gel showing a test purification of the full-length dynein com-
plex from 2L of CY286. 2L of CY286 were grown and a small-scale purification
was performed. After TEV cleavage and concentration, the entire sample was anal-
ysed by SDS-PAGE. The purified sample showed a clear band at the expected height
of the full-length DHC, but there were no visible bands at the expected heights for
the other three subunits. After TEV cleavage, a slurry of the IgG sepharose beads
was boiled and the supernatant was analysed by SDS-PAGE. This sample also has
a band at the height expected for the full-length DHC. In addition to the predicted
heights for the dynein subunits, the expected heights for the two IgG subunits are
indicated to the right of the gel.
that of the full-length DHC. Therefore, it was not possible to conclude whether the
entire complex was co-purifying or not.
In hopes of purifying enough protein to see all the subunits clearly on a gel I grew
another 36L of CY286 culture and purified the full-length dynein complex from it.
After TEV cleavage and concentration, there was ∼ 300µL of sample, with a protein
content of ∼ 5mg/mL. I loaded 20µL of this sample into both a 4 − 12% gradient
gel as well as a 12% gel in order to ensure adequate band separation for identifying
the dynein subunits (Fig. 2.5). Both gels showed bands at the expected heights
for the DHC, DLIC and DLC. While there was a band at the height expected for
the DIC, it was much less prominent than the other three. The DIC band was also
more broad than the DLIC band, possibly indicating degradation of the DIC. As
the DLCs only bind the dynein complex through the DIC, it was puzzling how there
could be so much DLC present without a stoichiometric amount of DIC. To confirm
that the bands observed correspond to the dynein subunits, I needed to excise the
bands and submit them for MS analysis. However, as these gels showed that the
sample had several non-specific proteins co-purifying with the dynein, I decided to
first purify the sample further.
In order to achieve the level of purity necessary for MS analysis and to test
32
Figure 2.5: Gel showing a large-scale purification of the full-length dynein
complex from 36L of CY286. 36L of CY286 were grown and a large-scale
purification was performed. After TEV cleavage and concentration, there was ∼
300µL of sample, with a protein content of ∼ 5mg/mL. A) SDS-PAGE analysis of
20µL of the sample using a 4−12% gradient gel. B) SDS-PAGE analysis of 20µL of
the sample using a 12% gel. In both A and B, boxes surround bands that appeared
at the predicted heights of the DHC (cyan), DIC (green), DLIC (yellow) and DLC
(magenta).
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Figure 2.6: The purification of full-length dynein complex from CY286 and
identification of subunits by mass spectrometry. A) Full-length dynein was
purified from 36L of CY286. 50µL of the 5mg/mL sample was loaded on a Superose6
column and 50µL fractions were collected. B) 20µL of each fraction (except for A10
and A11) were analysed by SDS-PAGE. C) The remainder of fractions A5, B7 and
B2 were concentrated and analysed by SDS-PAGE. D) Relevant bands from C were
excised and analysed by MS, confirming the identity of the four dynein subunits.
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whether the dynein complex remains intact after purification, I performed size ex-
clusion chromatography (SEC) on the sample. Using an A¨KTAmicro system, I
loaded 50µL of the 5mg/mL sample on a Superose6 column (GE Healthcare), col-
lected 50µL fractions and then analysed 20µL of each fraction using SDS-PAGE
(Fig. 2.6). The chromatogram shows that in addition to a large aggregate peak
eluting at the void volume of the column (∼ 0.85mL), three other peaks are present,
centred in fractions A5, B7 and B2 (Fig. 2.6A). The A5 peak eluted at ∼ 1.00mL
and overlaps significantly with the aggregate peak. The B7 peak eluted at ∼ 1.65mL
and the B2 peak eluted at ∼ 1.90mL.
I analysed all of the fractions collected except for A10 and A11 using SDS-PAGE
(Fig. 2.6B). It is clear from the gels that the A5 peak contains the full-length
dynein complex, whereas the B7 and B2 peaks consist of various contaminants.
However, the Superose6 column was not particularly well-suited for purification of
this ∼ 1.2MDa complex, as the dynein peak was very close to the void volume.
This means that the fractions containing the full-length dynein complex are likely
a mixture of well-behaved, monodisperse protein and aggregate. Nevertheless, the
column successfully separated the dynein complex from the lower molecular weight
contaminants, which allowed me to identify the components of the complex as well
as the contaminants by MS.
In order to ensure a clean sample, I ran the remainder of the protein from
fractions A5, B7 and B2 on a fresh gel (Fig. 2.6C). The four bands that correspond to
the MWs of the dynein subunits were all clearly visible in the A5 fraction. Therefore,
I excised these bands and submitted them for MS analysis (Fig. 2.6D). I also excised
the most prominent bands in the B7 and B2 fractions and identified them by MS
in order to determine whether they are non-specific contaminants or dynein-related
proteins that co-purified due to a specific interaction. The four bands in the A5
fraction were positively identified as Dyn1 (DHC), Pac11 (DIC), Dyn3 (DLIC) and
Dyn2 (DLC). The bands in B7 and B2 were all identified as other yeast proteins
with no apparent connection to dynein.
Finally, I calculated the yield of full-length dynein from the 36L culture of CY286.
As noted above, the total amount of protein after the TEV cleavage step was ∼
300µL at ∼ 5mg/mL. However, integration of the peaks in Fig. 2.6 showed that
only about 1/3 of the total protein is dynein. Therefore, the final yeild of full-length
dynein from 36L of culture can be estimated as ∼ 0.5mg.
2.2.3 First series of DHC truncations
With a means for expressing and purifying full-length dynein complex, I turned my
attention back toward identifying a DHC truncation that would yield a minimal tail
complex. In the CY286 background, I made a series of C-terminal DHC truncations
by inserting a stop codon into various positions within the DYN1 gene (Fig. 2.7).
In order to accomplish this, I first had to revert CY286 into a uracil auxotroph so
that I could apply a selection pressure to favour clones that successfully recombined.
I removed the functional URA3 gene that we had previously inserted and selected
for clones lacking this gene using plates containing 5-Fluoroorotic acid (5-FOA).
The Ura3 enzyme metabolises 5-FOA into 5-fluorouracil, which is toxic, therefore
growing yeast in the presence of 5-FOA is a way to select for clones that lack the
URA3 gene. Once CY286 was auxotrophic for uracil, I transformed the functional
35
Figure 2.7: Schematic diagram of the introduction of DHC truncations
into CY286. Using homologous recombination, CY286 was reverted back into a
uracil auxotroph by removing the functional URA3 gene that had been inserted
when it was first created. Then, a functional URA3 gene with a stop codon 5’ to
its promoter was targeted to various points throughout the DYN1 (DHC) gene. In
effect, this produced C-terminal truncations of the DHC.
URA3 gene back into the strain, targeting it to various points throughout the DYN1
(DHC) gene. By including a stop codon at the 5’ end of the URA3 promoter, I was
able to effectively truncate the DHC C-terminally at specific positions.
As the literature did not have any reliable descriptions of the DIC and DLIC
binding sites on the DHC, I designed 27 different truncations, spanning a very large
region within the DHC (Table 2.1). The shortest truncation (DHC-A) terminated
after residue 279, which was designed to be too short to bind any other dynein
subunits. The longest truncation (DHC-Ω) terminated after residue 1477, which is
well into the linker domain as shown by the previous motor domain crystal structure
(A. P. Carter et al. 2011). I also specifically included a truncation that terminated at
residue 1363 (DHC-Y), which is equivalent to the truncation I used for the polypro-
tein in Section 2.2.1. The remaining truncations were roughly evenly distributed
over the remaining sequence between residues 279 and 1477.
While designing the truncations, I referred to a document I created in order to
summarise several predictions about this region of the yeast DHC (Figs. A.1 and
A.2) including secondary structure predictions (McGuffin et al. 2000), coiled-coil
predictions (Lupas et al. 1991) and domain boundary predictions (Finn et al. 2013).
Starting just after the beginning of the predicted DHC N1 domain, I introduced a
pair of truncations every few α-helices. The first truncation in each pair was near the
middle of the predicted α-helix and the second was in the predicted loop following
the α-helix. This was done to reduce the likelihood that a single bad truncation due
to local secondary structure would prevent me from finding a more global domain
boundary.
The yeast strain for expressing truncation DHC-C was not completed due to
cloning difficulties, but the other 26 strains were created and verified. I then grew
1L of each of the 26 DHC truncations and performed a small-scale purification for
each pellet. I also grew 1L of CY286 and purified it alongside the truncations as a
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Name Length (aa) MW (kDa) Results
DHC-A 279 31.6 X
DHC-B 288 32.7
DHC-C 466 53.1 X
DHC-D 477 54.5
DHC-E 557 63.9 *
DHC-F 576 66.0
DHC-G 666 76.3
DHC-H 743 85.4
DHC-I 760 87.5
DHC-J 791 90.9
DHC-K 856 98.2
DHC-L 870 99.9 *
DHC-M 954 109.4 *
DHC-N 962 110.5 X
DHC-O 1048 120.7 **
DHC-P 1065 122.7
DHC-Q 1148 132.4
DHC-R 1175 135.4
DHC-S 1239 142.7
DHC-T 1254 144.6
DHC-U 1300 150.0
DHC-V 1310 151.0
DHC-W 1340 154.8 **
DHC-X 1346 155.4
DHC-Y 1363 157.4 **
DHC-Z 1459 169.0 X
DHC-Ω 1477 171.1 **
Table 2.1: List of the first set of 27 DHC truncations. The length in amino
acids and predicted MW after TEV cleavage is shown for each construct. In the
results column, an X indicates a a failed experiment either due to unsuccessful
cloning (DHC-C) or contamination of the truncated construct with full-length DHC
(DHC-A, DHC-N and DHC-Z). * indicates truncations that expressed well enough
to produce a visible DHC band on the gels in Fig. 2.8. ** indicates truncations that
successfully pulled down the DIC, DLIC and DLC.
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Figure 2.8: Test purifications of the first series of DHC truncations. A) 1L
of CY286 and each of the 26 successfully cloned DHC truncations was grown. Small-
scale purifications were performed and the samples were analysed by SDS-PAGE.
DHC-A and DHC-Z were contaminated with full-length DHC, but served as full-
length controls along with the CY286 lane. DHC-E expressed at high levels, but did
not bind any other subunits. DHC-W, DHC-Y and DHC-Ω all produced faint bands
for the truncated DHC, but no other subunits were clearly present. Boxes surround
bands that appeared at the predicted heights of the DHC (cyan), DIC (green), DLIC
(yellow) and DLC (magenta). B) The experiment shown in A was repeated, but
with fewer constructs. DHC-L, DHC-M, DHC-N and DHC-O all produced bands
for the truncated DHC. Only DHC-N and DHC-O produced bands for the accessory
subunits. C) The experiments done in A and B were repeated, but with only four
constructs and 3L of yeast culture for each. DHC-N was contaminated with full-
length DHC. All three accessory subunits co-purified with DHC-O, while none of
them appeared to co-purify with DHC-L or DHC-M.
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full-length control. After TEV cleavage was complete I concentrated each sample
down to ∼ 20µL and loaded the entire sample on a gel for SDS-PAGE analysis (Fig.
2.8A).
Two of the strains (truncations DHC-A and DHC-Z) appear to have been con-
taminated with full-length DHC, since their band pattern looks similar to that of
CY286. The majority of the other constructs did not produce visible bands for any
of the dynein subunits, indicating a failure either to express or to purify. However, a
few constructs did show bands for dynein subunits. DHC-E (557aa) was the shortest
truncation to produce a visible band, and it was almost as prominent as the CY286
DHC band. As the full length DHC is > 7 times the length of DHC-E, this indi-
cates that the yield of DHC-E was roughly sevenfold the yield of CY286. However,
DHC-E did not appear to bind any of the other subunits.
The only other truncations to show DHC bands for this initial experiment were
DHC-W, DHC-Y and DHC-Ω. Each of these three constructs produced weak DHC
bands, but it was difficult to determine whether the other three subunits were present
as the protein levels were low and this high-throughput method of purification is
not stringent enough to remove all background on the gel. In order to reproduce the
original results and improve the signal on the gel, I repeated the experiment using
only half as many constructs. For this second attempt, I included DHC-E, DHC-
W and DHC-Ω, which all produced visible DHC bands previously. I also included
DHC-F to DHC-O as these ten constructs were purified in parallel the first time
and I suspected that the fact none of the ten showed a single dynein band may have
been due to experimental error.
This second batch of constructs reproduced the results described above for DHC-
E, DHC-W and DHC-Ω. More importantly, it revealed four new DHC truncations
that expressed, DHC-L, DHC-M, DHC-N and DHC-O (Fig. 2.8). DHC-L (870aa)
had a very weak band for the truncated DHC and no bands for the other subunits.
DHC-M (954aa) showed a more prominent DHC band, but still no accessory sub-
units were visible. DHC-N (962aa) displayed all four dynein subunits prominently,
however this strain also produced a large amount of full-length DHC, so it is possible
that the accessory subunits were pulled down by this contaminant rather than the
truncated DHC itself. DHC-O (1048aa) was not contaminated by full-length DHC
and still pulled down all of the accessory subunits.
To reproduce these new results, I grew another 3L each of DHC-L, DHC-M,
DHC-N and DHC-O and purified them again. These purifications showed the same
results as above and the gel is more clear (Fig. 2.8C). Therefore, I was able to
conclude that somewhere between residues 954 and 1048 there is a position where
I can truncate the DHC as much as possible while retaining the ability to bind all
accessory subunits. This narrowed down the region where an ideal DHC truncation
for a minimal tail complex might exist from a range of 1198aa to one that is only
94aa.
2.2.4 Second series of DHC truncations
The 94aa region between DHC-M and DHC-O (residues 954 and 1048) is still fairly
large and includes four predicted α-helices and one β-strand (Fig. 2.9). Therefore, I
performed a finer screen of 12 new C-terminal truncations within this region (here-
after referred to as the ”N region”). Using the CY286 background again and the
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Figure 2.9: Secondary structure prediction of N region of the DHC with the
second series of truncations highlighted. E=predicted β-strand, H=predicted
α-helix, turquoise=predicted coiled-coil, red=final residues from the first series of
DHC truncations in this region: DHC-M, DHC-N, DHC-O and DHC-P, green=final
residues from twelve new N region DHC truncations. Note that the new DHC-NB
is equivalent to DHC-N from the first series.
Figure 2.10: Schematic diagram of the fusion of GFP onto the C-terminus
of DHC truncations. Into a strain of CY286 that was auxotrophic for uracil, I
transformed a DNA fragment that contained a GFP followed by a stop codon and
a functional URA3 gene. This fragment was targeted to various points throughout
the DYN1 (DHC) gene, producing truncations of the DHC with a GFP fused to the
artificial C-terminus.
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Name Length (aa) MW (kDa)
DHC-NA 958 109.9
DHC-NB 962 110.5
DHC-NC 968 111.3
DHC-ND 979 112.5
DHC-NE 981 112.7
DHC-NF 990 113.8
DHC-NG 995 114.2
DHC-NH 1004 115.3
DHC-NI 1016 116.7
DHC-NJ 1025 117.8
DHC-NK 1035 119.0
DHC-NL 1063 122.5
DHC-NA-GFP 958 136.9
DHC-NB-GFP 962 137.5
DHC-NC-GFP 968 138.3
DHC-ND-GFP 979 139.5
DHC-NE-GFP 981 139.7
DHC-NF-GFP 990 140.8
DHC-NG-GFP 995 141.2
DHC-NH-GFP 1004 142.3
DHC-NI-GFP 1016 143.7
DHC-NJ-GFP 1025 144.8
DHC-NK-GFP 1035 146.0
DHC-NL-GFP 1063 149.5
Table 2.2: List of the second set of 24 DHC constructs. The length of the
DHC truncation in amino acids and predicted MW of the entire DHC (including
GFP where applicable) after TEV cleavage is shown for each construct.
same strategy used for the first series, I inserted a stop codon into various positions
within the DYN1 gene (Table 2.2). The shortest (DHC-NA) terminated after residue
958, which lies halfway between the original DHC-M and DHC-N. DHC-N (termi-
nating after residue 962) was reproduced in order to eliminate the full-length DHC
contamination in the first series and was renamed DHC-NB. The longest truncation
terminated after residue 1063 (DHC-NL) in order to include the entire predicted
α-helix that runs from residue 1017 to residue 1061 (Fig. 2.9).
I also designed an equivalent construct for each of these truncations that fused
a green fluorescent protein (GFP) C-terminal to the site of truncation. This was to
ensure that if the DHC in a particular truncation was the right length for a minimal
tail complex, any disorder introduced by the truncation itself would be followed by
an ordered protein to help stabilise the protein and prevent it from being targeted
for degradation. In order to accomplish this, after the intended final residue in each
truncation I inserted a GFP gene in frame with DYN1, followed by a stop codon
(Fig. 2.10). These truncations are named DHC-NA-GFP, DHC-NB-GFP, etc.
The yeast strains for expressing DHC-NG and DHC-NF-GFP were not completed
due to cloning difficulties, but the other 22 strains were created and verified. I then
41
Figure 2.11: Test purifications of the second series of DHC truncations.
A) 1L of each N region DHC truncation was grown. Small-scale purifications were
performed and the samples were analysed by SDS-PAGE. DHC-NK was contami-
nated with full-length DHC. All of the N region truncations produced bands for the
truncated DHCs. Some had higher expression levels (e.g., DHC-NH) while others
had lower expression levels (e.g., DHC-ND). The expression levels of the DHC trun-
cation tended to correlate with the amount of accessory subunits that were pulled
down with it. Boxes surround bands that appeared at the predicted heights of the
DHC (cyan), DIC (green), DLIC (yellow) and DLC (magenta). B) As in A, but
with the set of N region truncations that included a C-terminal GFP.
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grew 1L of each N region construct and performed a small-scale purification for
each pellet. After TEV cleavage was complete I concentrated each sample down to
∼ 20µL and loaded the entire sample on a gel for SDS-PAGE analysis. Contrary
to the first round of heavy chain truncations, every one of the 22 new constructs
tested expressed the DHC truncation well enough to see a clear band on the gel
(Fig. 2.11). DHC-NK was contaminated by full-length dynein and was excluded
from further analysis.
My next goal was to test some of the N region constructs using SEC to eliminate
nonspecific proteins, to test the stability each construct and to determine whether
the sample was homogeneous. As 1L of culture did not produce enough protein for
SEC, I began with only 6 constructs, and scaled up the expression of each to 4L. In
order to test the effect of the C-terminal GFP, I used constructs that expressed well
both with and without the GFP. To begin with the three most different N-region
constructs I selected the shortest (DHC-NA), the longest (DHC-NL) and one in the
middle (DHC-NH). For the one in the middle, I chose DHC-NH because it had the
highest expression levels for all subunits as well as lower levels of the background
contaminants (Fig. 2.11A).
I grew 4L of each construct and the proteins were purified as before, except after
TEV cleavage the samples were concentrated to ∼ 50µL and loaded on a Superose6
column using an A¨KTAmicro system (both GE Healthcare). For each construct,
I looked for a peak that eluted between 1.2mL and 1.5mL since this is where a
complex the size of the dynein tail is expected to elute (for clarity, in this section
I refer to any peaks in this range as ”dynein peaks”). I then selected the fractions
that span the dynein peak, pooled them and concentrated them to ∼ 50µL. I did
the same for any other peaks of interest. These concentrated samples were then
analysed using SDS-PAGE and compared to the original samples that were loaded
for each SEC run (labelled as ”Input” in Figs. 2.12, 2.13 and 2.14).
DHC-NA and DHC-NA-GFP
Both DHC-NA and DHC-NA-GFP failed to produce clear dynein peaks. The chro-
matogram for DHC-NA was almost completely flat in the 1.2mL to 1.5mL range
(Fig. 2.12A), whereas DHC-NA-GFP had an increase in UV absorbance, but not
in the form of a prominent, symmetrical peak (Fig. 2.12B). Both constructs had a
very small peak at the void volume and a small, yet distinct peak at ∼ 1.7mL. To
isolate the indistinct dynein peak in the DHC-NA-GFP sample, I pooled fractions
A10-B2. I also pooled fractions B4-B8 in order to isolate the the peak that eluted
at ∼ 1.7mL. Despite DHC-NA’s lack of a distinct dynein peak, I pooled the same
fractions from this sample for a direct comparison with the GFP-tagged version.
SDS-PAGE analysis revealed that both DHC-NA and DHC-NA-GFP retained the
other three dynein subunits at least through the TEV cleavage and concentration
steps prior to SEC (Input, Fig. 2.12). Because the input contained all four dynein
subunits, but fractions A10-B2 contained only DHC, both constructs appear inca-
pable of maintaining an intact complex when subjected to the low concentrations
experienced during gel filtration. The A10-B2 lane in both gels shows a distinct
band for the truncated DHC, but the DIC, DLIC and DLC bands are not present.
The B4-B8 lane in both gels shows that SEC is successful in separating the most
abundant contaminants from the DHC.
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Figure 2.12: Purification of DHC-NA and DHC-NA-GFP by SEC. DHC-
NA (A) and DHC-NA-GFP (B) were each purified from 4L of yeast culture. Both
samples were concentrated to ∼ 50µL. 10µL were reserved as the ”input” sample
and the remainder was loaded on a Superose6 column using an A¨KTAmicro system
(chromatograms). Fractions of interest were pooled (green bars) and concentrated
to ∼ 50µL. Then 10µL of each sample was analysed by SDS-PAGE (gel insets).
Dynein subunits are highlighted in colour-coded boxes.
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Figure 2.13: Purification of DHC-NL and DHC-NL-GFP by SEC. DHC-
NL (A) and DHC-NL-GFP (B) were each purified from 4L of yeast culture. Both
samples were concentrated to ∼ 50µL. 10µL were reserved as the ”input” sample
and the remainder was loaded on a Superose6 column using an A¨KTAmicro system
(chromatograms). Fractions of interest were pooled (green bars) and concentrated
to ∼ 50µL. Then 10µL of each sample was analysed by SDS-PAGE (gel insets).
Dynein subunits are highlighted in colour-coded boxes.
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DHC-NL and DHC-NL-GFP
The chromatograms for DHC-NL and DHC-NL-GFP are similar overall with the
primary difference being that DHC-NL has a sharp, prominent peak at the void
volume whereas DHC-NL-GFP has a very small one (Fig. 2.13). This may indicate
that in the context of the DHC-NL truncation, the C-terminal GFP is effective in
preventing aggregation. Both constructs produced a small, yet fairly symmetrical
dynein peak and an equally small double-peak in the 1.6mL to 2.0mL range. The
dynein peak was isolated by pooling fractions G4-G8 from the DHC-NL run and
fractions F8-G1 from the DHC-NL-GFP run. The double-peak was isolated by
pooling fractions G11-H3 from the DHC-NL run and fractions G4-G8 from the DHC-
NL-GFP run. SDS-PAGE analysis showed that just like DHC-NA and DHC-NA-
GFP, both DHC-NL and DHC-NL-GFP contained all four dynein subunits through
the TEV cleavage and concentration steps (Input, 2.13). In contrast to DHC-NA and
DHC-NA-GFP, the DHC and DLIC are both present in the dynein peak, indicating
the formation of a subcomplex consisting of these two subunits. However, the DIC
and DLC bands are still largely absent from these samples, which may indicate that
the DHC-NL truncation introduces instability into the complex. The double peaks
from both DHC-NL and DHC-NL-GFP contain similar contaminants as the 1.7mL
peak in DHC-NA and DHC-NA-GFP and similarly demonstrates that it is possible
to separate these from the DHC/DLIC subcomplex using SEC.
DHC-NH and DHC-NH-GFP
The chromatograms for DHC-NH and DHC-NH-GFP both contain a sharp, promi-
nent dynein peak and a smaller double-peak that elutes at ∼ 1.7mL (Fig. 2.14). In
a reversal from the trend seen with DHC-NL, DHC-NH-GFP had a large aggregate
peak elute at the void volume, whereas the bare DHC-NH had a very small aggregate
peak. The dynein peaks were isolated by pooling fractions D9-E3 and D3-E8 from
the DHC-NH and DHC-NH-GFP runs, respectively. The double peaks were isolated
by pooling fractions E5-E8 and D11-E1 from the DHC-NH and DHC-NH-GFP runs,
respectively. SDS-PAGE analysis showed that DHC-NH and DHC-NH-GFP also
contained all four dynein subunits after the TEV cleavage and concentration steps
(Input, 2.14). In contrast to the other two truncations tested, the dynein peaks from
both DHC-NH and DHC-NH-GFP retained all four dynein subunits, indicating the
successful purification of a complete dynein tail complex. The double peaks from
both DHC-NH and DHC-NH-GFP contain the same contaminants as observed in
DHC-NA and DHC-NL, demonstrating that SEC is a useful technique for separating
these proteins from the minimal tail complex.
2.2.5 Large-scale production of DHC-NH from CY339 using
a 120L fermentor
As DHC-NH expressed, co-purified with the DIC, DLIC and DLC, and was fairly
pure even after a simple SEC run, it seemed a reasonable target for a first attempt
at solving a structure of the dynein tail complex. However, if I was going to use
X-ray crystallography, the low expression level needed to be addressed. I made
several attempts to improve the expression of DHC-NH from the same yeast strain
(hereafter referred to as CY339, Fig. A.4) by only modifying growth conditions,
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Figure 2.14: Purification of DHC-NH and DHC-NH-GFP by SEC. DHC-
NH (A) and DHC-NH-GFP (B) were each purified from 4L of yeast culture. Both
samples were concentrated to ∼ 50µL. 10µL were reserved as the ”input” sample
and the remainder was loaded on a Superose6 column using an A¨KTAmicro system
(chromatograms). Fractions of interest were pooled (green bars) and concentrated
to ∼ 50µL. Then 10µL of each sample was analysed by SDS-PAGE (gel insets).
Dynein subunits are highlighted in colour-coded boxes.
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such as media composition, growth temperature, density at the point of induction
and length of induction before harvesting. None of these experiments produced any
significant increase in the amount of protein produced per gram of CY339 harvested.
As a short-term solution, I decided to simply grow more yeast, which I hoped would
provide me with enough protein to decide whether this construct was really a good
crystallography target before investing time in more involved strategies for boosting
expression.
Logistically, growing more than 36L of CY339 in shaker flasks was not feasible,
so I used a large fermentor to grow 120L at a time, which simplified the growth and
harvest while quadrupling the amount of yeast per batch. A typical yield from a
36L shaker flask growth was ∼ 1kg wet mass of yeast, while the typical yield from
a 120L fermentor growth was ∼ 4.5kg wet mass.
I performed a large-scale purification of DHC-NH from ∼ 1kg of CY339 grown in
the fermentor. The increase in total protein after the TEV cleavage step allowed me
to introduce an anion exchange chromatography step using a MonoQ column (GE
Healthcare) before the final SEC step. This was not only beneficial for producing a
more pure sample, but also because it allowed me to avoid concentrating the sample
while several contaminants were still present. This second benefit arose because I
could load a large volume of dilute sample onto the MonoQ column, rather than
immediately concentrating it to a volume suitable for SEC. In this way, the dynein
tail was only concentrated once it was fairly clean.
The MonoQ run consisted of a shallow gradient from 20mM KCl to 500mM
KCl over 60 column volumes and produced a prominent peak at a conductance
of ∼ 35mS/cm (Fig. 2.15A,B). The peak began sharply, but had a shoulder that
eluted slightly after and then it tailed off gradually over several column volumes. I
analysed all the fractions that eluted around this peak using SDS-PAGE in order
to determine whether it contained the dynein tail complex, how clean it was, and
whether it remained intact (Fig. 2.15C). The prominent peak contained the dynein
tail complex, and aside from two bands in the 100kDa to 150kDa range and one
band around 75kDa, the sample was already very clean. While the majority of
the complex eluted in the sharp peak, there was still a considerable amount of
the complex eluting as the peak tailed off. The peak’s shoulder was created by
the presence of a ∼ 250kDa contaminant, preventing the inclusion of these later
fractions in the final sample. The complex also appeared robust at 170mM KCl, the
concentration required for elution, since all four subunits eluted together.
I pooled fractions E2-E7 from the MonoQ run, concentrated the sample down
to ∼ 500µL and then loaded it on a Superose6 column for SEC (Fig. 2.16). The
chromatogram revealed a single, prominent, symmetrical peak, which eluted at ∼
12mL (Fig. 2.16A). SDS-PAGE analysis confirmed that the peak consisted of a
very pure, complete dynein tail complex (Fig. 2.16B,C). I pooled fractions B11-B8
and concentrated the sample to ∼ 75µL. This sample had a final concentration of
∼ 5mg/mL, meaning the final protein yield from ∼ 1kg of yeast was ∼ 0.375mg.
I used 10µL of the final sample for SDS-PAGE, in order to confirm the purity
at a higher concentration (Fig. 2.16C). With the remaining 65µL, I set up a simple
PEG3350/pH crystal screen by hand, in order to get a first impression of how this
complex behaves in droplets. The majority of these droplets developed a heavy
brown precipitate, but those with a higher pH and/or lower PEG3350 concentration
remained clear. This indicated that this complex may be a suitable target for
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Figure 2.15: Large-scale purification of DHC-NH using anion exchange
chromatography. DHC-NH was purified from ∼ 1kg of CY339 grown in a 120L
fermentor. After TEV cleavage, the sample was bound to a MonoQ column and
then eluted using a salt gradient. A) The MonoQ chromatogram. UV absorbance
is shown in blue and conductivity is shown in brown, A prominent peak eluted just
before the mid-point of the gradient. B) A closer look at the prominent peak from
the chromatogram in A. The green bar indicates fractions that were pooled for SEC.
C) SDS-PAGE analysis of fractions around the most prominent peaks in A. The
green bar indicates fractions that were pooled for SEC.
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Figure 2.16: Large-scale purification of DHC-NH using size exclusion chro-
matography. DHC-NH was purified from ∼ 1kg of CY339 grown in a 120L fer-
mentor. After TEV cleavage, the sample was bound to a MonoQ column and then
eluted using a salt gradient. A) The MonoQ chromatogram. UV absorbance is
shown in blue and conductivity is shown in brown, A prominent peak eluted just
before the mid-point of the gradient. B) A closer look at the prominent peak from
the chromatogram in A. The green bar indicates fractions that were pooled for SEC.
C) SDS-PAGE analysis of fractions around the most prominent peaks in A. The
green bar indicates fractions that were pooled for SEC.
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crystallography, but the yield remained problematic if I hoped to perform a large
number of crystal screens.
I continued to grow CY339 in the 120L fermentor and performed several large-
scale purifications of the tail complex as described in Section 2.2.5. After several
such iterations, I was able to set up 15-20 crystal screens, none of which produced
any hits. Typically, I was only able to set up three 96-well plates for every kg of
yeast, using 200nL of protein at 5mg/mL per droplet. This made it clear that any
attempt to produce crystals of the dynein tail complex might require a long and
drawn out screening process, requiring much larger amounts of protein than I could
produce using this method. Therefore, while I continued performing these large-
scale purifications from the fermentor growths, I also began cloning new plasmids, in
hopes of finally increasing the yield of protein to a level suitable for crystallography.
2.2.6 Expression of DHC-NH from a plasmid
One possible explanation for the low yield observed when using CY339 is that even
though each of the dynein genes has a strong promoter at its 5′ end, there is only one
copy of each gene per cell. As plasmids provide a means of having multiple copies of
each gene per cell, I decided to express the NH construct using two different plasmid
systems. The first is a return to the polyprotein system described in Section 2.2.1,
but using the DHC-NH truncation. The other was a more conventional approach,
which includes placing each dynein gene in its own expression cassette (complete
with both a promoter and terminator sequence) and then expressing all four cassettes
from a single plasmid.
I also had to consider the different media necessary for these two expression
strategies. CY339 was created using selectable markers, but as the genome itself was
modified, it can be considered a stable strain that requires no selection pressure. On
the other hand, strains expressing plasmids are traditionally grown using a selection
pressure that encourages plasmid retention. However, the media used to exert this
selection pressure are defined, and therefore not as rich in nutrients. This means
there is a possible trade-off between ensuring a high percentage of cells contain the
plasmid and providing the maximal amount of nutrients to all cells. To investigate
this balance, when I first compared plasmid-based expression to CY339, I tested
each strain in both a defined media (Ura-) and a rich media (2xYP).
Polyprotein expression of DHC-NH
To create the NH polyprotein plasmid I first used PCR to linearise the polyprotein
plasmid described in Section 2.2.1. In the process of doing so, I also removed the
necessary base pairs from DYN1 so that only the first 1004 residues of the DHC
would be expressed. Then I ligated this linear fragment back into a circular plasmid
using Gibson assembly (Fig. 2.17).
The polyprotein plasmid was transformed into BCY123 and expressed in shaker
flasks. 1L was grown in Ura- media and 1L was grown in 2xYP. For a direct com-
parison, I also grew 1L of CY339 in each type of media as well. I performed a
small-scale purification on each of the four cell pellets and analysed the samples
using SDS-PAGE directly after TEV cleavage and concentration (Fig. 2.18).
For CY339, 2xYP media resulted in a much higher expression level than Ura-
media. This was expected as there is no need for a selective pressure in this strain,
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Figure 2.17: Schematic diagram of the DHC-NH polyprotein plasmid The
four subunits of the dynein complex were expressed from a single open reading
frame and then cleaved apart by the TEV protease that was expressed from the
same mRNA transcript. Only the part of DYN1 that codes for the first 1004 amino
acids was included. The open reading frame was preceded by the GAL1 promoter
(pGAL1 ) for high level inducible expression and followed by the CYC1 transcrip-
tional terminator (T) for efficient termination of mRNA. The genes were separated
by linker peptides containing TEV cleavage cites (TCS). An N-terminal ZZ-tag was
fused to the DHC by a PreScission cleavage site (PCS).
Figure 2.18: Gels comparing the expression of the NH tail construct from
both CY339 and a polyprotein plasmid in two different types of media.
Both CY339 and BCY123 transformed with the NH polyprotein were grown in
1L of Ura- and 1L of 2xYP media. Small-scale purifications performed and the
concentrated samples were analysed by SDS-PAGE. 2xYP provided a much higher
yield than Ura- when using CY339. However, the yield was roughly equivalent in
both media when using the polyprotein. When comparing CY339 to the polyprotein,
the amount of DHC is comparable, but there is a markedly lower amount of DLC
in the polyprotein samples.
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and 2xYP is much more nutrient-rich than defined media. For the polyprotein
plasmid, the expression is comparable in both media, suggesting a balance between
selective pressure and nutrient availability. As 2xYP showed a clear advantage for
CY339, which does not require any selective pressure, it is likely that a certain
percentage of cells grown in 2xYP did lose the plasmid. But the smaller number of
yeast cells that contained the plasmid in 2xYP must have expressed enough protein
to compensate, as there was as much total protein produced as in Ura-, where it is
assumed that the majority of the cells contain the plasmid. Therefore, at least for
this plasmid system, the media used does not have a large effect on the final protein
yield.
The CY339 and NH polyprotein samples grown in 2xYP appear similar in most
respects. The DHC, DIC and DLIC are present at similar levels in both samples,
with slightly more in the genomic sample. However, there is a clear decrease in the
DLC level when using the polyprotein. This is most likely due to the fact that there
should be two DLCs binding to each DIC and the polyprotein only has one copy of
the DLC gene, enforcing a strict 1:1:1:1 ratio between all four subunits. In conclu-
sion, it seemed that the polyprotein method works for expressing the dynein tail, but
not at the correct stoichiometry. Therefore, I tested another type of plasmid-based
expression strategy to see if this could overcome the problem of stoichiometry.
Expression of truncation NH using multiple cassettes
A plasmid was constructed by Andrew Carter using PCR and Gibson Assem-
bly, which contained four separate expression cassettes, each containing a different
dynein gene preceded by its own GAL1 promoter and followed by its own CYC1 ter-
minator sequence (Fig. 2.19). The cassettes were linked together by 40bp stretches
of unique sequence. Using these unique sequences as primer annealing sites for PCR,
individual cassettes can be amplified, altered, and reintegrated into the plasmid.
This was included in the design in order to make future modification of individual
subunits within the dynein complex more efficient. This plasmid is hereafter referred
to as the NH-MC plasmid.
In order to compare this new NH-MC plasmid with CY339 and the NH polypro-
tein, I grew 1L of each. The two plasmids were transformed into BCY123 for this
experiment. Since the polyprotein plasmid seemed to yield roughly the same amount
of protein regardless of the media (Fig. 2.18), I used 2xYP for all three strains in
this experiment. I performed a small-scale purification on each of the three cell
pellets and analysed the samples using SDS-PAGE directly after TEV cleavage and
concentration (Fig. 2.20).
The yeast strain containing the NH-MC plasmid expressed all four dynein sub-
units at a noticeably higher level than either the genomic expression strain or the
polyprotein plasmid strain (Fig. 2.20). From this point forward, I began using this
plasmid for expressing the tail complex from yeast. I also used it as the background
in which I created further dynein tail constructs, including phosphomutants and
truncations of the DIC and DLIC, as described in Chapter 3.
2.2.7 Expression of truncation NH in Sf9 cells
While the NH-MC plasmid did provide a roughly two-fold increase in expression
levels, this was not a significant enough difference to make crystallography trials
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Figure 2.19: Schematic diagram of the NH-MC plasmid. Each of the four
subunits of the dynein complex was cloned into its own expression cassette, including
both a GAL1 promoter (pGAL1 ) and CYC1 transcriptional terminator (T). Only
the part of DYN1 that codes for the first 1004 amino acids was included. An N-
terminal ZZ-tag (ZZ) was fused to the DHC by a TEV cleavage site (TCS).
Figure 2.20: SDS-PAGE analysis showing the protein yield from CY339,
the NH polyprotein plasmid and the NH-MC plasmid. 1L of CY339, 1L of
BCY123 transformed with the NH polyprotein plasmid and 1L of BCY123 trans-
formed with the NH-MC plasmid were grown in 2xYP. A small-scale purification
was performed on each pellet and the concentrated samples were analysed by SDS-
PAGE. The NH-MC plasmid has a much higher protein yield than the other two
expression strategies.
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any less labour-intensive. Around this time, my colleagues in the Carter lab were
establishing a baculovirus expression facility and beginning to express the dynein
motor domain using this system. They succeeded in obtaining much higher yields of
purified protein per litre of culture than possible with yeast. So I designed a plasmid
that would allow me to express the DHC-NH construct of the yeast tail complex
using the baculovirus system.
The specific expression system I used is called MultiBac (Bieniossek et al. 2008).
This system allows for the expression of multi-subunit protein complexes from a
single baculovirus, which is used to infect insect cells cultured in suspension. All
four dynein genes were synthesised by Epoch Life Science in order to optimise codon
usage for Sf9 cells. As in previous constructs, the DHC had a ZZ tag linked to its N-
terminus for purification. Then, similar to the multiple cassette approach I used in
yeast (Section 2.2.6), each gene was cloned into its own expression cassette, where it
was preceded by a polyhedrin promoter and followed by a SV40 terminator sequence,
and then inserted into the pACEBac1 vector. The polyhedrin promoter is used be-
cause it only becomes active at a very late stage of viral infection, ensuring that
high cell densities can be reached before recombinant expression begins. The com-
plete plasmid was then inserted into the EMBacY baculovirus genome, ultimately
producing a functional baculovirus that was capable of infecting Sf9 cells.
When amplifying the virus for the first time, I collected the cells used to produce
the P2 generation of virus and performed an expression test on them. As a positive
control, I also generated a P2 virus using a motor domain construct (CY184, Fig.
A.4), which was known to express well in Sf9 cells. I briefly spun down 100µL of
each cell suspension and removed the supernatant. Then I resuspended the pellet
in 1X LDS sample buffer, boiled for 5 min and loaded 10µL of this crude lysate on
Figure 2.21: Gel showing expression of NH truncation in crude lysate of
Sf9 cells. A virus known to successfully experess the dynein motor domain and
a virus created for the expression of the NH tail construct were used to infect Sf9
cells. The pellets from the 50mL P2 cultures were collected and lysed and 10µL of
crude lysate was loaded for each sample. Each subunit of the tail complex expressed
above background, suggesting that similar levels of the tail were produced as the
motor domain construct.
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a gel for SDS-PAGE analysis (Fig. 2.21).
As expected, the motor domain construct produced a single band near the
250kDa mark, which was clearly visible above the background proteins in the lysate.
The DHC band from the tail construct is as prominent as that of the motor domain
construct, which suggests that it expressed very well. The DIC, DLIC and DLC
bands are also all clearly visible above the background when compared to the motor
domain lane of the gel. From ∼ 100µL of Sf9 cell culture, there was almost as much
tail complex present in the lysate as there typically is from 1L of yeast culture, indi-
cating that expression is a few orders of magnitude higher in insect cells. This large
increase in the relative amount of dynein tail in the crude lysate not only suggested
that I might be able to get a much higher yield overall, but also that it would be
significantly easier to separate the dynein tail from impurities. Therefore, I began
to scale up the expression of this construct using Sf9 cells and performed a test
large-scale purification from 3L of cell culture.
This large-scale purification was done using the same buffers and protocol as the
large-scale purification from yeast, except cell lysis was performed manually using
a tissue homogeniser. The MonoQ chromatogram showed a similar pattern as the
sample purified from large amounts of yeast except for one clear difference. The
Sf9 sample showed a large increase in UV absorbance immediately after sample
loading was complete and the column was washed in low salt buffer (Fig. 2.22). By
comparing the ratio of absorbance at 280nm and 260nm, I was able to determine that
this peak is due to nucleic acids (most likely RNA) eluting off of the column rather
than protein. I confirmed this by analysing a sample from this peak using SDS-
PAGE. The fractions from this RNA peak produced no bands on the gel despite
having a UV absorbance at 280nm several times higher than that of some other
fractions that produced clear protein bands on the gel. The dynein peak, which
elutes at∼ 30mS/cm looked very similar in shape to the one observed when purifying
the tail complex from 1kg of CY339 (Fig. 2.15, but had a slightly larger amplitude.
Therefore, even at this stage of the purification, it was clear that from just 3L of
Sf9 cells (which produced a ∼ 45g pellet) it was possible to produce more protein
than I was able to get from a 1kg yeast pellet.
SDS-PAGE analysis of the fractions that eluted during the dynein peak revealed
that the dynein tail complex was present, intact and relatively pure. I pooled frac-
tions D2-E4, concentrated them to ∼ 500µL and ran the sample over a Superose6
column. Once again, the chromatogram was very similar to the one produced from
the yeast purification (Fig. 2.23A), producing a single prominent and symmetrical
dynein peak. The input for this SEC run and the individual fractions from the peak
were analysed by SDS-PAGE, which showed a very pure and complete dynein tail
complex (Fig. 2.23B).
The final yield of dynein tail from 3L of Sf9 cells was ∼ 0.5mg, which is com-
parable to the typical yield from 1kg wet mass of yeast. As expression in Sf9 cells
finally provided a much higher yield of the dynein tail, I continued crystal screening
using this sample. By performing dynein tail purifications from 6L of Sf9 cells at a
time, I was routinely able to obtain 2mg to 3mg of sample after the MonoQ step.
However, when concentrating this sample for the subsesquent SEC step, the protein
often precipitated out of solution and formed a slimy, white solid, which could not
dissolve back into solution. This seemed to occur whenever the concentration of
dynein tail exceeded ∼ 5mg/mL. SDS-PAGE analysis of the precipitate confirmed
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Figure 2.22: Anion exchange chromatography of the dynein tail complex
from Sf9 cells. 3L of Sf9 cells infected with the NH tail virus were harvested and
a large-scale purification was performed using a similar protocol to the one used
for CY339. A) The anion exchange chromatography chromatogram shows a similar
profile as in Fig. 2.15, suggesting the sample behaved similarly to the equivalent
construct expressed from yeast. One clear difference is the large amount of nculeic
acid that eluted off the column during the pre-gradient wash. B) A closer look
at the dynein peak. The green bar indicates the fractions that were pooled and
concentrated for SEC.
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Figure 2.23: Size exclusion chromatography of the dynein tail complex from
Sf9 cells. The dynein tail complex was purified from 3L of Sf9 cells. After anion
exchange chromatography, the dynein peak was pooled, concentrated and loaded on
a Superose6 column. A) The chromatogram shows that a single, symmetrical peak
eluted at a similar volume as when the dynein tail was purified from yeast. The green
bar indicates fractions that were analsyed by SDS-PAGE. B) SDS-PAGE analysis
comparing the input to the peak fractions for the SEC run. The gel revealed that
the dynein complex was intact and that SEC successfully removed any contaminants
that remained after the anion exchange step.
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that it contained the dynein tail. As this is not typically a characteristic associated
with proteins that are likely to crystallise (indeed, none of the screens I managed
to set up produced any promising hits), I spent a considerable amount of time and
effort trying to understand the cause of this precipitation, and to remedy it. Those
attempts to improve the behaviour of this protein sample are the focus of Chapter
3. However, as single particle EM requires only a dilute sample, I was already able
to begin exploring this other powerful structural technique immediately.
2.2.8 Negative stain EM of truncation NH
To produce the sample used for EM, I repeated the purification described in Section
2.2.7 using 6L of Sf9 cells. The SEC fraction with the most pure sample (B10, Fig.
2.24) was concentrated to ∼ 0.16mg/mL, which is equivalent to ∼ 350nM for this
construct. I made a series of dilutions, to produce samples at 50nM, 20nM and
10nM. Linas and I made several negative stain grids using all three of these sample
concentrations. We then screened them in the microscope and determined that the
optimal concentration, which gives a good distribution of single particles on the grid
was 20nM.
Using one of these grids, I collected 200 micrographs, one of which can be seen
in Fig. 2.25A. Then Andrew and I picked ∼ 10, 400 particles manually. A 2D
classification was used to sort the particles into 50 2D classes (Fig. 2.25B). Even a
cursory glance at the 50 classes is enough to get a sense of the tail structure (Fig.
2.25C,D,E,F). In many classes, the complex is clearly divided into two equal halves,
which is expected since the tail complex contains a dimer of each subunit (Fig.
2.25C). Going along the long axis of each monomer, there are three distinct domains
(Fig. 2.25C,D,E,F). Two of the three appear quite rigidly attached to each other,
and to their dimer partners. In some classes, the third domain is tightly dimerised
(Fig. 2.25C), while in other it appears flexible enough that the two monomers are
completely separate (Fig. 2.25F), suggesting that in this part of the complex there
is some inherent flexibility. The 50 2D classes offer several different views of the tail
complex, which allowed us to calculate an initial 3D model. We refined the initial
3D model and performed a 3D classification to separate the particles into 5 distinct
3D classes, one of which is shown in Fig. 2.25G.
Figure 2.24: Gel showing sample used to make EM grids. The NH tail
construct was purified from 6L of Sf9 cells. After SEC, the peak fractions were
analysed by SDS-PAGE and fraction B10 was selected for further study by negative
stain EM.
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Figure 2.25: A low-resolution structure of the dynein tail as determined by
negative stain EM. Negative stain grids were made using the dynein tail complex
purified from Sf9 cells. 200 micrographs were collected, and ∼ 10, 400 particles were
picked manually. The particles were sorted into 50 2D classes, which were used to
calculate an initial 3D model. A) Representative micrograph. B) 2D classes. Most
appear to be various views of the same structure, but some may be contaminants
or disordered complexes. C,D and E) Three 2D classes that offer different views
of the same structure. C is a front view, E is a side view and D is somewhere in
between. In all three classes, the dotted red lines separate the three distinct domains,
which are labelled Top, Middle and Bottom. In C, a green dotted line divides the
two halves that appear roughly equal in size. F)A view similar to C, but with the
top domain dissociated. Several 2D classes in B show the top domain in a tightly
dimerised conformation, while others show it in this open conformation. G) One
3D class from the refined 3D reconstruction. The three domains are labelled, but
the top domain is missing due to its flexibility. H) Schematic diagram of the dynein
tail based on the negative stain model as well as data described in chapter 4.
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2.3 Discussion
2.3.1 Overexpression of a recombinant full-length dynein
complex
The earliest in vitro studies of cytoplasmic dynein relied on a microtubule affin-
ity purification (Paschal et al. 1987). Several years later, it became possible to
overexpress mammalian DHCs recombinantly (Mazumdar et al. 1996). This even-
tually led to the introduction of modifications, such as those used to create minimal
motor constructs of the S. cerevisiae DHC used in motility assays (Reck-Peterson
et al. 2006) and structural studies (A. P. Carter et al. 2011). However, studies of
the full dynein complex remained constrained by the endogenous expression levels
of the dynein subunits. The yield from these techniques was enough for western
blots and motility assays (Kardon et al. 2009), but nowhere near abundant or pure
enough for structural studies. Here, I have presented the first successful strategy for
co-overexpressing all known subunits of a recombinant full-length dynein complex.
This is useful in its own right, as a means of producing larger amounts of high-
purity dynein for motility assays, biochemical studies and even structural studies.
Furthermore, it provided a background in which many other dynein constructs have
been created.
2.3.2 Description of a minimal tail complex: truncation NH
Taking advantage of the ability to overexpress the full dynein complex, I made sev-
eral DHC truncations and ultimately found one that eliminates the flexible linker
while retaining all four dynein subunits. This was the first time a dynein tail com-
plex was overexpressed recombinantly and the first report of a pure in vitro sample
containing the isolated tail region of dynein. The ability to purify the dynein tail
complex, along with the freedom to define and modify the components of the com-
plex was an important step in understanding its function and structure. In addition
to providing the requisite sample for structural studies it opened the door to myr-
iad biochemical experiments, such as well-controlled binding assays with known
interactors, discovery of unknown interactors via co-immunoprecipitation, and char-
acterisation and manipulation of post-translational modifications. I took advantage
of this myself and some of these biochemical experiments are described in Chapter 3.
Furthermore, the NH truncation I discovered in yeast has already been used by Max
Schlager to guide the creation of a similar human tail construct (discussed further
in Chapter 4). Since the alignment between these two species is fairly clear in the N
region of the DHC, he designed a human version of the dynein tail complex without
the need to tediously screen dozens of DHC truncations (Fig. A.3). This human
version of the NH truncation ultimately proved useful for structural studies that are
described in Chapter 4.
Some surprising observations
Even the process of defining this truncation resulted in some unexpected observa-
tions that are interesting in themselves. The first of these arose when making the
first series of DHC truncations (Section 2.2.3). Previous studies had suggested that
the DIC binds between residues 446 and 701 of the R. norvegicus DHC and residues
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629 and 730 of the D. discoideum DHC (Habura et al. 1999, Tynan et al. 2000)
and that the DLIC binds between residues 649 and 800 of the R. norvegicus DHC
(Tynan et al. 2000). Given this information, I expected to see some shorter DHC
truncations that bind the DIC and not the DLIC. Strikingly, there was a difference
of only 94aa between the longest S. cerevisiae DHC truncation to bind no accessory
proteins (truncation M, 954aa) and the next truncation (truncation O, 1048aa),
which bound all accessory proteins (Fig. 2.8C). One possibility is that the DIC and
DLIC binding sites are spatially separated from each other, but the entire region of
the DHC needed for binding both can be destabilised by truncations. If truncating
the DHC within this region disrupts it to the point that the protein is targeted
for degradation, this would also explain the observation that between truncation
E (557aa) and truncation L (870aa) no truncations expressed well enough to be
visible on a gel (Fig. 2.8B). Some evidence in support of this model arose from a
very recent study, which used negative stain EM to suggest that the DIC and DLIC
are not adjacent when bound to the DHC (Chowdhury et al. 2015). However, this
study was done using bovine dynein, and it is also possible that there are substantial
differences between mammalian and yeast dynein.
The second unexpected observation was made when performing SEC on selected
constructs from the second series of DHC truncations (Section 2.2.4). It was already
known that treating the dynein complex with the chaotropic salt potassium iodide
dissociates it into two distinct subcomplexes (S. Gill et al. 1994). One subcomplex
consists of the DLICs and DHCs while the second contains the DLCs and DICs.
Furthermore, it was shown that the DLIC is very tightly bound to the DHC and
that this subcomplex is highly unstable due to the absence of IC. (S. J. King et al.
2002). In light of all this, the way that truncations NA, NL and NH behaved over
gel filtration was intriguing.
First, it is worth noting that NA, NL and NH (as well as the equivalent trun-
cations fused to a C-terminal GFP) all retained the DIC, DLIC and DLC through
TEV cleavage and concentration, but some of these constructs lost subunits when
run over a SEC column (Figs. 2.12, 2.13, and 2.14). For example, both NA and
NA-GFP dissociated from all accessory chains completely (2.12). This suggests that
truncation NA (residues 1-958) may contain some of the residues involved in the DIC
and DLIC interfaces, but not all of them. As expected based on previous studies,
the bare NA truncation was not a stable protein, which may be due to its lack of
the DIC’s stabilising influence as reported by S. J. King et al. 2002.
A comparison of the NL and NH truncations is where things become much less
clear. The NH truncation (residues 1-1004) is long enough to bind all accessory
chains and form a stable complex (Fig. 2.14). However, truncation NL (residues
1-1063) only binds the DLIC despite being 59aa longer than truncation NH (Fig.
2.13). It seems that the additional 59aa actually have a destablising effect on the
entire complex and somehow prevent the DIC from binding. In agreement with the
previous subcomplex studies (S. Gill et al. 1994, S. J. King et al. 2002), the complex
formed between truncation NL and the DLIC is more stable than the bare NA
truncation, but still not a very well-behaved protein. Finally, the C-terminal GFP
actually had an opposite effect on truncations NL and NH; its presence resulted in
less aggregation of truncation NL, but more aggregation of truncation NH (Figs.
2.13 and 2.14). A possible explanation is that the additional 59aa on the NL C-
terminus are inherently disordered and the addition of a GFP serves to decrease
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aggregation, whereas the NH truncation is already stable, so fusing on a GFP gets
in the way and induces aggregation. This is why for all future work, I used the NH
construct that lacked the C-terminal GFP.
Suitability of truncation NH for crystallisation trials
When I was finally successful in increasing the yield of truncation NH by expressing
it in Sf9 cells, its suitability as a crystallisation target came under question. The first
warning sign was that the sample was very sensitive and would often form a white,
goopy precipitate if there were air bubbles present during the TEV cleavage step or
when it was concentrated to more than 5mg/mL. Initially, I resolved to simply be
very careful while purifying the delicate sample and set crystal screens at 5mg/mL,
However, when these screens produced no viable hits I began to think about possi-
ble explanations for this problem that might also prevent crystallisation. The most
simple explanation is that the NH truncation is good enough to make a fairly stable
complex, but its C-terminus is still somehow sub-optimal. Furthermore, I had not
yet tried making truncations of the accessory chains, so it is possible that the DHC
truncation is optimal, but the DIC, DLIC or DLC contain inherently disordered
regions that cause the entire complex to aggregate. Truncations of the DLIC and
DIC are described in Sections 3.2.3 and 3.2.4, respectively. Finally, whenever using a
heterologous expression system, it is possible that improper post-translational modi-
fications (PTMs) will arise, which can have a negative effect on protein stability. Sf9
cells are particularly notorious for hyperphosphorylation. I briefly investigated the
native phosphorylation state of the dynein complex, which is described in Chapter
3.
2.3.3 An initial 3D model of the tail complex
Although the NH truncation did not appear suitable for X-ray crystallography, it
did prove a useful sample for negative stain EM. I was able to collect enough single-
particle electron micrographs of the yeast dynein tail to calculate the initial 3D model
presented in Section 2.2.8. This model provides the first 3D structural information
on the tail region of cytoplasmic dynein. Despite being low-resolution, it already
provides some insights into the overall architecture of the dynein tail.
The general shape approximated a rectangular prism with side-lengths that were
roughly 1:2:3 (10nm x 18 nm x 35nm) (Fig. 2.25). The complex was clearly organised
as a dimer of two equal halves, but the resolution was too low to see whether this
is a rotational or translational symmetry. Each monomer could be divided into
three globular domains, with the middle one being the largest of the three. The
”middle” and ”bottom” domains (as labelled in (Fig. 2.25C-G) appear tightly bound
together and have a rigid dimer interface with no conformational changes between
these domains visible in the 2D class averages. Strikingly, the ”top” domain does
adopt a variety of conformations, which are visible in different 2D class averages (Fig.
2.25C,F). In some classes, the two small domains form a tight dimer, appearing more
as one larger globular domain centred on the axis of symmetry. In other classes,
they stretch away from the axis of symmetry, oriented in opposite directions, giving
the complex the appearance that it is ”fraying” at the end.
Without a higher resolution structure or labelling experiments, I was not able
to assign the electron density in the 3D models to specific structures within the tail
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complex. Based on further work carried out by my colleagues and myself (described
in Chapter 4), it later became possible to assign the density. Fig. 2.25H provides
a schematic diagram of the dynein tail organisation, which takes into account data
from Chapters 2 and 4 of this thesis, as well as a recently published paper by
Chowdhury et al. 2015. The crystal structure and cryo-EM maps used to help
determine this model and a further discussion of the organisation of the dynein tail
are included in Chapter 4.
2.3.4 Future directions
While the NH truncation did not prove a promising crystallography target, many
other strategies for getting a useful crystal structure of the dynein tail remained. The
most obvious first step would be to go back and test some more N region truncations
using SEC. I only tested NA, NH and NL, but it is possible that the most similar
truncations to NH (for example NG and NI) would have a slightly more stable C-
terminus and behave better overall in solution. It might also be worth trying to fuse
proteins other than GFP onto the C-terminus and to try including a short flexible
linker between the GFP and the DHC.
Next, as until this point I had only modified one of the four dynein subunits, I
would see if modification of the DIC, DLIC and/or DLC might improve overall com-
plex stability. The DIC is a particularly good candidate for N-terminal truncations
as this region is thought to be important for binding many of dynein’s interaction
partners, and it may be disordered in their absence. Another angle to solve the same
problem would be to co-express some of these known interactors with the dynein
tail, so that they might bind and lock any inherently disordered regions within the
DIC into a more rigid conformation.
Furthermore, I would try to describe the PTMs present in the dynein tail, ex-
pressed from both yeast and Sf9 cells. This would serve two purposes. First de-
scribing the native state of yeast dynein would contribute to a better biochemical
understanding of the dynein tail’s functions. Phosphorylation of both the DIC and
DLIC is thought to be an important part of how mammalian dynein is regulated, so
it would be interesting to see if it plays a significant role in yeast despite the more
limited role of dynein in this organism. And a description of the yeast dynein’s
ubiquitination may shed light on how dynein levels are regulated throughout the
cell cycle, not to mention the potential for finally understanding why it is so dif-
ficult to express dynein at high levels from yeast. Second, it is possible that the
dynein expressed in Sf9 cells has PTMs that are not present in native dynein, or
lacks PTMs which are present in native dynein. This alone may be causing the
solubility problems I observed with the dynein tail.
Finally, after successfully creating negative stain grids using the NH truncation,
a logical next step would be to attempt imaging the same sample using cryo-EM.
Even a modest improvement in the resolution of the 3D structure of the dynein tail
may prove invaluable in understanding the function of this complex better. At the
very least, it might provide useful information for designing future constructs that
could be used for x-ray crystallography.
Together, the NH-MC plasmid that I used to express the dynein tail from yeast
and the plasmid I used for baculovirus expression provide the basic foundation nec-
essary for all of the above experiments. Chapter 3 describes my attempts to carry
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out some of the experiments described above using these two plasmids.
2.3.5 Conclusions
In this chapter I have presented the design, purification and initial characterisation
of a dynein tail complex. This is the first description of a successful attempt to
isolate the dynein tail in vitro. The results presented here have opened the door
to further biochemical and structural studies on this important part of the dynein
complex, which may contribute to a better understanding of both cargo binding
and regulation of dynein. I have also presented the first structural insights into the
overall architecture of the dynein tail, providing a foundation upon which future
structural studies may continue to build.
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Chapter 3
Further biochemical
characterisation of the minimal
dynein tail complex
3.1 Introduction
Although expressing the yeast dynein tail complex in Sf9 cells increased the yield
significantly, the sample often precipitated out of solution during concentration,
making it ill-suited for crystallography experiments. This chapter describes some of
my efforts to improve the stability of the sample using a variety of techniques. It
also describes the tools I developed in order to perform these experiments, which
may be a useful resource for future studies in their own right.
When initially searching for the optimal dynein tail complex in Chapter 2, I
varied only one characteristic of a single dynein subunit, namely the length of the
DHC. Having optimised that one parameter, I broadened my focus to include the
other three subunits, as well as the complex as a whole. These experiments, which
were always done in the context of the minimal tail complex (truncation DHC-NH)
described in Chapter 2, are the topic of the current chapter. First, I addressed
the stability of the complex as a whole by testing various buffer conditions. When
this failed to improve the behaviour of the complex, I addressed each subunit one
by one. I attempted to find another yeast DLC and truncate both the DLIC and
DIC to eliminate inherently disordered regions. I also considered the possibility
that adding yet another subunit, or at least a fragment of one, might improve the
stability of the DIC, and consequently the entire tail complex. I also investigated
the phosphorylation state of the complex as a whole.
Andrew Carter proposed the idea that Tda2 may be a yeast homologue of Tctex-
1 (Section 3.2.2). Carina Motz helped purify the DIC truncations (Seciton 3.2.4).
The remainder of the experiments described in this chapter were my own work.
3.2 Results
3.2.1 Stability of the dynein tail in various buffers
One simple explanation for why a protein might aggregate at high concentrations is
that the buffer conditions are not favourable. In particular, salt concentrations often
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require tweaking as some proteins are most soluble at very low concentrations while
other require a much higher salt level. Until this point, I had always used 150mM
KCl since this is near physiological conditions and worked well for the dynein motor
domain, so I set out to optimise the salt concentration for the dynein tail. One
complication of studying a protein complex is that higher salt concentrations may
disrupt the protein-protein interactions required for complex formation, so I first
performed a simple experiment to determine the salt tolerance of the dynein tail
complex.
I began by performing a standard large-scale purification of the dynein tail from
∼ 1kg of yeast that had been grown in the fermentor. Once the sample was bound
to IgG beads and had been washed in lysis buffer, I divided the beads into 12 equal
parts and put them into separate columns. I then washed each sample with 50mL
of modified TEV buffers, each of which had the same composition except for the
concentration of KCl, which varied from 100mM to 3M. Then I washed each sample
back into standard TEV buffer (150mM KCl), cleaved the samples off of the IgG
beads, concentrated and compared the samples using SDS-PAGE (Fig. 3.1).
Figure 3.1: Stability of the dynein tail complex in various salt conditions.
12 samples of the dynein tail were subjected to various concentrations of KCl and
then analysed by SDS-PAGE. Boxes surround bands that appeared at the predicted
heights of the DHC (cyan), DIC (green) and DLIC (yellow).
There is a clear trend that as the concentration of KCl increases, the amount of
DHC in the sample decreases. This continues up to somewhere between 500mM and
1M. At this point, the amount of DHC remains fairly constant all the way up to 3M,
but there is much less present than at lower salt concentrations. Furthermore, the
amounts of DIC and DLIC rapidly diminish within the 100mM to 500mM range.
Above 500mM there is virtually no DIC or DLIC visible in any of the samples. Even
the 200mM KCl sample appears to have slightly less of the dynein tail complex
than the 100mM one. The effect is not large enough to exclude experimental or gel-
loading error, but it at least suggsets that 150mM KCl may already be approaching
the maximum salt concentration that the dynein tail can tolerate.
The only other major component of TEV buffer is 20mM Tris-HCl (pH = 8.0).
Once I had established the useful range of KCl concentrations, I wanted to test
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whether the Tris itself might be problematic. First, I purified some dynein tail from
yeast and set up a solubility screen using a 96-well plate with various buffers titrated
to different pH ranges. Using a robot to set up droplets with 200nL of sample plus
200nL of buffer, I was able to see how the dynein tail responds to different buffers
and different pHs. The sample was most soluble in Tris-HCl (pH = 8.0) and ADA
(pH = 7.0). So I performed another simple experiment, exactly as described above
except the KCl ranged from 0mM to 500mM and each salt concentration was tested
with both 20mM Tris-HCl (pH = 8.0) and 20mM ADA (pH = 7.0). The samples
were analysed using SDS-PAGE (Fig. 3.2).
Figure 3.2: Stability of the dynein tail complex in varoius salt concentra-
tions and pH values. 12 samples of the dynein tail were subjected to various
concentration of KCl and two different buffers titrated to different pH values before
being analysed by SDS-PAGE.
The most striking result in this experiment is that 0mM KCl results in almost
no protein in the final sample, including contaminants. This is expected as with
no salt in the buffer, the proteins would tend to shield themselves by aggregating
and binding non-specifically to the sepharose resin in the IgG beads. There is
no clear difference between the Tris-HCl sample and ADA sample at any single
salt concentration, suggesting that Tris-HCl is a suitable buffer for the dynein tail.
Interestingly, this experiment did not show as clear of a trend for the DIC and DLIC
to dissociate at higher salt conentrations, although they do still seem to decrease
slightly as the concentration of KCl is increased. One last observation is that the
100mM sample for both buffers has a noticeably higher background of non-specific
proteins. Therefore, after these two experiments, I was unable to find any convincing
reasons to change the TEV buffer from the 20mM Tris-HCl (pH = 8.0) and 150mM
KCl composition I had been using all along.
3.2.2 Tda2: a potential yeast homologue of human Tctex-1
As discussed in Chapter 1 (Section 1.3.2), human cytoplasmic dynein has at least
three distinct DLCs (LC8, Tctex-1 and Roadblock/LC7) bound to each DIC, while
only one DLC is known to exist in yeast (Dyn2). However, there are two DLC
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Figure 3.3: Secondary structure predictions and alignment of Tda2 and
Tctex-1. A) Secondary structure prediction of the yeast protein of unknown func-
tion, Tda2. E=predicted β-strand, H=predicted α-helix. B) Secondary structure
prediction of the human dynein light chain, Tctex-1. Key as in A. C) Align-
ment between Tda2 and Tctex-1 performed in ClustalX and visualised in Jalview
2. Coloured by sidechain character of conserved and similar residues.
Figure 3.4: Gels showing co-expression and purification of the dynein tail
complex with Tda2. A) Gel comparing the crude lysate of Sf9 cells that were not
infected, cells that were infected with a virus encoding the dynein tail complex and
two samples of cells that were infected with different viruses encoding the dynein
tail complex and Tda2. B) Gel comparing the purified dynein tail complex from
cells that did not overexpress Tda2 to two samples that did.
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binding sites present on the yeast DIC, suggesting that there are two DLCs present
for each DIC (Stuchell-Brereton et al. 2011). These two binding sites are found in
a region of the yeast DIC that aligns with the LC8 and Tctex-1 binding sites of
the human DIC. Furthermore, in human cytoplasmic dynein, LC8 and Tctex-1 are
structurally similar and bind the DIC through a similar mechanism, despite being
very different in amino acid sequence (Williams et al. 2007). Previously, these data
were understood by a model that describes two copies of Dyn2 per DIC (Stuchell-
Brereton et al. 2011). However, there were no studies that directly tested this model,
and so it remained possible that there are two distinct DLCs in yeast. This provided
another possible explanation for the aggregation problem observed with the dynein
tail complex described in Chapter 2. Therefore, it seemed worthwhile to search the
yeast genome for any proteins of unknown function that are similar to either the
human Tctex-1 or the yeast Dyn2 in sequence and/or structure.
Andrew Carter performed a search of the S. cerevisiae genome database and
found one promising candidate for a yeast homologue of Tctex-1. The function of
this protein, called Tda2, remains unknown, but its predicted size and pI (14.5kDa
and 4.93, respectively) are similar to those of Tctex-1 (12.5kDa and 5.00, respec-
tively)(Gasteiger et al. 2005). Furthermore, the sequence is predicted to contain a
Tctex-1 domain from residues 42-124 (Finn et al. 2013) and is predicted to have a
secondary structure (McGuffin et al. 2000, Fig. 3.3A,B) and have a 3D fold similar
to Tctex-1 (Kelley & Sternberg 2009). I performed an alignment between yeast Tda2
and human Tctex-1 using ClustalX (Larkin et al. 2007) and visualised the alignment
using Jalview 2 (Waterhouse et al. 2009, Fig. 3.3C). Since all these bioinformatics
techniques indicated a possible relationship between Tda2 and Tctex-1, I cloned a
Tda2 cassette into the plasmid used for baculovirus expression (Section 2.2.6).
After verifying the sequence and amplifying virus, I infected a 50mL culture of
Sf9 cells and co-expressed Tda2 with the dynein tail complex. By analysing a sample
of crude lysate with SDS-PAGE, I was able to confirm the presence of a new protein
being overexpressed, which ran at a height of ∼ 14kDa (Fig. 3.4A). However, after
performing a small-scale purification and analysing the final sample by SDS-PAGE,
the extra band is missing, suggesting that Tda2 does not interact with the dynein
complex (Fig. 3.4B) However, the two bands ran very close together in Fig. 3.4A,
showing some overlap. Furthermore, the DLC bands in Fig. 3.4B ran slightly higher
in the two lanes with Tda2 in the sample. So to test in a more quantitative way, I
determined the ratio of DLC to DLIC in each of the three lanes of 3.4B using Image
Lab (Bio-Rad). The tail only sample had a ratio of 0.93, and the two +Tda2 samples
had ratios of 0.99 (left) and 1.08 (right). The fact that the difference between the
two +Tda2 samples is larger than the difference between the tail only sample and
one of the +Tda2 samples suggests that the variation between all three samples is
within the range of experimental error, and that there is no Tda2 present in any of
the samples.
3.2.3 DLIC truncations
Since the DLCs did not seem to be the subunit responsible for the instability of
the dynein tail complex, I next tried to modify the DLIC. The DLIC was predicted
to consist of a N-terminal G-protein domain followed by an inherently disordered
C-terminus (Perrone et al. 2003 and Finn et al. 2013). Therefore, in the context
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of the DHC-NH minimal tail complex, I attempted to find a C-terminal truncation
of the DLIC that might eliminate its flexible C-terminus while preserving an intact
dynein tail complex.
First, I used a variety of bioinformatics techniques to guide construct design.
To begin, I performed a secondary structure prediction (McGuffin et al. 2000) and
created a document to summarise all my findings (Fig. 3.5). This secondary struc-
ture prediction already shows that the C-terminal 100 residues are predicted to
contain long stretches of sequence with no predicted secondary structure. Next, I
predicted disordered regions (Prilusky et al. 2005), which provided a more specific
region within the C-terminus that is predicted to be disordered (Fig. 3.6). Then
I confirmed the location of the predicted G-protein domain (Kelley & Sternberg
2009), which begins within 30 residues of the N-terminus and ends within the pre-
dicted disordered region. Having narrowed down the region of interest to be between
residues 150 and 312 (the C-terminus) I analysed all possible C-terminal truncations
within this region using PPCPred (Mizianty & Kurgan 2011) to see if any potential
truncations were predicted to be particularly crystallisable.
Using all of the bioinformatics predictions, I designed a series of 20 C-terminal
DLIC truncations (Table 3.1). The shortest (DLIC-A) would terminate after residue
167 and the longest (DLIC-T) would terminate after residue 301. Once I had de-
signed the truncations themselves, I modified the multiple cassette plasmid described
in Section 2.2.6 so that they would each be expressed in the context of the full tail
complex in yeast.
Name Length (aa) MW (kDa)
DLIC-A 167 19.3
DLIC-B 181 21.0
DLIC-C 187 21.8
DLIC-D 196 22.9
DLIC-E 200 23.4
DLIC-F 204 23.9
DLIC-G 206 24.2
DLIC-H 210 24.7
DLIC-I 214 25.8
DLIC-J 222 26.2
DLIC-K 231 27.2
DLIC-L 237 27.8
DLIC-M 242 28.3
DLIC-N 251 29.4
DLIC-O 258 30.3
DLIC-P 268 31.5
DLIC-Q 275 32.4
DLIC-R 282 33.1
DLIC-S 292 34.4
DLIC-T 301 35.4
Table 3.1: List of 20 DLIC truncations. The name, length and predicted MW
after TEV cleavage is shown for each DLIC construct.
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Figure 3.5: Secondary structure prediction of DLIC. E=predicted β-strand,
H=predicted α-helix, green=predicted G-protein domain, yellow=predicted disor-
dered regions, red=last residue in truncations, turquoise=potential phosphorylation
site, blue text=DLIC domain predicted by Pfam.
Figure 3.6: Disorder prediction of DLIC. Red=predicted disordered regions,
green=predicted ordered regions.
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I grew a 1L culture of yeast expressing each of the 20 DLIC truncation constructs
and performed a small-scale purification on each one. Unfortunately, I unknowingly
used a new batch of TEV protease for these purifications, which had not been tested
and was not functional. Since I performed all 20 purifications in parallel, none of
the final samples showed any dynein bands when analysed using SDS-PAGE. Any
constructs that expressed and purified successfully would have remained bound to
the IgG beads as a result of the faulty TEV protease. Due to time constraints, I
never repeated this experiment with functional TEV protease, but these constructs
remain in the Carter lab plasmid database and may be of interest for future studies.
3.2.4 DIC truncations
Similar to the DLIC, the DIC is composed of a highly structured domain and an
inherently disordered region. The DIC is thought to contain a WD40 domain at
the C-terminus (Finn et al. 2013), while the N-terminus was predicted to be largely
unstructured (Barbar 2012). The N-terminus also contains binding sites for other
proteins, including the DLCs and some of dynein’s regulators, such as dynactin
and LIS1/NUDE (McKenney et al. 2011 and Barbar 2012), which may induce a
more structured conformation upon binding. Therefore, while it was predicted to
be unstructured in isolation, it is possible that in cells, the DIC spends the majority
of its time in highly structured complexes with other proteins. At least one example
of this has been clearly shown by solving a crystal structure of two DLCs bound to
a peptide fragment of the DIC, which becomes more structured upon binding the
Figure 3.7: Secondary structure prediction of DIC. E=predicted β-strand,
H=predicted α-helix, yellow=DLC binding sites, turquoise=predicted coiled-coil
and Nip100 binding site, red=first residue in truncations, blue text=predicted WD40
domain.
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DLCs (Williams et al. 2007). Nevertheless, for the purpose of solving a structure
of the minimal dynein tail, a simple solution would be to simply eliminate any
flexible regions entirely. Therefore, at the same time that I was designing the DLIC
truncations, I applied a similar method as the one described above (Section 3.2.3) to
design a series of 21 truncations that, within the context of the minimal tail complex
(DHC-NH) eliminate the N-terminus of the DIC.
Again, I began by performing a secondary structure prediction (McGuffin et
al. 2000) and created a document to summarise all my findings (Fig. 3.7). The
secondary structure prediction shows that residues 170-533 contain only β-strands,
while the majority of the N-terminus is α-helical in structure. The only β-strands
predicted within the N-terminus are the two DLC binding sites, which had already
been mapped to residues 47-54 and residues 77-84 (Stuchell-Brereton et al. 2011).
The secondary structure prediction is in agreement with the Phyre2 alignment,
which predicts that residues 187-507 constitute a WD40 domain (Kelley & Stern-
berg 2009). The disorder prediction (Prilusky et al. 2005) further strengthens the
Figure 3.8: Disorder prediction of DIC. Red=predicted disordered regions,
green=predicted ordered regions.
75
Name First residue MW (kDa) Results
DIC-A 24 57.1
DIC-B 30 56.5
DIC-C 41 55.3 *
DIC-D 44 55.0 *
DIC-E 55 53.8
DIC-F 74 51.6 *
DIC-G 76 51.3 *
DIC-H 85 50.3 *
DIC-I 92 49.5
DIC-J 99 48.6 *
DIC-K 115 47.0
DIC-L 118 46.6
DIC-M 123 46.1
DIC-N 141 44.1
DIC-O 144 43.8 *
DIC-P 165 41.6
DIC-Q 182 39.6
DIC-R 187 39.0
DIC-S 189 38.8
DIC-T 191 38.6
DIC-U 197 37.9
Table 3.2: List of 21 DIC truncations. The N-terminal residue and predicted
MW after TEV cleavage is shown for each DIC construct. In the results column,
*=truncations that expressed and purified well enough to see a clear peak using
SEC.
argument as residues 1-189 are predicted to be largely disordered (Fig. 3.8), whereas
the C-terminal WD40 domain is well structured. A coiled-coil prediction (Lupas et
al. 1991) calculated a very high score for the first 25 residues, which are also thought
to bind to Nip100 (the yeast homologue of mammalian p150Glued), a major dynactin
component (McKenney et al. 2011). Having narrowed down the region of inter-
est to the N-terminal 200 residues, I analysed all possible N-terminal truncations
within the first 200 residues using PPCPred (Mizianty & Kurgan 2011) to see if any
potential truncations were predicted to be particularly crystallisable.
Using the bioinformatics-based predictions in combination with the previously
mapped binding sites for Nip100 and the DLCs, I designed a series of 21 C-terminal
DIC truncations (3.2). In addition to simply eliminating the flexible N-terminus, I
also placed truncations to eliminate the binding sites to Nip100 and/or the DLCs.
The longest truncation (DIC-A) would begin with residue 24 and the shortest (DIC-
U) would begin with residue 197. Once I had designed the truncations themselves, I
modified the multiple cassette plasmid described in Section 2.2.6 so that they would
each be expressed in the context of the full tail complex in yeast.
I grew a 1L culture of yeast expressing each of the 21 DIC truncation constructs
and performed a small-scale purification on each one. Rather than perform SDS-
PAGE immediately after the TEV cleavage step, we first loaded each sample on a
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Figure 3.9: Representative chromatograms of two DIC truncations. A) The
chromatogram for the DIC-A construct, which is an example of a truncation that
failed to produce a peak. B) The chromatogramp for the DIC-C construct, which
is an example of a truncation that produced a peak.
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Superose6 column and performed SEC. Out of the 21 samples tested, 7 produced
peaks in their chromatograms: DIC-C, DIC-D, DIC-F, DIC-G, DIC-H, DIC-J and
DIC-O (Table 3.2, Fig. 3.9). We then concentrated the peak fraction from each of
those 7 truncations and analysed using SDS-PAGE (Fig. 3.10). Truncations DIC-C
and DIC-D, which are only three residues apart, appeared very similar. Aside from
the slightly lower MW DIC, they looked identical to the standard tail complex.
This result is in line with the fact that these two truncations only eliminate the
N-terminal helix, which is thought to bind Nip100. Truncation DIC-F, eliminates
the first of the two DLC binding sites as well, and just as one might predict, the
amount of DLC seen on the gel is reduced significantly. Interestingly, truncation
DIC-G, which is only two residues shorter, seems to lose all but a trace of DLC
binding capacity despite including the entire second DLC binding site. Truncations
DIC-H and DIC-J are visibly shorter and lack both DLC binding sites, and no DLC
is visible on the gel whatsoever. DIC-O looks similar except the DIC is much smaller
as it is 45 residues shorter than DIC-J.
From an analysis of the SEC chromatograms alone, all of the DIC truncations
that produced peaks appeared to be stable, homogeneous samples. Furthermore,
even the shortest of those truncations, DIC-O, eluted where a dimer would be ex-
pected. Although SEC-MALS analysis would provide more confidence in this obser-
vation, it seemed that even those complexes that lacked the DLCs completely formed
stable dimers. The implications of this unexpected observation are discussed further
in the discussion of both Chapters 3 and 4.
Figure 3.10: SDS-PAGE of DIC truncations after SEC. The seven DIC trun-
cations which produced peaks in SEC were compared using SDS-PAGE. The bar on
the right indicates the range over which the various DIC truncations appear. The
DLC disappears as more of the DIC N-terminus is eliminated.
3.2.5 The interaction between dynein and dynactin
Rather than removing it completely, another potential way to stabilise the flexible
N-terminus of the DIC is to bind it to one of dynein’s binding partners. The N-
terminal 25 residues of the yeast DIC were thought to bind Nip100 (McKenney
et al. 2011), the largest subunit of the dynactin complex and yeast homologue of
the mammalian p150Glued. So, I set out to purify yeast dynactin in order to bind
it to and stabilise the dynein tail. This would have also been a more biologically
78
relevant solution than removing the DIC N-terminus since dynactin is known to
be necessary for virtually all of dynein’s cellular functions, but the mechanism by
which dynactin binds dynein was largely unknown. Therefore, any biochemical or
structural information on this interface may have been useful and interesting in
itself.
To obtain dynactin, I used a previously described yeast strain that has a ZZ-
tag fused onto the N-terminus of the Arp10 subunit by a linker containing a TEV
cleavage site (Kardon et al. 2009). This allows endogenous dynactin to be immuno-
precipitated and purified, which was demonstrated to be functional in motility assays
(Kardon et al. 2009). I grew 24L of this strain and harvested when the OD600 was
between 0.8 and 1.0. I performed a large-scale purification using the same buffers
and protocol I use for dynein. After TEV cleavage, I concentrated the entire sample
down to ∼ 20µL and analysed by SDS-PAGE (Fig. 3.11). There were prominent
bands at the expected heights for Nip100, Arp1 and Arp10, as well as a lot of back-
ground on the gel. I cut the entire lane into 30 slices and had each sample analysed
by MS. Each of the known subunits of yeast dynactin was positively identified at
approximately the correct height on the gel for its size. Interestingly, some full-
length DHC was also identified in this sample, indicating that some of the dynactin
remained bound to dynein throughout the purification process.
Figure 3.11: Endogenous yeast dynactin sample used for MS analysis. En-
dogenous dynactin was purified from 24L of yeast and analysed by SDS-PAGE. The
entire gel lane was separated into 30 bands for MS analysis. Black bars to the
right of the gel indicate the approximate width of the bands excised that contained
each dynactin subunit. Even when bands were not visible by eye, the subunit was
detected by MS.
While this seemed a promising way to produce yeast dynactin capable of binding
dynein, the yield was far too low to perform any assays that could detect the inter-
action. One option would have been to insert GAL1 promoters in front of each of
the dynactin genes in this strain, theoretically increasing the yield in the same way
the dynein yield was originally increased. Unfortunately, with seven known dynactin
genes and the possibility that there are others that remain unknown, this seemed
both time-consuming and less than likely to be successful. However, right around
this time a study was published that described a recombinant complex formed be-
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tween small fragments of rat DIC and the rat homologue of Nip100, which is called
p150 (Siglin et al. 2013). Since this interaction was described as robust and of high
enough affinity to be studied in vitro, I decided to make a yeast equivalent of the
p150 fragment.
Figure 3.12: Alignment of rat p150 and yeast Nip100. A somewhat conserved
region of p150 from R. norvegicus and Nip100 from S. cerevisiae was aligned using
Blast. Red=conserved residues (26% within this region), yellow=similar residues
(also 26%), *=indicates the conserved N-terminus of a fragment of p150 that binds
DIC.
I performed an alignment between rat p150 and yeast Nip100 in order to ensure
that I could make an equivalent construct to the fragment used by Siglin et al. 2013
(residues 415-530 of p150). Overall, the fragments contained 52% similarity, and
26% of the sequence which was fully conserved. The N-terminus of this fragment
aligned well to the yeast sequence and it was easy to identify residue 249 of Nip100
as the equivalent of residue 415 of p150 (Fig. 3.12). However, the C-terminus of
the fragment was not as clear, so I made five different fragments, all beginning at
residue 249, but each ending at different points near residue 343 since this was my
best guess as the equivalent of residue 530 in p150 (Table 3.3).
Name Residues MW (kDa) Concentration (mg/mL)
Nip100-A 249-323 8.7 6.6
Nip100-B 249-336 10.2 29.1
Nip100-C 249-343 11.0 4.9
Nip100-D 249-352 12.0 9.7
Nip100-E 249-355 14.6 45.7
Table 3.3: List of five Nip100 fragments. The range of residues, predicted
MW after TEV cleavage and final concentration after purification is shown for each
Nip100 fragment.
Since Siglin et al. 2013 successfully expressed their p150 fragment in E. coli, I
cloned my five Nip100 fragments into a bacterial expression vector. I grew 1L of
each construct and purified all five using affinity chromatography followed by SEC.
After SEC I pooled each peak and concentrated all samples to a volume between
1mL and 2mL. The final concentration of each construct is listed in Table 3.3.
Meanwhile, I performed a standard dynein tail purification from 1L of Sf9 cells
up until the point where the tail was bound to the 2mL of IgG beads in TEV
buffer. I divided the 2mL of dynein-bound beads into 6 tubes, one for each Nip100
construct and incubated with ∼ 1mg of Nip100 fragment. I also did the same
with IgG beads that had been washed into TEV buffer, but never had dynein tail
bound as a control for non-specific binding to the sepharose resin. With all twelve
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Figure 3.13: SDS-PAGE analysis shows that five Nip100 fragments fail to
bind to the dynein tail complex. A) Five different Nip100 fragments and a
buffer control were incubated with bare IgG beads (-) or IgG beads that already
had dynein tail bound (+). After washing the beads, TEV cleavage and concentra-
tion, the samples were analysed by SDS-PAGE. None of the five Nip100 fragments
co-purified with the dynein tail complex. The two prominent bands in every lane are
self-cleaving TEV protease. B) SDS-PAGE analysis performed during the purifica-
tion of the Nip1000 fragments. The lanes labelled in black are the final products of
Nip100 B-E (A was not analysed). The lanes with grey labels show the uncleaved
protein and cleaved lipoyl tag that bound to the Ni-NTA column after TEV cleav-
age. This was eluted and analysed on the gel as well to compare the ratio of cleaved
to uncleaved protein. In the red boxes, Nip100B-E have purified and run at the
expected heights on the gel. Therefore, the failure to see them in A is not due to a
failure to purify the fragments, but rather a failure for them to bind the dynein tail.
samples, I washed the beads to remove unbound protein and then performed TEV
cleavage, concentrated the samples and analysed by SDS-PAGE. The gel shows that
the dynein tail purifications were successful, but none of the Nip100 fragments were
pulled down by the dynein tail or the bare IgG beads (Fig. 3.13).
In conclusion, I was not able to reproduce the results reported by Siglin et al.
2013 in the context of the entire dynein tail complex. There are many reasons why
this might have been the case, including a failure to reproduce the exact constructs,
too low of concentrations to observe a stable complex, inherent differences between
yeast dynein/dynactin and mammalian dynein/dynactin, and steric clashes resulting
from the presence of the entire dynein tail complex. These possibilities are explored
in more detail in the Chapter 3 discussion.
3.2.6 Phosphorylation of the dynein tail
Each time I attempted a new strategy for the expression of the dynein complex, I
verified the presence of all four dynein subunits by MS. There were often peptides
with modifications that are typically introduced during the MS analysis, for example
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carbamylation, acetylation and methylation. I never observed any of these modifi-
cations consistently across different samples, and so I dismissed them as artifacts.
However, every construct that I expressed in yeast produced the same DLIC peptide
showing phosphorylation of residue S278. Since in humans, the C-terminus of the
DLIC is thought to have phosphorylation sites (Dell et al. 2000), I set out to test
whether this might be a relevant phosphorylation site in the yeast dynein tail. My
goals were to confirm a previously unknown phosphorylation site in the yeast tail
and to see whether the phosphorylation state of this site would have an effect on
the stability of the behaviour of the complex in vitro.
I performed two small-scale purifications of the dynein tail complex from yeast
grown in the 120L fermentor. The yeast used for this experiment expressed the
dynein tail using the genomic expression strategy (Section 2.2.2). One purification
was performed as usual. For the other purification, I included Halt Phosphatase
Inhibitor Cocktail (Thermo Fisher Scientific) in the lysis buffer to prevent the de-
phosphorylation of cytoplasmic dynein by phosphatases released from other cellular
compartments during and after cell disruption. After the lysis step, both purifica-
tions were carried out as usual, without Halt included in any other buffers for either
sample. After TEV cleavage and concentration, the +Halt sample was ∼ 1mg/mL
and the -Halt sample was ∼ 1.5mg/mL. Next, I incubated equal amounts of each
sample with Lambda Protein Phosphatase (λPP, New England BioLabs) or ddH2O
to test whether any native phosphorylation that remained could be removed. I then
analysed all four samples using SDS-PAGE. Phosphorylated proteins were imaged
using Pro-Q Diamond Phosphorylation Gel Stain and total protein was imaged using
SYPRO Ruby (both Thermo Fisher Scientific).
The total protein stain revealed that all four samples contained the full dynein
complex and that an equal amount was loaded in each lane of the gel (Fig. 3.14A).
The phosphorylation stain revealed that the Halt cocktail had no effect, since each
of the bands that showed up in + Halt lanes, showed up with an equal intensity
in the - Halt lanes (Fig. 3.14B). However, there were clear differences between
samples treated with λPP and those that were only treated with ddH2O. The most
obvious difference was in the DLIC, which was not unexpected as this is the subunit
that contained the phosphorylated residue in the MS results. The DLIC is clearly
phosphorylated in the water control samples, and the amount of phosphorylation is
markedly decreased in the samples treated with λPP. Although it is less obvious,
the DHC also appears to have some amount of phosphorylation in the water control
samples, which is mostly removed by λPP treatment. The DIC and DLC do not
appear to be phosphorylated at all in any of the samples.
As the DHC showed some evidence of being phosphorylated, I looked back
through all my old MS data, but could not find any evidence for phosphoryla-
tion sites within the DHC. Since the DHC bands in the phosphorylation stained gel
are much weaker than the DLIC bands, it is possible that only a small population
of dynein is phosphorylated on the DHC, and the MS that was performed simply
for identification of proteins was not sensitive enough to detect low levels of phos-
phorylation. However, I did find a previous high-throughput study that identified
thousands of phosphorylation sites within the yeast proteome, including three phos-
phorylation sites in the DHC tail region: S620, T623 and S890 (Holt et al. 2009). In
order to confirm the presence of these specific phosphorylation sites, as well as the
S278 site within the DLIC, I created 12 phosphomutant constructs. I mutated each
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of the four potential phosphorylation sites to alanine (to eliminate phosphorylation
completely) as well as the phosphomimetic amino acids aspartate and glutamate
(Table 3.4).
The mutations were introduced in the same background in which the DLIC and
DIC truncations were made (Sections 3.2.3 and 3.2.4). I verified the sequence and
grew a 1L culture of each. Due to time constraints I was not yet able to perform
a small-scale purification of these constructs, but they remain in the Carter lab
plasmid database and may be of interest for future studies. For example, if a struc-
ture can be determined of the entire dynein tail, it may be interesting to compare
the phosphomutants to test whether they have an observable effect on the overall
conformation. Furthermore, if it becomes possible to reproducibly bind dynein to
various binding partners (e.g., dynactin, Num1, Pac1) it would be interesting to
test whether any of these phospho-sites act as a regulatory switch that prevents or
allows this binding to occur.
3.3 Discussion
In this chapter, I describe several different approaches to improving the stability
and solubility of the dynein tail complex. While some were inconclusive, and others
showed no clear improvement, the experiments were included because they each
contribute either a little more knowledge about dynein or describe constructs that I
created that may be useful to others in the future. Some of the information in this
chapter also becomes more interesting in light of the results I describe in Chapter 4.
3.3.1 The DIC/DLC subcomplex
Perhaps the most intriguing results in this chapter came from the series of DIC
truncations. The fact that several of these constructs were expressed and behaved
well in solution is interesting in itself. I successfully purified dynein complexes that
lack what was thought to be the primary binding site for the dynactin complex. This
makes possible many interesting experiments concerning the interaction between
dynein and its most important regulator.
By removing even more of the DIC N-terminus, I was also able to purify dynein
complexes that have only one of the two DLCs bound, as well as complexes that lack
the DLCs completely. This is relevant for several reasons. First, the fact that the
intensity of the single DLC band in Fig. 3.10 is halved when the first DLC binding
site is removed corroborates the results of the Tda2 experiment and supports the
model that both DLCs are the same protein. Furthermore, a study was published
shortly after I completed this experiment, which presented a crystal structure of a
fragment of the yeast DIC bound to Dyn2 (Rao et al. 2013). However, the DIC
peptide used in the crystal structure corresponds to the C-terminal DLC binding
site (the one that binds LC8 in mammalian dynein). An equivalent peptide for the
N-terminal DLC binding site (the one that binds Tctex-1 in mammalian dynein)
was designed and synthesised, but proved insoluble due to its hydrophobicity (Rao
et al. 2013). Therefore, even after this study, there is no conclusive evidence that
there are two copies of the same DLC (Dyn2) bound to each DIC in yeast dynein.
The Rao et al. 2013 paper also argues that deletion of the DLCs inhibits ho-
modimerisation of the dynein complex and results in a slower motor capable only
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Figure 3.14: Phosphorylation of the dynein tail complex expressed in S.
cerevisiae. Two small scale purifications of the dynein tail complex expressed in
yeast were performed, one with Halt Phosphatase Inhibitor Cocktail in the lysis
buffer and the other without. One sample from each purification was incubated
with buffer (-) and the other was incubated with λ protein phosphatase (λ). All
samples were analysed by SDS-PAGE. * indicates phosphoproteins. A) The gel is
stained with SYPRO Ruby to reveal total protein in the sample. This gel showed
that an equal amount of tail complex had been loaded into each lane. B) The same
gel is stained with Pro-Q Diamond Phosphorylation Gel Stain to reveal phospho-
rylated proteins only. This suggested that DLIC is phosphorylated, and that this
phosphorylation can be partially removed by λ treatment. The DHC may also show
a low level of phosphorylation, which is also decreased after λ treatment, but it is
less clear.
Subunit Mutation
DLIC S278A
DLIC S278D
DLIC S278E
DHC S620A
DHC S620D
DHC S620E
DHC T623A
DHC T623D
DHC T623E
DHC S890A
DHC S890D
DHC S890E
Table 3.4: List of 12 dynein tail phosphomutants. The subunit and specific
point mutation are listed for each phosphomutant.
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of short run lengths. I did not subject any of my constructs to in vitro motility
assays. However, the SEC chromatograms show that the elution volumes of DIC-C
(which retains both DLC sites), DIC-F (which lacks the N-terminal DLC site) and
DIC-G (which lacks both DLC sites) are very similar, suggesting that all of these
constructs homodimerise. So, while I cannot say whether the truncations that lack
the DLCs would have similar motile deficiencies, it seems unlikely that the effects
described by Rao et al. 2013 were due to a failure to homodimerise. One key dif-
ference between their study and mine is that they use full-length DIC and delete
the DLC gene, while I have actually removed the region of the DIC that binds the
DLCs altogether. Therefore, it is possible that the motility defects they observe are
caused by the disordered DIC N-terminus without the stabilising influence of the
DLCs.
The observation that dynein complexes completely lacking DLCs still dimerise
is unexpected as the consensus within the dynein field for the past several years has
been that the primary role of the DLCs is to drive homodimerisation of the dynein
motor (Barbar 2008). While it remains possible that the DLCs play some role in this
process, my results suggest that they are not essential for homodimerisation. Other
experiments I performed, which I describe in Chapter 4, provide further evidence
that the DLCs are not the only part of the dynein complex driving homodimerisa-
tion.
3.3.2 The dynein/dynactin supercomplex
There are several possible explanations for why my attempt to bind Nip100 frag-
ments to the dynein tail failed. The simplest is simply that none of the five fragments
contained the DIC binding site used by Siglin et al. 2013, but this seems unlikely
as the alignment between the rat p150 fragment and yeast Nip100 showed 52%
similarity and 26% identity. It could also have been that the 10:1 ratio of Nip100
fragment:dynein tail that I used was not enough to reach the concentration necessary
for binding. Finally, the fragments may have bound initially only to be removed by
the subsequent washes due to a weak or transient interaction. However, the fact that
some endogenous DHC co-purified with the dynactin complex described above (Fig.
3.11) suggests that the interaction between these two complexes is strong enough to
survive several washes with TEV buffer.
So, how is it possible that the two fragments bind in vitro, but the Nip100
fragment doesn’t bind the whole dynein complex? It could be that a DIC fragment
would have bound the Nip100 fragment, but in the context of the whole dynein
complex the DIC is sterically hindered from interacting unless some other interaction
with dynactin occurs first, i.e. the minimal fragments can bind each other, as can
the full complexes, but the Nip100 fragment cannot bind the full dynein complex.
At this point I felt that any further studies investigating the interaction between
dynein and dynactin would best be done using the full dynactin complex. Since I
was not able to produce this in sufficient amounts, I set this project to the side until
a better way of producing dynactin was available.
Incidentally, some colleagues in the Carter lab successfully purified large quan-
tities of endogenous dynactin from pig brains, which they used to make a super
processive dynein motor (Schlager et al. 2014). They also showed that recombi-
nantly expressed human dynein is not processive, neither on its own, nor after the
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addition of pig brain dynactin. The complex only formed upon the addition of a
third component, a fragment of a cargo adaptor called BICD2. This was quite sur-
prising given the model that had been established in yeast a few years earlier. A
slightly older study showed that endogenous yeast dynein is processive on its own,
but the addition of endogenous dynactin increases the processivity roughly two-fold
(Kardon et al. 2009). These two results seem to show a clear difference between
how the dynein/dynactin supercomplex forms in yeast and mammals. However, the
fact that the yeast components were all purified from endogenous levels of yeast
means that it is possible some third component, like a yeast homologue of BICD2
was co-purified with either the dynein and dynactin. Therefore the mechanism for
how yeast dynein/dynactin is formed, and if it is fundamentally different from the
equivalent mechanism in mammals remains unknown. As a result of further work
on the triple complex formed by pig brain dynactin, recombinant human dynein and
BICD2, we now have a clear picture of how this complex comes together (Urnavicius
et al. 2015). This will be discussed in more detail in Chapter 4.
3.3.3 Future directions
A source of the whole dynactin complex
As the primary obstacle in the way of studying the dynein/dynactin complex was
the limiting amount of dynactin, I would consider producing the full yeast dynactin
complex a priority. Although it has more subunits and a much more skewed sto-
ichiometry than dynein due to the presence of an actin-like filament, I would first
try to apply the same strategies I successfully used for expressing dynein in Chap-
ter 2 to the expression of dynactin. If those methods are unsuccessful, it may also
be possible to develop a higher-throughput protocol for purifying endogenous dyn-
actin from large amounts of yeast. Since yeast is cheap to grow and the IgG beads
used for affinity purification are the most expensive aspect of purifying recombinant
dynein, it might be possible to use an adapted MT-affinity purification, similar to
those commonly used for purifying dynein and dynactin from mammalian tissue.
As I mentioned above, some of my colleagues have already established a protocol
for purifying dynactin from pig brains. So as a last resort, I might test whether pig
dynactin can bind to yeast dynein and see if this helps elucidate any fundamental
differences between the mammalian and yeast dynein/dynactin complexes.
Biochemical and structural characterisation of the DIC truncations
Having only purified each of the DIC truncations once, I would scale up the seven
constructs that produced SEC peaks and characterise them further. The first thing
I would do is perform SEC-MALS to get a more accurate estimate of the MW of
each construct. This would confirm that the constructs that lack the DLCs are still
homodimerising. I would also try to prepare negative stain grids, at least with the
shortest of the constructs that expressed, DIC-O. If I could collect enough images
to create a 3D reconstruction similar to the one I presented in Section 2.2.8, I might
be able to compare the two structures and locate the DIC N-terminus and DLCs
within the dynein tail. Furthermore, in light of the interplay between my data and
the data reported by Rao et al. 2013, I would also be interested in making these
truncations in the background of the full-length dynein so that I could perform
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motility assays with them. Finally, if the DLIC truncation series was tested again,
and some truncations appeared useful for eliminating disordered regions, I would
make a construct that combines the best of the DIC truncations with the best of
the DLIC truncations and screen it for crystallisation.
3.3.4 Conclusions
In this chapter, I successfully identified several DIC truncations that are useful due
to their ability to selectively prevent the DIC from binding to dynactin, or one or
both DLCs. These truncations are important because they shed new light on the
role of DLCs within the dynein complex by providing evidence that the complex can
homodimerise even in the complete absence of DLCs. They may also be useful in fur-
ther dissecting the role of the DIC/Nip100 interface in forming the dynein/dynactin
supercomplex. I also provided evidence for at least one phosphorylation site within
the yeast DLIC at residue S278. At this stage, I began to doubt that the dynein tail
complex was a good crystallography target. So I tried to crystallise one of the other
original DHC truncations, DHC-E, which expressed at a very high level (Section
2.2.3). This is the topic of Chapter 4.
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Chapter 4
The crystal structure of the
dynein heavy chain N-terminus
4.1 Introduction
While attempting to make the full dynein tail complex into a suitable crystallography
candidate, I decided to revisit one of the other DHC truncations described in Chapter
2. This construct, DHC-E, contained only the N-terminal 557 of the DHC, did not
bind any of the accessory subunits and expressed at very high levels. I selected this
construct as a potential crystallography target and ultimately solved its structure.
This chapter describes the process of solving this crystal structure, the first of any
part of the DHC tail region.
The crystals from initial screening were very small and did not diffract to high
resolution, but through optimisation I was able to increase the crystal size and
diffraction power. Since no homology models existed, I screened heavy atoms for
experimental phasing, and ultimately got initial phases from a selenomethionine
derivative. From the initial phases, I obtained an electron density map good enough
to build an initial model, which I used to design new constructs in an effort to
further increase the resolution.
This crystallography project was done in collaboration with Minmin Yu. All
of the construct design, protein expression, protein purification, crystallisation and
model building were my own work. The crystal harvesting, data collection and data
processing were done with Minmin’s guidance.
The crystal structure of DHC-E has been deposited in the PDB with the acces-
sion code 5AFR in connection to the following article:
Urnavicius, L.*, Zhang, K.*, Diamant, A. G.*, Motz, C., Schlager, M. A., Yu,
M., Patel, N. A., Robinson, C. V. and Carter, A. P. The structure of the dynactin
complex and its interaction with dynein. Science 347, 1441-1446 (2015).
Much of the work presented in Section 4.2.8 was carried out by my colleagues,
who were co-authors of the above article. In particular, Linas Urnavicius and Kai
Zhang performed the EM work I describe. My contribution was essential to the
paper as it allowed for the interpretation of a cryo-EM structure that was otherwise
difficult to interpret. I also include figures adapted from those that Linas and Kai
generated, which I indicated by citing Urnavicius et al. 2015 in the figure legends.
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4.2 Results
4.2.1 Purification of DHC-E from Sf9 cells
At the time I decided to revisit expression of the DHC-E construct, I had switched
from yeast to baculovirus expression due to the large increase in expression. So I
had the DHC-E truncation of the yeast DYN1 gene codon optimised for Sf9 cells
and synthesised, and I cloned it into a baculovirus. When generating P2 virus,
I harvested the cell pellet and analysed the crude lysate by SDS-PAGE. The gel
showed a prominent band at ∼ 75kDa, which is close to the predicted MW of DHC-
E when when still fused to its ZZ-tag (Fig. 4.1A). The 75kDa band was much larger
and more intense than any other bands in the lysate of uninfected Sf9 cells.
Figure 4.1: SDS-PAGE analysis of DHC-E expressed in and purified from
Sf9 cells. DHC-E was cloned into a baculovirus and expressed in Sf9, then purified
by affinity chromatography and SEC. A) A crude lysate sample from the p2 gener-
ation, which shows a high level of DHC-E expression above that of all background
proteins in a sample of uninfected Sf9 cells. B) The purified DHC-E after affinity
chromatography, TEV cleavage and SEC. The difference in MW between A and B
is accounted for by the ZZ-tag, which is removed before SEC.
After this indication of high expression levels, I grew 8L of Sf9 cells infected
with the DHC-E baculovirus. The DHC-E protein was easily purified, requiring
only affinity chromatography (with the ZZ-tag), TEV cleavage and SEC to produce
a large amount of highly pure sample (Fig. 4.1B). From 8L of culture, there was
55mg of total protein after TEV cleavage. One caveat is that despite being easy
to purify, only ∼ 10% of the protein was usable after SEC; the other 90% formed
either aggregates or higher-order structures and eluted far earlier than a dimer of
DHC-E would be expected to (Fig. 4.2A). Nevertheless, I pooled and concentrated
the smaller, symmetrical peak that did elute where a dimer was expected, and then
ran it back through the column. There was ∼ 5mg of dimer after the first run,
and I was able to recover nearly 100% of it after the second run (Fig. 4.2B). This
demonstrated that the dimer form of DHC-E is stable in solution and that it is not
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Figure 4.2: SEC of DHC-E purified from 8L of Sf9 cells. DHC-E was purified
from 8L of Sf9 cells and loaded on a Superdex200 for two consecutive runs. A)
Immediately after TEV cleavage, there was ∼ 55mg of protein. After SEC, the
majority of it eluted sa higher-order structures or aggregates. A small peak eluted
at ∼ 180mL, the expected volume for a dimer of DHC-E. B) The dimer peak from A
was pooled, concentrated and loaded on the same column under the same conditions.
There was only ∼ 5 mg of protein left, but the second run had a very high recovery
rate and all 5mg eluted as a dimer again. There was no sign of aggregation or
higher-order structures forming.
in equilibrium with the higher-order species, which most likely form in the cells or
an earlier stage of purification. I concentrated the final product down to 5.3mg/mL
and checked the purity by SDS-PAGE (Fig. 4.1B). The final purity and yield were
high enough that I proceeded to set up some initial crystal screens using this sample.
4.2.2 Initial crystal screens
The MRC-LMB has a dedicated X-ray crystallography suite, which provides more
than 20 distinct screens for protein crystals. These screens are assembled from com-
mercial screens produced by Hampton, Emerald, Jena Bioscience and Molecular
Dimensions. There is a certain amount of overlap between conditions, with several
appearing in more than one LMB screen. However, if all 20 LMB screens are set, this
inherent redundancy can be advantageous as comparing crystals produced in iden-
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Screen/Well Buffer (pH) Precipitant(s) Morphology Diffraction (A˚)
LMB3/A10 0.1M HEPES (7.0) 1.6M (NH4)2SO4 fine needles none
LMB3/B3 0.1M MES (6.0) 2.4M (NH4)2SO4 fine needles 37
LMB3/C12 0.1M Bicine (9.0) 1M LiCl, 10% PEG (MW=6,000) fine needles 9.7
LMB5/G4 0.05M HEPES (7.0) 1.6M Li2SO4, 0.05M MgSO4 thick needles 8.0
LMB9/A9 0.1M Tris-HCl (8.5) 0.2M Li2SO4, 18% PEG (MW=8,000) small nuggets 7.9
Table 4.1: Initial DHC-E crystal hits. DHC-E was purified from 8L of Sf9 cells
and concentrated to 5.3mg/mL. Several 96-well plate LMB crystal screens were set
with 200nL of protein and 200nL of reservoir per droplet. The crystal screens were
set and incubated at 4°C. After 24 hours, the five conditions listed in the table
produced crystal hits. Some crystals from each condition were tested for diffraction
using synchrotron radiation. The conditions, crystal morphology and diffraction
resolution limit are listed for each of the initial crystal hits.
tical or similar conditions can often provide useful insights about which conditions
are truly favourable for a particular protein to crystallise.
Using the DHC-E sample purified from 8L of Sf9 cells, I was able to set up
several of these LMB screens. I used a Mosquito robot (TTP Labtech) at 4°C to
dispense 200nL of protein and 200nL of reservoir solution for each drop. Then I
sealed the plates and incubated at 4°C. Within 24 hours, there were already at least
three different conditions with crystal growth (Table 4.1). The crystals grew over
a wide range of pH values, from 6.0 to 9.0. Most of the conditions had a high
salt concentration as the precipitant, but a couple also used PEG. I allowed the
crystals to grow for several more days to ensure they had equilibrated fully and to
give the crystals time to reach their maximum size. Then I harvested some crystals
from each condition, washed them into a cryo-solution and flash-cooled them in
LN2. I screened the crystals for diffraction using beamline I03 at Diamond Light
Source. The best crystals diffracted to a maximum resolution of 7.9A˚ (Table 4.1). In
conclusion, even from the very first large-scale purification of the DHC-E construct,
I was able to produce diffracting protein crystals. As there were so many variables in
the expression, purification and crystallisation of DHC-E left to optimise, I focused
my attention and efforts toward this project and began by attempting to optimise
the expression.
4.2.3 The expression of DHC-E from E. coli
Although Sf9 cells produced much more protein than yeast, the fact that only 10%
of the DHC-E construct was suitable for crystallisation trials meant that producing
enough sample for crystal optimisation would have been quite labour-intensive and
time-consuming. I was already familiar with a modified pRSET(A) plasmid (Dodd
et al. 2004) that I used to express fragments of Nip100 and other proteins in E.
coli (Section 3.2.5). This plasmid was capable of producing as much as 50mg of
protein per litre of culture for some constructs. Furthermore, the DHC-E construct
contained only a single subunit, which is 557aa in length, so it was well within the
range of what E. coli are typically capable of producing. Therefore, I cloned the
DHC-E fragment into this bacterial expression vector and attempted to express it
in E. coli.
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I purified DHC-E from 6L of E. coli using affinity chromatography and SEC.
From 6L of E. coli, I was able to purify nearly 50mg of pure DHC-E, whereas from
8L of Sf9 cells, the yield was only 5mg. The expression of DHC-E in E. coli avoided
the aggregation problem described in Section 4.2.1. Figs. 4.3A and 4.3B provide
a direct comparison of the two expression systems. The total amount of protein
present in the Sf9 sample (4.3A) is not significantly less than the protein present
in the E. coli sample (4.3B). However, the distribution shifted dramatically so that
there is only a negligible aggregate peak in the E. coli sample, with the majority
of the protein eluting as a dimer. This accounts for the dramatic increase in the
final yield of dimeric DHC-E from E. coli. Figs. 4.3C and 4.2B provide a direct
comparison of the final products after the second SEC run (note the difference in
scale). One possible explanation for the aggregate formation occurring in Sf9 cells
and not in bacteria is that the Sf9 cells may have been putting on unnecessary
post-translational modifications that interfere with protein stability.
With a glut of DHC-E on hand, I not only set the same LMB screens that
produced the initial hits, but all 20 of the LMB screens in duplicate. The first set
was under the same conditions as the initial hits: I used a protein concentration
of 5.3mg/mL, 200nL of protein and 200nL of reservoir per drop, and the plates
were set at 4°C. The second set was under the same conditions except at room
temperature (RT, ∼ 20°C). After 24 hours, 58 of the 1920 conditions screened at
RT and 11 of the 1920 conditions screened at 4°C already had signs of crystalline
growth. The majority of the RT hits and all of the 4°C hits were clusters of fine
needles. However, four of the RT hits produced more three-dimensional, nugget-
shaped crystals that looked similar to the LMB9/A9 initial hits that diffracted to
7.9A˚ (Table 4.1). After one week, there were no visible changes, indicating that
these droplets reached equilibrium within the first 24 hours.
The inherent redundancy within the 20 LMB screens was useful in this case
because the four most promising hits shared certain characteristics, which I was
able to use for crystal optimisation (Section 4.2.4). The most striking similarity
between these conditions was that they all contained 10-20% PEG (MW=8,000).
Many of them also had a salt present at a concentration of 0.2M, although the
specific salt varied from condition to condition. Finally, the formation of crystals
did not appear to be very sensitive to the pH of the reservoir solution as two of the
conditions contained no buffer at all. However, the protein solution itself contained
20mM Tris-HCl (pH=8.0), which may have still buffered the final concentration to a
pH near 8.0. Taking this into account and looking at the buffers present in the other
conditions that produced similar crystals suggested that crystal formation occured
anywhere between a pH of 8.0 and 10.5.
Overall, not only did the expression of DHC-E in E. coli provide a ten-fold
increase in yield while simultaneously reducing the amount of time it takes to express
the construct (24 hours instead of 72), but it unexpectedly solved the aggregation
problem observed when using the baculovirus system. Having optimised both the
expression and purification in one step, I was now able to make large amounts of
DHC-E with ease. By reproducing the initial crystal hits that formed from DHC-
E expressed in Sf9 cells, I showed that the DHC-E expressed in E. coli behaves
similarly. This provided me with the material necessary to attempt the dozens of
different techniques I employed for crystal optimisation. Hereafter, unless otherwise
noted, all DHC-E samples were purified from E. coli.
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Figure 4.3: A comparison of DHC-E purified from 8L of Sf9 cells vs. 6L
of E. coli. DHC-E was purified from 8L of Sf9 cells and 6L of E. coli, then each
was loaded on the same Superdex200 column. A) The same chromatogram from
Fig. 4.2A re-scaled for a direct comparison with B. B) 6L of E. coli produced much
more DHC-E total. Also, the percentage of total protein that remained in the dimer
form was much higher. C) The dimer peak from B was pooled, concentrated and
run over the column again. There is much more protein in this peak than the one
in Fig. 4.2B.
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Screen/Well Buffer (pH) Precipitant(s)
LMB2/H3 0.1M CAPS (10.5) 0.2M NaCl, 20% PEG (MW=8,000)
LMB8/H10 none 0.2M 0.2M Mg(CH3CH2)2, 10% PEG (MW=8,000)
LMB9/A6 none 0.05M (NH4)2SO4, 0.1M Na Citrate, 15% PEG (MW=8,000)
LMB11/F2 0.1M Tris-HCl (8.5) 0.2M Li2SO4, 10% PEG (MW=8,000), 10% PEG (MW=1,000)
Table 4.2: Initial crystal hits reproduced using DHC-E expressed in E.coli.
DHC-E was purified from 6L of E. coli and concentrated to 5.3mg/mL. 20 different
96-well plate LMB crystal screens were set in duplicate with 200nL of protein and
200nL of reservoir per droplet. Each LMB screen was set and incubated once at
4°C and once at 20°C. After 24 hours, 58 conditions produced crystals at 20°C
and 11 produced crystals at 4°C. Of the 20°C hits, four conditions produced large,
nugget-shaped crystals, similar in appearance to those that diffracted to 7.9A˚. These
four conditions are listed in the table, including the composition of each one. One
ingredient that is common to all four conditions is 10-20% PEG (MW=8,000).
Initial condition Across variable Down variable Buffer (pH)
LMB3/C12 0-2.0M LiCl 0-20% PEG (MW=6,000) 0.1M Bicine (9.0)
LMB5/G4 0-2.0M Li2SO4 0-0.5M MgSO4 0.05M HEPES (7.0)
LMB9/A9 0-2.0M Li2SO4 0-30% PEG (MW=8,000) 0.1M Tris-HCl (8.5)
Table 4.3: Optimisation matrices for three initial crystal conditions. A
48-well plate optimisation matrix was designed for each of the three initial crystal
hits that diffracted with sub-nanometer resolution. All three matrices were created
using a Dragonfly robot so that the across variable would increase in even steps
across the six columns and the down variable would increase in even steps across all
eight rows. The buffer was held constant in all 48 conditions.
4.2.4 Crystal optimisation
48-well plate optimisation matrices
With large amounts of highly pure DHC-E finally available, I began a systematic
attempt to improve the diffraction resolution limit of the crystals I had obtained
in the initial screens. Of the three initial hits that were capable of sub-nanometer
diffraction (Table 4.1), one had a high salt concentration (LMB5/G4), one had
a high PEG concentration (LMB9/A9) and one had moderate amounts of both
salt and PEG (LMB3/C12). Using a Dragonfly robot (TTP Labtech) I created
48-well plate optimisation screens from four corner solutions that centred on each
of the three initial hits. Each 48-well plate had eight rows and six columns, so I
varied the concentration of the salt across the columns and the concentration of the
precipitant/second salt down the rows (Table 4.3). All 48 conditions for each plate
had the buffer concentration and pH that was present in the initial hit condition
being optimised since crystals were not pH sensitive (Table 4.3).
I set up the three optimisation matrices in duplicate, once at 4°C and once at RT,
using a Dragonfly robot. Each droplet was set with 500nL of DHC-E (5.3mg/mL)
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Figure 4.4: Preliminary optimisation of DHC-E crystals. DHC-E was purified
from E. coli and concentrated to 5.3mg/mL. The sample was used to screen for
crystals by adding 500nL protein to 500nL reservoir solution from several 48-well
plate optimisiation matrices that were based on initial crystal hits. The crystals
shown were grown in a condition that was similar to the one that produced many
small crystals (0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4, 6.3% PEG (MW = 8, 000,
v/v)). When screened with synchrotron radiation, these crystals diffracted to 6.4A˚.
Measure bar = 100µm.
and 500nL of reservoir solution. The plates were checked for crystal growth after 24
hours and again after one week. The LMB3/C12 and LMB5/G4 screens only pro-
duced needles that were visually indistinguishable from the initial hits. A selection
of needles from both screens were screened for diffraction using the I03 beamline at
Diamond Light Source, but none of them diffracted beyond 8A˚. The 4°C LMB9/A9
screen only produced nugget-shaped crystals that were similar in appearance to the
initial crystal hit and failed to diffract beyond 8A˚. However, the RT screen had a
few conditions that produced crystals that were rod-shaped and more translucent in
appearance than the initial nugget-shaped crystals (Fig. 4.4). When these crystals
were screened using synchrotron radiation, they diffracted to 6.4A˚.
The best diffracting crystals grew in a condition that was identical to LMB9/A9,
except the concentration of PEG (MW=8,000) was reduced from 18% to 6.3% (0.1M
Tris-HCl (pH = 8.5), 0.2M Li2SO4, 6.3% PEG (MW = 8,000)). Interestingly, the
Li2SO4 concentration was already optimal, which is in agreement with the previous
result that almost every hit in the initial screens had a salt concentration of 0.2M,
regardless of the specific salt (Table 4.1). The PEG concentration however, needed
to be much lower, which may have resulted in fewer nucleation events and favoured
crystal growth instead. This would explain why crystals in this optimised condition
were fewer in number, but larger in size than the initial hit (∼ 50µm in the longest
direction compared to∼ 10µm in all directions). Despite being larger than the initial
hit, the crystals produced in this condition were still less than 100µm in their longest
direction, and less than 10 µm in their shortest direction (Fig. 4.4). So, I aimed to
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increase the size even further in hopes that this would also lead to another increase
in diffraction power. From this point on, I focused on the LMB9/A9 condition and
applied a variety of crystallisation techniques in order to decrease the number of
crystals per droplet and increase their size.
Crystal seeding
Phase diagrams are a useful way to illustrate the process of protein crystallisation
by vapour-diffusion and provide a useful background for the theory behind crystal
seeding (Fig. 4.5). When a droplet is first set, if protein and/or precipitant concen-
trations are low enough, the sample exists in a soluble zone (S in Fig. 4.5) below
the saturation point and the protein remains in solution. As the droplet equilibrates
with the higher concentration of precipitant in the reservoir, the concentration of
protein and precipitant both increase, bringing the sample across the saturation
point and into the metastable zone (M in Fig. 4.5). In this zone, the addition of
soluble protein onto existing crystals is favourable, but the more energetically costly
nucleation of new crystals is not yet spontaneous. If the protein and precipitant
concentrations increase further, the sample moves into the labile zone (L in Fig.
4.5), where nucleation of new crystals in spontaneous. Finally, if the protien and/or
precipitant concentrations become too high, the sample moves into the precipita-
tion zone (P in Fig. 4.5). Here, the protein becomes insoluble too quickly for the
formation of ordered crystals and forms amorphous precipitate instead.
Therefore, a common approach for producing larger crystals when small crystals
are readily available is to break up a mature crystal into very small crystal fragments
that are still capable of growing (called seeds), and then transfer them into a new
solution that is within the metastable zone (Asherie 2004, Fig. 4.5C). I already had
the crystals necessary for making seeds, but had not identified a condition suitable
for seeding into, i.e., a condition in the metastable zone. So I set up screens using
conditions similar to LMB9/A9, but with various PEG concentrations, in order to
identify the threshold below which the drops would be in the metastable zone at
equilibrium. Since I planned to use hanging-drop vapour diffusion for seeding, I
identified the threshold using this format. Using 15-well EasyXtal hanging-drop
plates (QIAGEN) I set up a screen where every condition had 0.1M Tris-HCl (pH
= 8.5) and 0.2M Li2SO4 and the concentration of PEG (MW=8,000) ranged from
1.4% to 21% in 1.4% increments (Table 4.4).
Using this screen I set up three droplets for each condition, all on the same screw
cap. I set up each droplet with 1µL of DHC-E (at 5.3mg/mL) and 1µL of reservoir
solution. The plate was set and left to equilibrate at room temperature (∼ 20°C)
for 24 hours and then I examined each droplet for crystal growth and/or precipitate
formation. The droplets remained clear for all PEG concentrations from 1.4% to
8.4%. Several clusters of crystals formed in the droplets that had between 9.8%
and 12.6% PEG. PEG concentrations from 14% to 21% produced only amorphous
precipitate (Table 4.4). The crystals in the hanging-drop format grew larger than
those in the sitting-drop format. Therefore, from this point on I primarily used the
hanging-drop format.
After identifying 8.4% PEG (MW=8,000) as a condition that was potentially in
the metastable zone, I used a reservoir solution with this PEG concentration for two
different seeding techniques. The first technique, called streak seeding, is based on
the direct transfer of very small crystal fragments from a pulverised donor crystal to
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Figure 4.5: Theoretical phase diagrams comparing two crystallisation
scenarios. S=soluble zone, where protein and/or precipitant concentrations are
low enough that protein remains completely soluble and droplets appear clear.
M=metastable zone, where protein is supersaturated enough that crystal growth
is supported, but not nucleation of new crystals. L=labile zone, where protein is
supersaturated enough to favour crystal nucleation. P=precipitation zone, where
protein is so supersaturated that it comes out of solution too quickly to form or-
dered crystals and forms amorphous precipitate instead. A) An ideal scenario for
crystal growth. The red arrows show the droplet becoming supersaturated as it
approaches equilibrium just across the boundary between the metastable and labile
zones. At equilibrium, a few crystal nuclei form, reducing the protein concentration
enough that the droplet passes into the metastable zone where only growth of the
existing crystals can occur. This results in few, large crystals per droplet. B) A
less ideal scenario for crystal growth. As in A, the droplet becoming supersaturated
as it approaches equilibrium, which lies much deeper within the labile zone. As
a result, new crystals will continue to nucleate even as the protein concentration
gradually decreases, resulting in crystals that are greater in number and smaller in
size. C) The idea scenario for an acceptor droplet for seeding. The droplet reaches
equilibrium in the metastable zone, meaning no new nucleation will occur and all
crystal growth will take place on seeds. D) A demonstration of the effects of chang-
ing protein:reservoir ratios when setting up droplets. Each ratio reaches equilibrium
at the same precipitant concentration, but different protein concentrations, which
can cause dramatic changes in crystal nucleation and growth.
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% PEG (v/v) Result
1.4 clear drop
2.8 clear drop
4.2 clear drop
5.6 clear drop
7.0 clear drop
8.4 clear drop
9.8 crystals
11.2 crystals
12.6 crystals
14.0 precipitate
15.4 precipitate
16.8 precipitate
18.2 precipitate
19.6 precipitate
21.0 precipitate
Table 4.4: Screening for the nucleation threshold of DHC-E crystals in
PEG (MW=8,000). I created a screen in a 15-well EasyXtal hanging drop plate
that had 0.1M Tris-HCl (pH = 8.5) and 0.2M Li2SO4 in every condition, but con-
centrations of PEG (MW=8,000) ranging from 1.4% to 21.0%. For each condition,
three droplets were set. Each droplet was set with 1µL of DHC-E (at 5.3mg/mL and
1µL of reservoir solution. The plate was set and left to equilibrate at room temper-
ature (∼ 20°C) for 24 hours and then each droplet was examined for crystal growth
and/or precipitate formation. The highest PEG concentration tested to maintain a
clear drop was 8.4%. Crystals formed between 9.8% and 12.6% PEG. Higher PEG
concentrations produced only amorphous precipitate.
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a droplet that is already in the metastable zone via a cat whisker or similar fibre. I set
up a 15-well EasyXtal hanging-drop plate with all of the wells containing 500µL of
the same reservoir solution, which included 0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4
and 8.4% PEG (MW=8,000). Then I pipetted 1µL of DHC-E and 1µL of reservoir
solution onto the screw caps and sealed them so that the droplets could equilibrate
at RT for 24 hours and reach the metastable zone. After the droplets equilibrated I
smashed some fully-grown crystals using a streak seeding tool (Hampton Research)
and then dragged the fibre once through each equilibrated droplet. I allowed the
plate to incubate at RT for 24 hours and then checked for crystal growth. All of
the droplets contained showers of tiny crystals along the path that the fibre took
through the droplet. Although the amount of seeds on the tool diluted with each
successive droplet, there were never any droplets with large single crystals. The
crystals always grew as clusters of small crystals that were impossible to separate
without damaging them, thus rendering them less useful for X-ray crystallography.
In order to increase control over the number of crystal seeds delivered to the
metastable droplets, I employed another technique that makes use of a tool called a
Seed Bead (Hampton Research). First, I made a 1X seed stock by smashing the crys-
tals from a single droplet using a a mesh LithoLoop (Molecular Dimensions). Then
I pipetted the entire 2µL drop into an Eppendorf tube containing 98µL of reservoir
solution (0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4 and 8.4% PEG (MW=8,000))
and a Seed Bead. Before doing this, I checked that crystal were stable in reservoir
solution overnight. By vortexing this solution for 30 seconds, the bead pulverised
the crystals into tiny seeds. Then I made serial dilutions by pipetting 10µL of the
1X seed stock into 90µL of reservoir solution, and repeating until I had seed stocks
all the way down to a 10-7 dilution.
I set up a 15-well EasyXtal plate with every well containing the same 500µL
8.4% PEG reservoir solution used to make the seed stocks. Then I pipetted 1µL of
DHC-E and 1µL of the various seed stock solutions onto the screw caps. I set up at
least three droplets for each dilution of the seed stock and then sealed the plate so
that the droplets could equilibrate at RT for 24 hours before checking them for any
crystal growth. The 10-6 and 10-7 seed stocks failed to produce any crystals, but
all of the others produced large amounts of very irregular looking crystals in each
droplet. These crystals did not look as ordered as the crystals that grow de novo
and when screened for diffraction using synchrotron radiation, they did not diffract
to better than 15A˚ resolution.
I therefore concluded that seeding was not an effective way to improve the diffrac-
tion resolution limit of DHC-E crystals and focused instead on improving the de novo
crystals. However, in the process of attempting these seeding techniques I did dis-
cover that using the hanging-drop vapour diffusion method produced slightly larger
crystals than the ones I grew using the sitting-drop method and that it was easier
to harvest intact crystals from the 15-well EasyXtal plates than from sitting-drop
plates. I also found a very narrow range of PEG concentrations that promote crystal
growth using this method (9.8% to 12.6%). I incorporated these findings into the
next set of strategies I used to improve the diffraction power of the DHC-E crystals.
Oil vapour-diffusion barriers and protein:reservoir ratios
I attempted several other strategies for improving the quality of the DHC-E crystals.
Some of these strategies include adding various concentrations of glycerol to the
100
10% 30% 50% 70% 90%
0.5 : 1.0 O O O X X
1.0 : 1.0 * * * X X
1.0 : 0.5 * * ** X X
Table 4.5: Oil barriers and protein:reservoir ratios. I created a screen in 15-
well EasyXtal hanging-drop plates that had 0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4
and either 9.5%, 11% or 12.5% PEG (MW=8,000) in all 15 conditions. Two plates
were created for each PEG concentration. Three droplets were set in each screw
cap, following the protein:reservoir ratios indicated on the left. For example, in the
top row, 0.5µL of DHC-E was mixed with 1µL of reservoir solution. One plate for
each PEG concentration was left without adding any oil to the reservoir. The other
plate had 500µL of oil added on top of the reservoir before re-sealing the screw cap.
The oil for each column contained the indicated percentage of paraffin oil, with the
remainder being silicone oil. The plates was set and left to equilibrate at room
temperature (∼ 20°C) for 24 hours and then each droplet was examined for crystal
growth and/or precipitate formation. All 90% droplets and most 70% droplets
dried out completely (X). All 0.5:1.0 droplets remained clear (O). The remaining
conditions all had crystals of some sort (*). The largest crystals were observed in
the 11% and 12.5% PEG plates when a 1.0:0.5 drop ratio was used in combination
with 50% paraffin oil (**).
reservoir solution, Silver Bullets Bio and HT additive screens (Hampton Research)
and beginning with lower or higher concentrations of DHC-E itself. All of these were
attempts to change the crystallisation dynamics slightly in order to favour fewer,
larger crystals. None of those strategies led to an improvement in DHC-E crystals.
However, a significant increase in both crystal size and diffraction resolution limit
came from an experiment that combined two different strategies.
The first of these strategies was a variation of a popular method for slowing down
droplet equilibration, and therefore crystal growth, known as under oil crystallisa-
tion. Typically this strategy is performed by covering the droplet itself with an oil
that slows down the rate of vapour-diffusion between the droplet and the reservoir
(Chayen et al. 1992). However, as I was using a hanging-drop approach, I opted
to use a slightly different technique, which involves covering the reservoir with a
layer of oil instead of the droplet (Chayen 1997). This also provides the benefit
that harvesting crystals is no different from normal, whereas in traditional under
oil experiments one must carefully remove the oil from the droplet before crystals
can be harvested. I tested various mixtures of two oils to see which would provide
the most effective barrier for slowing crystal growth without preventing it entirely.
100% paraffin oil (mineral oil) allows very little vapour diffusion to occur, while
100% silicone oil allows vapour diffusion to occur at approximately the same rate as
when there is no oil present at all. By mixing the two oils in various proportions,
it is possible to fine tune the rate of vapour diffusion for optimal crystal growth. I
prepared five different mixtures: 10%, 30%, 50%, 70% and 90% paraffin oil, with
the remainder of each mixture being silicone oil (Table 4.5).
The second strategy that I used in combination with the oil vapour-diffusion
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P:R [PEG]i (% v/v) [DHC-E]i (mg/mL) [PEG]f (% v/v) [DHC-E]f (mg/mL)
0.5:1.0 7.33 1.77 11.0 2.65
1.0:1.0 5.50 2.65 11.0 5.30
1.0:0.75 4.71 3.03 11.0 7.07
1.0:0.5 3.67 3.53 11.0 10.6
Table 4.6: Various protein:reservoir drop ratios and the effects on protein
concentration before and after reaching equilibrium. All calculations were
done assuming a 5.3mg/mL DHC-E sample and 11% PEG in the reservoir solution.
If 1µL of 5.3mg/mL DHC-E is added to 1µL of 11% PEG, the initial protein con-
centration in the droplet is 2.65mg/mL and the initial PEG concentration is 5.5%.
In order for the PEG to return to equilibrium with the 11% reservoir, the droplet
must shrink to half its original volume through vapour diffusion, doubling the pro-
tein concentration back up to 5.3mg/mL. If only 0.5µL of 11% PEG is added to 1µL
of 5.3mg/mL DHC-E, the initial PEG concentration is 3.67mg/mL and the initial
protein concentration is 3.53mg/mL. In order for the PEG to return to equilibrium
with the reservoir solution, the droplet must shrink to one third of its original vol-
ume through vapour diffusion, tripling the protein concentration to 10.6mg/mL.
The other two ratios were calculated using similar logic.
barriers was to change the ratio of protein sample to reservoir solution added when
setting droplets. Crystal growth dynamics are not only determined by where on a
phase diagram the droplet ends up after reaching equilibrium, but also where it be-
gins and the path that it takes to get there (Luft et al. 2007). Therefore starting with
different ratios of protein and reservoir solution in the droplet may have dramatic ef-
fects on the number and size of crystals formed. Figure 4.5D qualitatively illustrates
the effect of different drop ratios on the initial condition, equilibrium condition and
the path between the two. Table 4.6 demonstrates the theoretical initial and fi-
nal DHC-E concentrations calculated for four different protein:reservoir ratios when
5.3mg/mL DHC-E is mixed with 11% PEG. The predicted values do not change for
different PEG concentrations because my calculations oversimplify the system and
don’t account for the DHC-E and other solutes present in the protein sample, but
they provide an overall trend for what happens to the protein concentration when
different drop ratios are used.
I combined both the oil barrier and drop ratio experiments into a single 15-well
EasyXtal hanging-drop screen, which is represented by Table 4.5. As I mentioned
above, when I was determining the PEG concentration at which a droplet would be
in the metastable zone at equilibrium for hanging-drop experiments, I discovered
that 9.8% to 12.6% yielded crystals (Table 4.4). Therefore, when creating the oil
barrier and drop ratio screens I used three new PEG concentrations that spanned
this narrow range: 9.5%, 11% and 12.5%. I made the screen in Table 4.5 twice for
each of these three PEG concentrations. All six plates were set up using 5.3mg/mL
DHC-E, with three droplets set per condition. The drop ratios described in Table
4.5 were used for each row. One of the two plates for each PEG concentration was
left without oil, while the other had 500µL of oil added to each reservoir before
re-sealing the screw caps. Each column of the plate had a different percentage of
paraffin oil (Table 4.5) with the remainder being silicone oil. The plates were set up
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Figure 4.6: Larger, optimised crystals of DHC-E. DHC-E was purified and
concentrated to 5.3mg/mL. 1µL of protein was added to to 500nL reservoir solu-
tion (0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4, 11% PEG (MW = 8, 000, v/v)) on
the screw cap of a 15-well EasyXtal hanging-drop plate. The 500µL reservoir solu-
tion was covered with 500µL of an oil mixture (50% paraffin oil, 50% silicone oil)
before re-sealing. After 24 hours, the largest crystals had grown up to ∼ 200µm
by 100µm. When screened with synchrotron radiation, these crystals diffracted to
6.4A˚. Measure bar = 100µm.
and left to incubate at RT (∼ 20°C for 24 hours, then examined for crystal growth.
All of the conditions that had 90% paraffin oil, and most of the ones that had
70% paraffin oil on the reservoir dried out completely. All of the conditions that were
set with a drop ratio of 0.5:1.0 remained clear. The remaining conditions contained
crystals of various sizes and shapes. Most of them contained crystals similar in
size and appearance to those already obtained by hanging-drop, described in Table
4.4. However, the 11% and 12.5% PEG plates had a few conditions that contained
far fewer and much larger crystals. The largest of these crystals (∼ 200µm in one
direction and ∼ 100µm in another) were found in conditions that were set up with
a 1.0:0.5 drop ratio and had 50% paraffin oil covering the reservoir (Fig. 4.6).
I harvested some of these optimised crystals and screened them for diffraction
using the I03 beamline at Diamond Light Source. The best-diffracting crystals I
tested had spots out to 4.2A˚ in the best direction, but were fairly anisotropic with
a resolution of only 5.5A˚ in the worst direction. However, as this resolution is often
high enough to at least see α-helices, I decided to try to solve a low-resolution
structure using these crystals. I also thought that even a low-resolution structure
might guide the design of future constructs that would form crystals with a higher
resolution diffraction limit. Therefore, I collected several native datasets using these
crystals and began setting up experiments to begin the phasing process.
4.2.5 Phasing the DHC-E crystals
I first searched for a homologous protein with a known structure that I could use as
a search model for molecular replacement. However, when the amino acid sequence
of DHC-E was used as the query sequence in a PSI-BLAST search (Altschul et al.
1997), the only hits were DHCs from other species. Since none of these have known
structures for the N-terminal region, molecular replacement was not an option. I
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instead tried two different strategies for calculating experimental phases, heavy atom
soaks of native DHC-E crystals and crystallisation of a selenomethione (SeMet)
derivative of DHC-E.
Heavy atom derivatives of native DHC-E crystals
I attempted to produce heavy atom derivatives of the native DHC-E crystals de-
scribed in Section 4.2.4 using two different strategies. The first, was to soak native
DHC-E crystals in various heavy atom solutions before freezing. The second, was
to derivatise DHC-E with heavy atoms by co-crystallisation of the protein with the
heavy atom compounds already in the reservoir solution used to set the droplet.
I first tried soaking DHC-E crystals in a variety of heavy atom compounds from
the commercial Heavy Atom Screens M1 and M2 (Hampton Research). To accom-
plish this, I determined a stabilising solution into which I could transfer DHC-E
crsytals for several hours without them dissolving or cracking. The stabilising solu-
tion I used was identical to the cryo-protectant solution I use for freezing crystals
(0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4, 11% PEG (MW = 8,000, v/v) and 30%
ethylene glycol (v/v)). For each of the heavy atom compounds tested (Table 4.7), I
prepared a 10mM solution in the stabilising solution. Then I placed 1µL droplets of
these solutions on the screw caps of a hanging-drop plate that contained stabilising
solution in the reservoirs. A few crystals were also soaked in stabilising solution
without any heavy atom compound as a control to ensure the treatment itself was
not detrimental to the crystals. I transferred freshly grown native DHC-E crystals
into each heavy atom solution and allowed the crystals to incubate for two hours.
After the soak was complete I transferred the crystals to fresh stabilising solution
and washed them for one minute before mounting them in cryoloops and freezing
them in LN2.
Although the majority of the heavy atom soaks did not visibly damage the
crystals when observed under a dissecting microscope, none of the crystals diffracted
as well post-treatment as native crystals that were soaked in stabilising solution
without a heavy atom compound (4.5A˚, Table 4.7). Some compounds caused the
crystals to lose the ability to diffract completely, whereas others only reduced the
resolution to ∼ 8A˚.
In addition to the Heavy Atom Screens made by Hampton Research, I tried
derivatising DHC-E with two compounds that were specially designed for experi-
mental phasing: a tantalum bromide cluster, [Ta6Br12]
2+ · 2Br- (Jena Bioscience),
and the highly substituted benzene ring 5-Amino-2,4,6-triiodoisophthalic acid (I3C,
Hampton Research). [Ta6Br12]
2+ · 2Br- has proven useful for experimental phasing
due to its large size, high electron density, and the presence of two different anoma-
lous scatterers, Ta and Br (Kna¨blein et al. 1997). Furthermore, [Ta6Br12]
2+ · 2Br-
is green in solution and turns crystals green upon binding, providing a convenient
way to visually determine whether a soak has been successful. I3C, binds protein
through its amino group and carboxyl groups more readily than traditional heavy-
metal ions. Furthermore, it contains a 6A˚ equilateral triangle of iodine atoms, which
simplifies recognition of compound within electron density (Beck et al. 2008).
I prepared a 10mM [Ta6Br12]
2+ · 2Br- solution in stabilising solution and set up
drops in a hanging-drop plate as described above. Then I soaked 10 native DHC-
E crystals in this solution for various lengths of time, ranging from 10 minutes to
two hours. Roughly every ten minutes, I transferred one crystal to a fresh droplet
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Heavy atom compound Result
Thallium(I) chloride 9A˚
Thallium(III) acetate hydrate 11A˚
Cadmium chloride hydrate 21A˚
Sodium hexachloroiridate(III) 38A˚
Ammonium hexabromoosmate(IV) 8A˚
Ammonium tetrathiotungstate(VI) 12A˚
Samarium(III) acetate hydrate 13A˚
Lanthanum(III) nitrate hexahydrate N/A
Europium(III) nitrate hexahydrate 40A˚
Gadolinium(III) chloride hydrate N/A
Lutetium(III) acetate hydrate 12A˚
Ytterbium(III) chloride hydrate 19A˚
Neodymium(III) chloride hydrate 13A˚
Control (no heavy atom compound) 4.5A˚
Table 4.7: Heavy atom soaks of DHC-E crystals in various compounds and
subsequent diffraction resolution limits. Native DHC-E crystals were soaked in
a 10mM solution of various heavy atom compounds for two hours. After soaking the
crystals were washed briefly and screened for diffraction. The results column reports
the resolution limit for the best-diffracting crystal from each compound. The crystals
lost diffraction power after soaking with all of the heavy atom compounds. The most
detrimental soaks resulted in no diffraction at all (N/A), whereas crystals soaked
in at least two compounds were still able to diffract to sub-nanometer resolutions.
Crystals soaked in stabilising solution alone diffracted to 4.5A˚.
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of stabilising solution, allowed it to wash for 1 minute and then snap froze it in
LN2. The crystals were tinged with green even after 10 and 20 minutes of soaking,
but the amount of green colour increased steadily until about one hour of soaking.
From this point on all the crystals were deeply stained green and showed no signs
of physical damage. When screened for diffraction with synchrotron radiation, most
of the crystals diffracted to between 7A˚ and 8A˚, with the best (the crystal that had
been soaked for 30 minutes) reaching 6.5A˚. I performed a fluorescence scan on this
crystal and found the K edge for bromine. Using this scan I determined the peak
wavelength to be 0.91882A˚ and the inflection wavelength to be 0.91956A˚. I collected
a dataset at each of these wavelengths, but subsequent attempts to calculate initial
phases using single-wavelength anomalous dispersion (SAD) and multi-wavelength
anomalous dispersion (MAD) failed due to a lack of anomalous signal. This was
determined by looking at the CCanom=0.5 when scaling and merging the datasets in
Aimless (Evans & Murshudov 2013). None of the datasets had a value below 10A˚,
indicating that any [Ta6Br12]
2+ · 2Br- binding may have been non-specific.
I repeated this process using I3C, except I began with a 500mM I3C solution
for the crystal soaks. Since I could see that the crystals were dissolving over time
in this solution, I diluted the I3C to 100mM and repeated the experiment with new
crystals. At this concentration I did not observe any physical defects in the crystals,
even after one hour. The best diffraction of these crystals came from a crystal that
had been soaked in 100mM I3C for only four minutes and diffracted to 4.5A˚. Using a
fluorescence scan, I found the LI edge of iodine and determined the peak wavelength
to be 2.3879A˚. I collected a dataset at this wavelength and attempted to calculate
initial phases using SAD, but as with the [Ta6Br12]
2+ · 2Br- datasets, there was no
anomalous signal and so I could not use the dataset for experimental phasing.
I also attempted to co-crystallise DHC-E with I3C by setting up hanging-drop
trays using a reservoir solution that contained 10mM I3C. Crystals formed in the
same way as native DHC-E crystals and were visually indistinguishable. Of the 16
that I screened for diffraction using synchrotron radiation, the best one diffracted
to 5.6A˚. However, a fluorescence edge scan of this crystal suggested that insufficient
I3C was bound to produce a measurable signal.
In conclusion, none of the heavy atom derivitisation strategies I attempted,
whether through soaking or co-crystallisation, were successful in obtaining experi-
mental phases for the DHC-E crystals. Since I could express DHC-E from E. coli
and there were several well-established protocols for producing SeMet derivatives of
proteins using bacteria, I decided to try this approach before investing more time in
heavy atom soaks and co-crystallisation screens.
A selenomethionine derivative of DHC-E
To express the SeMet derivative of DHC-E, I transformed the plasmid described in
Section 4.2.3 into a a methionine auxotrophic strain of E. coli called B834(DE3)
(Novagen). I grew these cells in M9 media supplemented with selenomethionine and
the other 19 standard amino acids, as well as all the other nutrients and vitamins
required for optimal bacterial growth (Ramakrishnan et al. 1993). The remainder of
the bacterial growth, protein expression and purification of the SeMet DHC-E were
performed as with native DHC-E, except all buffers were thoroughly degassed and
made with double the normal amount of DTT or BME in order to minimise SeMet
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Figure 4.7: SeMet DHC-E crystal in cryoloop, aligned for data collection.
SeMet DHC-E was purified and concentrated to 5.3mg/mL. 1µL of protein was
added to to 500nL reservoir solution (0.1M Tris-HCl (pH = 8.5), 0.2M Li2SO4,
12.5% PEG (MW = 8, 000, v/v)) on the screw cap of a 15-well EasyXtal hanging-
drop plate. The 500µL reservoir solution was covered with 500µL of an oil mixture
(50% paraffin oil, 50% silicone oil) before re-sealing. Crystals grew overnight, were
washed in cryoprotectant and flash frozen the next morning in LN2. When screened
with synchrotron radiation, this crystal diffracted out to 3.7A˚. Measure bars =
100µm. A and B are two views of the same crystal, rotated 180°around the long
axis of the cryoloop.
oxidation. SeMet DHC-E crystallised in the same conditions as native DHC-E to
yield crystals that were similar in size and appearance (Fig. 4.7).
32 SeMet DHC-E crystals were screened for diffraction using the I03 beamline at
Diamond Light Source. The majority of the crystals diffracted to between 5A˚ and
8A˚, but several diffracted to 4A˚ and the best crystal had spots visible out to 3.7A˚.
While screening, the auto processing software provided at the beamline suggested
that the crystals belonged to the P222 point group and had unit cell parameters of
A=72.13A˚, B=149.28A˚ , C=179.56A˚ , and α=β=γ=90°.
Using one of the poorly diffracting crystals, I performed a fluorescence scan and
found the K edge for selenium. I determined the peak wavelength to be 0.97952A˚,
the inflection wavelength to be 0.97970A˚, and a high-energy remote wavelength to be
0.91841A˚. There were two crystals that showed better diffraction in screening than
the rest. These two crystals were large enough that I could collect multiple datasets
off of each one without any signs of radiation damage by moving to a new region
of the crystal each time. For each anomalous dataset, I used only 20% transmission
and collected between 300°and 360°of data even though P222 crystals require only
90°of data collection for a complete dataset. These measures were taken in order
to minimise radiation damage and collect high-redundancy datasets, in hopes of
maximising the anomalous signal necessary for phasing. Table 4.8 provides a full
summary of all datasets collected from these two crystals . After collecting at least
one dataset at each anomalous wavelength from each crystal, I collected two ”native”
datasets using a wavelength of 0.97626A˚. These datasets were of a lower redundancy
(180°) and were collected using 100% transmission. These were collected to allow
for future phase extension after a successful initial phasing experiment.
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Crystal Dataset λ (A˚) Ω oscillation (°) Exposure (s) No. images Transmission Resolution (A˚)
1 PeakA 0.9795 0.2 0.25 1500 20% 3.5
1 InflectionA 0.9797 0.2 0.25 1500 20% 3.5
1 RemoteA 0.9393 0.2 0.25 1500 20% 3.5
2 PeakB 0.9795 0.2 0.17 1500 20% 4.0
2 InflectionB 0.9797 0.2 0.14 1800 20% 4.0
2 RemoteB 0.9184 0.2 0.15 1500 20% 4.0
2 PeakC 0.9795 0.2 0.13 1800 20% 4.0
2 NativeA 0.9763 0.2 0.20 900 100% 3.0
2 NativeB 0.9763 0.2 0.19 900 100% 3.0
Table 4.8: Summary of the datasets collected from two SeMet DHC-E
crystals. The parameters used to collect nine datasets from two crystals, including
wavelength, Ω oscillation, exposure time, number of images, transmission and the
maximum resolution used to define the distance of the detector from the crystal.
Calculation of initial phases
I indexed and integrated the nine datasets described in Table 4.8 using iMosflm
(Battye et al. 2011), which agreed with the auto processing results that both crys-
tals belonged to the P222 point group and, on average, had unit cell parameters of
A∼ 72A˚, B∼ 150A˚, C∼ 180A˚ and α=β=γ=90°. Each dataset was then scaled and
merged using Aimless (Evans & Murshudov 2013) from within the CCP4 package
(Winn et al. 2011). A summary of the diffraction statistics for datasets that were
used in further steps can be found in Table 4.9. For crystal 1, all three datasets
were scaled together, but merged independently so that one merged MTZ file was
produced for each wavelength (PeakA, InflectionA and RemoteA in Table 4.9). For
crystal 2, all six datasets were scaled together and one merged MTZ was produced
for each wavelength. This resulted in the six original datasets being reduced to four
since PeakB and PeakC were merged into a single dataset as well as NativeA and
NativeB. The only dataset used from this crystal in future steps was the one that
resulted from merging NativeA and NativeB together (Nativecomb in Table 4.9). I
tried phasing using many different combinations of datasets and empirically deter-
mined that combining datasets in this way and omitting the others gave the best
initial phases.
With these datasets, I began trying to calculate initial phases using a variety of
techniques and software packages. I first tried the SAD approach using the PeakA
dataset, but this failed to produce any useful solution. I also tried the MAD approach
using the PeakA, InflectionA and RemoteA datasets, but this also failed to produce
credible electron density maps. It was only by also incorporating the Nativecomb
dataset and using the multiple isomorphous replacement with anomalous scattering
(MIRAS) approach that I successfully calculated experimental phases. This was ac-
complished by running AutoSHARP (Vonrhein et al. 2007) in MIRAS mode using
SHELXD (Sheldrick 2010) for heavy atom detection with all four datasets described
in Table 4.9. After initial phasing and automated density modification by solvent
flattening, the AutoSHARP run produced an electron density map with a clear sol-
vent boundary and features that were consistent with α-helices (Fig. 4.8A). There
was also one region, which appeared to be a β-sheet and showed some signs of sepa-
ration between the individual β-strands (Fig. 4.8B). The observed electron density
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of the initial map suggested that the majority of the density could be accounted for
by α-helices rather than β-strands. This observation was in line with the predicted
secondary structure of DHC-E, so I used the map to build an initial model.
Nativecomb PeakA InflectionA RemoteA
Diffraction data
Space group P212121 P212121 P212121 P212121
Unit cell (A˚) a = 71.9 a = 72.0 a = 72.1 a = 72.1
b = 148.9 b = 149.0 b = 148.9 b = 149.2
c = 179.6 c = 179.4 c = 179.5 c = 178.8
Unit cell (°) α = 90.0 α = 90.0 α = 90.0 α = 90.0
β = 90.0 β = 90.0 β = 90.0 β = 90.0
γ = 90.0 γ = 90.0 γ = 90.0 γ = 90.0
Resolution (A˚) 52.6 - 4.0 64.9 - 4.0 61.0 - 4.0 64.9 - 4.0
RSym
1 10.6 (80.2)* 19.6 (126.9) 14.0 (96.8) 13.0 (85.6)
<I>/< σI> 10.4 (3.9) 7.9 (2.3) 8.5 (2.4) 8.9 (2.7)
Completeness (%) 100.0 (100.0) 99.8 (99.3) 99.8 (99.3) 99.8 (99.3)
Redundancy 11.6 (11.7) 10.0 (10.1) 10.0 (10.1) 9.7 (9.8)
No. reflections 196,661 (55,179) 169,522 (47,577) 169,334 (47,518) 163,986 (45,845)
No. unique reflections 16,985 (4,732) 16,985 (4,699) 16,984 (4,699) 16,986 (4,699)
Wavelength (A˚) 0.9763 0.9795 0.9797 0.9393
CCanom=0.5 cutoff (A˚) - 6.7 - -
Phasing statistics
FOM2 0.31 - - -
Table 4.9: Data collection and phasing statistics for the four datasets used
to solve the SeMet DHC-E structure. *Values in parentheses refer to the
highest resolution shell. 1RSym (I) = (ΣhklΣi |I hkl,i - <I hkl> |) / ΣhklΣiI hkl,i for n
independent reflections and i observations of a given reflection. 2FOM = mean
figure of merit.
4.2.6 Initial model building and density modification
I began building the DHC-E model by manually placing ideal α-helices into each
tube of density that resembled an α-helix using Coot (Emsley et al. 2010). By vi-
sualising crystallographic symmetry mates, I ensured that all the α-helices I built
belonged to the same asymmetric unit and were not related to each other by crys-
tallographic symmetry. Once all of the obvious helical density had been filled in
this manner, I also modelled eight β strands into the β-sheet (Fig. 4.8B). The re-
sulting model consisted of a globular domain framed on either side by elongated
bundles of α-helices (Fig. 4.9A). The majority of the globular domain was situated
in a different plane than the elongated domains with only one α-helix per monomer
appearing close enough to make a contact with the elongated domains (Fig. 4.9B).
The globular domain was made up of a β-sheet sandwiched between α-helices (Fig.
4.9C). The elongated domains consisted only of α-helices, which could be divided
roughly into two bundles, one slightly longer than the other (Fig. 4.9D). The overall
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Figure 4.8: Initial electron density map of DHC-E after experimental phas-
ing by MIRAS and solvent flattening. Three anomalous datasets and one ”na-
tive” dataset collected from SeMet DHC-E crystals, were used to calculate initial
phases. Phases were calculated using AutoSHARP in MIRAS mode followed by sol-
vent flattening in order to produce an initial map. Electron density was contoured
to 1.5σ. A) A global view of α-helical bundles. B) A close-up view of a β-sheet
region. Some strand separation was already visible in the initial map.
structure revealed an obvious two-fold symmetry, centred on the globular domain,
which displayed internal symmetry within itself (Fig. 4.9A). These observations led
me to conclude that the globular domain was a previously unknown dimerisation
domain within the DHC. I expected the DHC-E might crystallise as a dimer, since
this is how it eluted during SEC, but the extensive dimerisation interface observed
in the crystal structure confirmed that this dimer is biologically relevant and not
just an artifact of purification.
I also combined the anomalous difference amplitudes from the PeakA dataset
with the experimental phases in order to create an anomalous difference density
map using FFT (Read & Schierbeek 1988). Although there are eight methionine
residues for each copy of DHC-E (not including the N-terminal methionine), only five
SeMet peaks per monomer where visible in the anomalous difference map. However,
the five SeMet peaks that were visible were useful in beginning to assign specific
residues to the initial model. For example, the fact that M358 and M366 are only
separated by eight residues and were predicted to be within a single α-helix allowed
me to assign that α-helix with great confidence. Furthermore, M394 was predicted
to be in the middle of the next α-helix and M216 was predicted to be at the very N-
terminus of a 24-amino acid α-helix, which made assigning those α-helices possible,
as well as determining their orientations. Finally, M186 was predicted to be in a
loop region, just after a short β-strand. This corresponded to the location of the
final anomalous peak, which could be found within an extended loop located at the
joint between the dimerisation domain and the elongated domains.
Once I assigned these key regions using the SeMet peaks, I was able to identify
the majority of the α-helices by referring to the secondary structure predictions
(Fig. A.1). The prediction began with two α-helices followed by four consecutive
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Figure 4.9: An overview of the initial DHC-E model. An initial DHC-E model
was built by placing α-helices and β-strands in in tubes of electron density that were
of the correct diameter for each type of secondary structure motif. A) A view of the
entire model that highlights the 2-fold non-crystallographic symmetry of the DHC-E
dimer. The axis of symmetry comes out of the page, directly in the centre of this
image. The dimerisation domain is coloured red (Chain A) and pink (Chain B). The
elongated domains are coloured dark blue (Chain A) and light blue (Chain B). B)
A view of the entire model after rotating A 90°about a horizontal axis through the
centre of the molecule. This view highlights the fact that the dimerisation domain
sits in a different plane than the elongated domains, with the exception of the bottom
two α helices, which appear to make bridge the two domains together. C) A closer
look at the dimerisation domain, which reveals the intricate dimer interface. A single
β-sheet is formed by eight β-strands, with each monomer contributing four. Above
the β-sheet, there are two anti-parallel α-helices that appear to contact each other.
Below the β-sheet, there are four more α-helices, two from each monomer, which
appear to form a tight bundle. D) A closer look at one of the elongated domains,
which demonstrates that it is made up of two smaller bundles of α-helices.
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β-strands and then two more α-helices, which corresponds well with the structure
of the dimerisation domain. After the dimerisation domain, the SeMet positions,
as well as the variation in the length of predicted α-helices allowed me to trace the
carbon backbone through each α-helix that I had built. However, I could not always
determine the orientation due to a lack of density for the connections between α-
helices. In this way I assigned all the α-helices until residue 412. At this point,
five α-helices remained in the secondary structure prediction, but no more α-helices
could be modelled due to a lack of clear electron density. There were also three more
methionine residues in the part of the DHC-E sequence that I could not build. Since
this density was missing from both the full map, as well as the anomalous difference
map, I concluded that the final five α-helices were disordered in the crystal. There
was enough empty space within the crystal structure to accommodate the missing
α-helices without disrupting the crystal packing. With the initial model complete,
I was also able to determine that the asymmetric unit consisted of a single DHC-E
dimer, meaning that the only non-crystallographic symmetry (NCS) I would be able
to take advantage of when improving the model and/or map would be the symmetry
that existed between the two monomers.
I next attempted to improve the map quality using various techniques. First, I
re-processed all of the original datasets used for phasing with Diffraction Anisotropy
Server in order to perform anisotropic scaling and ellipsoidal truncation (Strong et
al. 2006). This was to correct for any negative effects of the inherent anisotropy
in the DHC-E crystals. Next, I created a NCS mask for each subdomain of each
monomer of the initial model and determined the superposition matrix necessary to
transform the subdomains from one monomer onto the other. I used the anisotropy
corrected amplitudes, experimental phases, NCS masks and superposition matrix
to run DM (K. Cowtan 1994). In the DM job, I performed 200 cycles of phase
extension to 3.25A˚ with NCS averaging, solvent flattening and histogram matching.
The resulting map showed a dramatic improvement in some regions of the map, but
other regions were relatively unaffected. In the most improved regions, the tubes of
density for α-helices were covered with bumps that corresponded to the side chains
of larger amino acids and more connections between α-helices were visible (Fig.
4.10). Despite these improvements in the parts of the map I had already modelled,
the density for the C-terminal five α-helices did not appear. In order to make sure
this was not because the mask used for NCS averaging only covered the region of
the assymetric unit I had already modelled, I added several α-helices in the open
space where the C-terminus must be, made new NCS masks and repeated the DM
run. This still didn’t result in any new density becoming visible in this region. So I
concluded that the C-terminus is disordered and would not become visible without
changing the crystals themselves.
Using the new electron density map, I assigned all residues and modelled the
majority of the connections between α-helices. I was not able to confidently assign
the individual strands within the β-sheet, nor determine their orientation, since
the connections between them were not clear enough. I also modelled larger side
chains when there were bumps in the density at the expected places. For α-helices
with multiple large side chains visible, I was able to rotate the α-helix and check
that the registry was correct, but this was not possible for all of them. While
building, I alternated between the two copies of the DHC-E dimer in order to take
advantage of the regions of the map that were best in each copy. Once I had modelled
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Figure 4.10: A comparison of the electron density map before and after
DM. All datasets used for experimental phasing were corrected for anisotropy. After
anisoptropic scaling and ellipsoidal truncation, the amplitudes from these datasets
were combined with the experimental phases. Phases were extended and NCS av-
eraging was performed between the two monomers within the asymmetric unit. A
and B) A region within one of the elongated domains of Chain A where the map im-
proved dramatically after running DM. Three large sidechains were able to be built
into electron density after DM, whereas only the carbon backbone could be built be-
fore. C and D) The loop that connects the two first α-helices at the N-terminus was
not visible in the initial map, preventing correct assignment and orientation of these
two α-helices. After DM, the connection became visible, allowing the orientation of
the two α-helices to be determined. Both maps were contoured to 1.5σ.
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Figure 4.11: An overview of the final DHC-E model. The initial DHC-E
model was updated after improving the electron density map (PDB accession code
5AFR). Loops connecting some of the α-helices were built in, including the one that
connects the dimerisation domain to the elongated domain. A) A view of the entire
model equivalent to the one used in Fig. 4.9A. The dimerisation domain is coloured
red (Chain A) and pink (Chain B). The elongated domains are coloured dark blue
(Chain A) and light blue (Chain B). B) A view of the entire model after rotating A
90°about a horizontal axis through the centre of the molecule. This view highlights
the new loops that have been built in to the dimerisation domain as well as at the
near end of the elongated domain. C) A view of the entire model after rotating
A 180°about a horizontal axis through the centre of the molecule. This view high-
lights the underside of the dimerisation domain and provides a clearer view of the
connections between the dimerisation domain and the elongated domains. D) A
view that emphasises the distance between the dimerisation domain and the elon-
gated domain. With the exception of the peptide backbone that connects these two
domains, at this resolution there are no visible contacts between the two domains,
suggesting that they may rotate freely with respect to each other.
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as much as possible into the post-DM map (Fig. 4.11), I carried out refinement
of the model against the experimental data using REFMAC5 (Murshudov et al.
2011). Despite attempting many different types of refinement (including restrained
refinement, and rigid body refinement), and changing many of the parameters (with
and without experimental phases, with and without local NCS, with and without
jelly-body refinement), the best R-factor and R-free I obtained were 0.39 and 0.43,
respectively. I also tried running the refinement after deleting various α-helices and
loops, to check whether I had over-interpreted the electron density. In every case,
the difference density always suggested that what I had built belonged there. This
most likely indicates that there is some larger problem with the model, though I was
never able to determine what this might be. Working with such a low-resolution
density map, it is possible that the α-helices are slightly out of position. If enough
α-helices are off by a half a rotation, this might be enough to prevent the R-factors
from decreasing.
Since it seemed the DHC-E crystals I had already obtained would not provide
me with the quality of data I needed to obtain a higher-resolution density map, nor
a complete model of the construct, I designed several new constructs. Many of these
were designed rationally using the initial model to make specific predictions about
how to improve the crystals, but others still relied on a trial and error approach.
As the low quality of the phases seemed to be the limiting factor in improving the
original density map, my goal was to collect better phase information or to find a
new crystal form, which would allow me to take multi-crystal averaging.
4.2.7 Creating and screening new crystal constructs of the
DHC N-terminus
Expressing DHC-E in E. coli not only increased the yield and solubility of the
sample, but also made the screening of new constructs much higher-throughput.
For most constructs, 1L of E. coli culture produced enough protein to set up all 20
of the LMB initial crystal screens at ∼ 5mg/mL. So once the plasmids were created
and transformed into the correct expression strain, it was convenient to express 12
or 24 constructs in parallel. Furthermore, the purification protocol, which relied
only on an affinity chromatography step followed by SEC, was compatible with
performing up to six purifications in parallel. With this high-throughput system for
screening constructs and an initial model on which I could base specific predictions
about obtaining better crystals, I designed and screened several new constructs. My
two goals were to improve the diffraction resolution limit of the crystals and/or the
completeness of the model, which still lacked the C-terminus.
DHC-E equivalent constructs in 12 new species
One well known strategy for improving crystal quality is to crystallise an equivalent
construct from a different species. The aim is to find a species that has enough
differences in the protein structure to subtly affect the formation of crystals, while
remaining similar enough to the original construct that it will still crystallise and
provide a relevant structure. As this strategy relies on a ”trial and error” approach
and I had established the high-throughput system for screening constructs, I selected
twelve different species to compare. I included a diverse assortment of species across
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Species Length MW (kDa) Results
S. cerevisiae 557 60.1 E,P,C,D (Sections 4.2.3-6)
A. gossypii 540 61.3 E,P
C. elegans 597 67.9 E,P
C. thermophilum 646 71.1 E,P
D. discoideum 656 73.8 E,P,C
D. melanogaster 609 69.9 X
D. rerio 614 69.9 X
G. gallus 582 66.9 E
H. sapiens 615 70.3 E,P
K. lactis 542 62.5 E,P
M. musculus 613 70.1 E,P
N. crassa 640 71.1 E,P
T. thermophila 581 67.3 E,P
Table 4.10: List of equivalent constructs of DHC-E from 12 different
species. The C-terminal residue and predicted MW after TEV cleavage are shown
for each DHC-E equivalent. In the results column, X=expression level was too
low for purification, E=expression level was high enough to complete purification
through SEC step, P=SEC produced a peak that was clean enough to set up crys-
tal screens, C=crystal screens produced hits that were optimised and screened for
diffraction, D=crystals diffracted.
eukaryotic taxa in order to increase the chances of finding one species that would
have the optimal amount of divergence with S. cerevisiae. I included some fungal
species, which align more closely with S. cerivisiae, as well as several more distantly
related metazoans. I performed an alignment between the full-length cytoplasmic
DHCs from all twelve species plus S. cerevisiae using ClustalX (Larkin et al. 2007).
A visual inspection of the alignment in Jalview 2 (Waterhouse et al. 2009) revealed
that all thirteen sequences clearly aligned in the region surrounding the S. cerevisiae
DHC-E truncation (Fig. 4.12). So I designed the twelve equivalent constructs (Ta-
ble 4.10), ending each with the residue that aligned with D557 of S. cerevisiae (red
arrow, Fig. 4.12). I had each fragment synthesised and codon optimised for expres-
sion in E. coli and then I cloned the fragments into the same bacterial expression
vector I had used previously Section 4.2.3).
I grew 1L of E. coli for each of the twelve DHC-E equivalents from different
species. Two of the constructs (D. melanogaster and D. rerio) did not express at
high enough levels to purify the protein (Fig. 4.13). Of the remaining constructs, all
but the G. gallus construct were clean enough after SEC to set up crystal screens.
However, the D. discoideum construct was the only one to produce any crystal hits. I
attempted to optimise these crystals using many of the same techniques described in
Section 4.2.4, but I was unable to improve any of them significantly. I screened some
of the initial crystals for diffraction using the I03 beamline at Diamond Light Source,
but they did not diffract, indicating that they may have been very disordered.
Although none of these constructs proved useful for crystallography, at least two
of those that purified well may be of use for future experiments. At 613 amino acids
in length, the M. musculus construct includes residue F580, which is the site of a well
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Figure 4.12: An alignment of the DHC N-terminus from thirteen differ-
ent species. Full-length DHCs from thirteen different species were aligned us-
ing ClustalX. The alignment was visualised with Jalview 2 using the ”percentage
identity” colour scheme (darker purple indicates higher conservation). Only the N-
terminal ∼ 15% is shown. DHC-E equivalent constructs were designed in twelve
other species by truncating at the residues above the red arrow, which aligned
with the C-terminal residue of the S. cerevisiae construct. Ag=Ashbya gossypii,
Ce=Caenorhabditis elegans, Ct=Chaetomium thermophilum, Dd=Dictyostelium
discoideum, Dm=Drosophila melanogaster, Dr=Danio rerio, Gg=Gallus gallus,
Hs=Homo sapiens, Kl=Kluyveromyces lactis, Mm=Mus musculus, Nc=Neurospora
crassa, Sc=Saccharomyces cerevisiae, Tt=Tetrahymena thermophila.
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Figure 4.13: SDS-PAGE analysis of equivalent constructs of DHC-E from
twelve different species. 1L of E. coli was grown for each equivalent con-
struct of DHC-E from twelve different species. Protein was purified using a Ni-
NTA column before removing the His-tag by TEV cleavage. The gels presented
show the samples after TEV cleavage and just before the SEC polishing step.
Ag=Ashbya gossypii, Ce=Caenorhabditis elegans, Ct=Chaetomium thermophilum,
Dd=Dictyostelium discoideum, Dm=Drosophila melanogaster, Dr=Danio rerio,
Gg=Gallus gallus, Hs=Homo sapiens, Kl=Kluyveromyces lactis, Mm=Mus mus-
culus, Nc=Neurospora crassa, Sc=Saccharomyces cerevisiae, Tt=Tetrahymena ther-
mophila.
described point mutation called leg at odd angles (Loa). Despite resulting from the
addition of a single hydroxyl group (F580Y), the Loa mutation has dramatic effects
on development in mice, which have been linked to defects in neuronal migration Ori-
McKenney & Vallee 2011). It might be interesting to express both the wild-type and
mutant versions of this construct and then characterise them biochemically to see if
the mutant version folds properly or if it adopts an entirely different conformation.
Additionally, in light of some of my colleagues’ recent work in the Carter lab, which
will be discussed in detail in Section 4.2.8, the human construct may be useful in
further dissecting the interraction between dynein and dynactin.
A finer screen of C-terminal truncations near DHC-E
The next set of constructs consisted of a finer screen of C-terminal truncations in the
region surrounding the DHC-E truncation (hereafter referred to as the E region).
I based these truncations on the secondary structure prediction (Fig. 4.14), the
same way I designed the first and second of DHC truncations in Sections 2.2.3 and
2.2.4. I was not able to use the crystal structure to guide the design, since all of
the E region truncations fall within the region of the DHC-E construct that was not
visible in the electron density. However, I made a fine screen in this region in hopes
of altering or introducing new crystal contacts that might force the C-terminus into
a more ordered state. The shortest constructs (DHC-EA, DHC-EB and DHC-EC)
removed the last few α-helices from the DHC-E construct in order to test whether
removing the predicted coiled-coil would produce higher quality crystals. I thought
that disruption of one of the α-helices that forms the coiled-coil might have caused
the entire C-terminus to be disordered in the crystal lattice. I also made a few
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Figure 4.14: Secondary structure prediction of E region of the DHC
with the new series of truncations highlighted. H=predicted α-helix,
turquoise=predicted coiled-coil, red=final residues from the first series of DHC trun-
cations in this region: DHC-C, DHC-D, DHC-E and DHC-F, green=final residues
from twelve new E region DHC truncations. Note that the new DHC-EI is equivalent
to the original DHC-E truncation.
truncations that were longer than the original DHC-E construct. I designed DHC-
EK and DHC-EL to include the remainder of the predicted coiled-coil that DHC-E
falls halfway through. Finally, I reproduced the original DHC-E construct as a
control, DHC-EI. This was necessary becasuse although the constructs shorter than
DHC-E were made by modifying the original DHC-E plasmid, the longer ones had
to be made by amplifying the gene from a different template. So to ensure this
difference in cloning procedure for the longer constructs did not lead to differences
in expression, I re-cloned the DHC-E construct in the same way as DHC-J, DHC-K
and DHC-L. One of the PCR reactions necessary for the creation of DHC-EE failed,
so this construct was not completed.
I grew 1L of each construct, plus one extra litre of the E. coli that had been
transformed with the DHC-EL construct, which I did not induce wth IPTG. This
uninduced culture served as a control to test for leaky expression and to identify non-
specific proteins that are present in the cell lysate in the absence of overexpression. I
performed a purification on all twelve pellets by lysing the cells, incubating with Ni-
NTA agarose beads, and then washing. After eluting bound protein, I performed a
TEV digest and analysed all samples by SDS-PAGE (Fig. 4.15). Several constructs
expressed just as well as the original DHC-E construct (equivalent to then new
DHC-EI in Fig. 4.15). However the shortest four constructs and the longest one
expressed only at very low levels. Therefore, I proceeded to complete the purification
only for the constructs that expressed well: DHC-EF, DHC-EG, DHC-EH, DHC-EI,
DHC-EJ and DHC-EK.
I ran the samples of the six highly expressed constructs back through a Ni-
NTA column in order to re-bind all of the non-specific proteins, TEV protease and
the His-tagged lipoyl domain, which had been cleaved off. Then I concentrated
each sample in order to perform SEC. DHC-EF and DHC-EG produced complex
chromatograms, with several peaks, and no prominent one at the expected elution
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Figure 4.15: SDS-PAGE analysis during test purifications of 11 E region
truncations from 1L of culture each. 1L of E. coli was grown for each E region
construct except DHC-EE, which was not completed due to difficulties with cloning.
1L of the E. coli strain that had been transformed with the DHC-EL plasmid was
also grown without inducing expression with IPTG (-). This control served to check
for leaky expression and to identify non-specific proteins in the E. coli lysate by
direct comparison with the 1L culture that was induced for DHC-EL expression
(+). Protein was purified from lysates using a Ni-NTA column before removing
the His-tag by TEV cleavage. The gels presented show the samples after TEV
cleavage but before running the eluate back through the Ni-NTA column to re-bind
non-specific proteins, TEV protease and the His-tagged lipoyl domain.
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Name Last residue MW (kDa) Results
DHC-EA 460 52.4 X
DHC-EB 467 53.3 X
DHC-EC 472 54.0 X
DHC-ED 495 56.7 X
DHC-EE 515 59.0 PCR failed
DHC-EF 524 60.0 E
DHC-EG 531 60.9 E
DHC-EH 548 62.9 E,P
DHC-EI 557 63.9 E,P,C,D
DHC-EJ 560 64.3 E,P,C
DHC-EK 569 65.2 E,P,C
DHC-EL 575 66.0 X
Table 4.11: List of 12 E-region truncations. The C-terminal residue and pre-
dicted MW after TEV cleavage are shown for each construct. In the results column,
X=expression level was too low for purification, E=expression level was high enough
to complete purification through SEC step, P=SEC produced a peak that was clean
enough to set up crystal screens, C=crystal screens produced hits that were opti-
mised and screened for diffraction, D=crystals diffracted.
volume for a dimer. The remaining four constructs (DHC-EH, DHC-EI, DHC-
EJ an DHC-EK) all produced chromatograms very similar to the original DHC-E
construct. Therefore, I pooled the prominent dimer peaks and concentrated each
sample to 5.3mg/mL for crystal screening. I set up all 20 LMB crystal screens using
each of these four samples with droplets composed of 200nL protein plus 200nL
reservoir. The plates were set up and incubated at ∼ 20°C.
After 24 hours of incubation, the DHC-EI construct had already produced dozens
of crystal hits in dozens of conditions, similar to the original DHC-E construct
Sections 4.2.2 and 4.2.3, confirming that the template used for PCR had no effect and
that the high-throughput purification techniques I was using were not detrimental
to crystal quality. DHC-EJ and DHC-EK each produced a single crystal hit, both in
the same condition. This condition, LMB2/H3, has a reservoir solution composed
of composed of 0.1M CAPS (pH = 10.5), 0.2M NaCl and 20% PEG (MW=8,000,
w/v). This condition is strikingly similar to the initial hit that led to successful
optimisation of the DHC-E crystals, LMB9/A9. Both had 0.2M of a salt, and
both had 18% or 20% PEG (MW=8,000). I harvested some of the initial crystals
from both DHC-EJ and DHC-EK and screened them for diffraction using the I03
beamline at Diamond Light Source. Neither showed any diffraction, but as these
crystals were smaller and much more fragile than DHC-E crystals, this might have
been due to difficulties in crystal harvesting.
Interestingly, these results suggest that the construct is most stable when α-
helices H14, H15 and H16 (Fig. 4.14) are included, since constructs DHC-EA
through DHC-ED, which eliminated these α-helices all failed to express at high
levels. This was somehwat unexpected as these α-helices are apparently not ordered
enough to be visible in the original DHC-E crystals. Furthermore, the crystallisation
of DHC-EJ showed what a large effect including even three more amino acids can
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Figure 4.16: Crystal hits from two new E region truncations, DHC-EJ and
DHC-EK. Each construct was purified from 1L of E.coli, concentrated to 5.3mg/mL
and used to set up all 20 96-well plate LMB crystal screens. Each droplet was set
with 200nL of protein and 200nL of reservoir solution. Plates were incubated at
∼ 20°C and examined after 24 hours and one week for crystal growth. A) Crystals
observed from DHC-EJ in a condition with a reservoir solution composed of 0.1M
CAPS (pH = 10.5), 0.2M NaCl and 20% PEG (MW=8,000, w/v). B) Crystals
observed from DHC-EK. These crystals grew in the same condition as those shown
in A. Measure bars = 100µm.
have on crystallisation. DHC-EJ is just three residues longer than DHC-EI, yet it
produced a single initial hit out of 20 LMB screens, which did not diffract, whereas
DHC-EI produced dozens of initial hits, several of which diffract with sub-nanometer
resolution.
Model-based DHC-E constructs
In an attempt to take advantage of the new information revealed by the DHC-E
crystal structure, I made one last set of rationally designed constructs, which were
based on observations made while building the model. The first observation is that
the four and a half α-helices that are predicted to be at the C-terminus of DHC-E
(H13-H17 in Fig. 4.14) were not ordered enough to be found within the electron
density map. Although some of the shorter constructs in Table 4.11 eliminated
three of these αhelices, none of the truncations went far enough to eliminate all of
them. Therefore, I designed two new C-terminal truncations, both of which would
terminate shortly after H12, the final α-helix that I was able to build in the DHC-E
model. I called these constructs C-terminal A and C-terminalB (Table 4.12).
The second observation I used was that the DHC-E construct is sub-divided into
two distinct domains. The N-terminal ∼ 180 residues constitute a globular dimeri-
sation domain (Fig. 4.9C), whereas the remainder forms an α-helical elongated
domain (Fig. 4.9D). Furthermore, in the crystal structure, there are no apparent
contacts between these two domains other than the protein backbone that joins
them together. I hypothesised that the connection between these two domains may
be flexible and hinder crystal formation. I also hoped that by crystallising even one
of the two domains on its own, I would be able to build a higher resolution model
for that domain, and that by incorporated this into the complete DHC-E model,
the refinement would finally succeed for the entire DHC-E structure. Therefore I
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Name Last residue MW (kDa) Results
C-terminalA 1-411 47 X
C-terminalB 1-418 48 E
DimerA 1-177 20 E
ElongatedA 178-557 45 E,P
DimerB 1-181 21 E
ElongatedB 182-557 44 E,P,C,D
Table 4.12: List of six model-based constructs. The residues included and
predicted MW after TEV cleavage are shown for each construct. In the results
column, X=expression level was too low for purification, E=expression level was
high enough to complete purification through SEC step, P=SEC produced a peak
that was clean enough to set up crystal screens, C=crystal screens produced hits
that were optimised and screened for diffraction, D=crystals diffracted.
designed two pairs of constructs that would express each domain separately. The
first pair separated the two domains between residues 179 and 180 (DimerA and
ElongatedA) and the second pair separated the two domains between residues 181
and 182 (DimerB and ElongatedB) (Table 4.12).
I grew 1L cultures for each of these six model-based constructs and purified
the proteins. C-terminalA did not express at high enough levels to complete the
purification. DimerA and Dimer B, as well as C-terminalB expressed fairly well, but
did not perform well during SEC. Both elongated domain constructs expressed very
well and produced prominent, single, symmetrical peaks during SEC. Therefore, I
concentrated both samples to 5.3mg/mL and set up all 20 LMB crystal screens with
each sample, using the same conditions described above for the E region truncations.
ElongatedA failed to produce any crystal hits, but ElongatedB produced one
promising hit (Fig. 4.17). The condition, LMB9/B10 had a reservoir solution
composed of 0.1M MES (pH = 6.5), and 10% PEG (MW=20,000, w/v). Using
the in-house X-ray generator I confirmed that the crystals were protein and pro-
duced some reflections at ∼ 9A˚. Using the same strategies I described in Section
4.2.4, I optimised the ElongatedB crystals. The initial hit produced extremely thin,
2-dimensional plates, which were difficult to handle. After optimisation, I found a
condition (0.1M Tris (pH = 8.5) and 15% PEG (MW=10,000) that produced slightly
thicker, more durable crystals. When screened for diffraction using synchrotron ra-
diation, these crystals produced spots as far as 2.8A˚, but the highest resolution I
ever observed after processing a complete dataset was 3.3A˚.
I truncated the model from Section 4.2.6 to include only the residues that consti-
tute the ElongatedB construct. Using this as a search model, I performed molecular
replacement with the 3.3A˚ ElongatedB dataset. However, all attempts to phase
the ElongatedB crystals failed. I used several different datasets and processed the
datasets in various ways using different programs. For example, I tried integrating
with both XDS and iMOSFLM. I also tried imposing different sized unit cells, as
XDS sometimes calculated a unit cell that was twice the size of the one that iMOS-
FLM calculated, possibly indicating non-crystallographic pseudosymmetry. I also
made several variations of the search model by including more or fewer α-helices,
side-chains, loops, etc. I put all of these different datasets and search models into
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Figure 4.17: Crystal hits of the ElongatedB construct, which is the equiva-
lent of DHC-E without the dimerisation domain. The construct was purified
from 1L of E.coli, concentrated to 5.3mg/mL and used to set up all 20 96-well plate
LMB crystal screens. Each droplet was set with 200nL of protein and 200nL of
reservoir solution. Plates were incubated at ∼ 20°C and examined after 24 hours
and one week for crystal growth. Crystals formed in a condition with a reservoir
solution composed of 0.1M MES (pH = 6.5), and 10% PEG (MW=20,000, w/v).
Measure bar = 100µm.
various molecular replacement programs, experimenting with different parameters,
but I never obtained a clear solution. I looked at the models and electron density
produced by some of the highest scoring solutions, but there was always a problem
either with the crystal packing or the density itself was not realistic. This led me
to believe that there may be a significant conformational change between the elon-
gated domain in the DHC-E construct and the ElongatedB construct. Therefore,
I decided to phase the ElongatedB crystals experimentally, using the same SeMet
approach that was successful for the entire DHC-E construct. I successfully puri-
fied and crystallised a SeMet derivative of ElongatedB. A fluorescence scan of the
crystals showed that SeMet was successfully incorporated, but none of the SeMet
crystals diffracted beyond 6A˚. As I have only purified the SeMet derivative of Elon-
gatedB and crystallised it once, this could be due to day-to-day variations in the
protocol and may not indicate an inability of the SeMet protein to crystallise as well.
However, due to time constraints I have not been able to reproduce the experiment
and/or optimise the crystallisation of the SeMet sample in order to collect higher
resolution anomalous datasets.
Another possible explanation for why molecular replacement failed, which I could
not exclude at that point in time, was that the DHC-E model itself had serious errors.
Based on the experiments using REFMAC5 that I described in Section 4.2.6, this
did not seem likely, but the low resolution of the map and the very high R-factors
left it an open question. However, at the same time I was solving the structure of the
DHC N-terminus using X-ray crystallography, my colleagues in the Carter lab were
solving the structure of dynactin as well as a dynein tail/dynactin complex using
cryo-EM. This was relevant to my work for two reasons. First, their cryo-EM maps
of the dynein tail agreed with the model I had built using X-ray crystallography,
which provided some validation for the DHC-E model I had built. Second, the cryo-
EM structure of the dynein/dynactin complex revealed the interface between these
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two large complexes for the first time, and in doing so, shed light on why the DHC
N-terminus is required to take the 3-dimensional shape I had observed.
4.2.8 The DHC N-terminus at the dynein/dynactin inter-
face
Around the same time that I was building the initial model of the DHC-E construct,
my colleagues in the Carter group were solving a cryo-EM structure of the dynactin
complex purified from pig brains (Fig. 4.18). They showed that dynactin is made
up of 23 subunits, most of which are involved with forming and capping an actin-
like filament. The remaining subunits, including p150Glued, form the shoulder, a
subcomplex that wraps around part of the filament. They ultimately achieved an
overall resolution of 4.0A˚, reaching 3.5A˚ in the interior of the rigid filament.
Before the dynactin structure was solved, two other studies had already shown
that dynein and dynactin only form a stable complex in the presence of an adap-
tor, like BICD2N. Furthermore, only after forming this dynein/dynactin/BICD2N
triple-complex (DDB), does dynein become highly processive (Schlager et al. 2014,
McKenney et al. 2014). After the success my colleagues had in solving the dynactin
structure by cryo-EM, they set out to solve the structure of the DDB complex as
well. DDB proved an unsuitable sample for single-particle cryo-EM due to the in-
herent flexibility that the linker provides between the dynein motor domains and the
tail. So they focused instead on the triple-complex of a recombinant human dynein
tail, pig brain dynactin and a recombinantly mouse BICD2N (TDB). In fact, the
human tail complex, which was expressed in Sf9 cells, was designed using a DHC
truncation based on the one I had previously discovered in yeast when making the
DHC-NH tail construct Section 2.2.4).
The TDB complex was sufficiently stable that my colleagues were able to solve
the structure by cryo-EM (Fig. 4.19), although the overall resolution of 8.2A˚ was
lower than that of dynactin alone (4.0A˚). Nevertheless, the TDB structure provided
the first glimpse of the dynein/dynactin interface, and immediately provided new
insights into DDB function. For example, BICD2N runs along the entire length of
the dynactin filament, and makes extensive contacts with both dynein and dynactin.
This explains why dynein and dynactin fail to assemble in vitro in the absence of
Figure 4.18: Cyro-EM structure of the dynactin complex. A) A 4.0A˚ cryo-
EM map of dynactin segmented and coloured according to its components (EMDB
accession code 2857). B) A molecular model of dynactin (PDB accession code
5AFT). Figure adapted from Urnavicius et al. 2015 with permission of the author.
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Figure 4.19: Cyro-EM structure of the dynein tail/dynactin/BICD2N com-
plex (TDB). A) A cartoon model of the TDB complex. B) An 8.2A˚ cryo-EM
structure of TDB (EMDB accession code 2860). C) Another view of the cryo-EM
structure of TDB. The red box outlines a region of the dynein tail that resembles
the DHC-E crystal structure. D) A closer look at the boxed region from C and a
surface representation of the DHC-E crystal structure (PDB accession code 5AFR),
showing the similarity between the two structures. Figure adapted from Urnavicius
et al. 2015 with permission of the author.
BICD2N or other adaptors (Schlager et al. 2014, McKenney et al. 2014). However,
the limited resolution of the TDB structure made it difficult to interpret the dynein
tail region, the majority of which was even lower than 8.2A˚ resolution. The low
resolution cryo-EM map wasn’t sufficient to positively identify the C-terminus or
N-terminus of the dynein tail, as no labels had been included. Nor was it possible
to assign density to the different subunits within the tail complex with any amount
of certainty. For example, there were three globular domains visible, but it was not
clear whether they were made up of the DHC itself or the accessory subunits (DIC,
DLIC and DLCs) (Fig. 4.19).
Before the TDB structure was solved, I had already built the DHC-E model
based purely on the X-ray density map. But once the TDB structure was solved,
even a cursory glance at the region of the dynein tail closest to dynactin and BICD2N
was enough to see that it bore a resemblance to the DHC-E crystal structure (Fig.
4.19D). There were two elongated domains bridged together by a globular domain
and the dimensions of and spacings between these domains were similar to those of
the DHC-E model. By concluding that this part of the EM structure corresponds
to the DHC-E model, we identified one of the three globular domains (shown in
red in Fig. 4.20A) as the dimerisation domain, and therefore the N-terminus of the
DHC. Consequently, we concluded that the other end of the dynein tail was formed
by the C-terminus. By modelling the DIC WD40 domains using Phyre2 (Kelley &
Sternberg 2009), we were able to show that the DIC WD40 domains are roughly the
correct size and shape to fit into the other two globular domains at this end of the
dynein tail (Fig. 4.20B).
However, there was one clear difference between the DHC-E crystal structure and
the cryo-EM map of the dynein tail. In the crystal structure, the dimer contains a
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Figure 4.20: Assignment of density within the cryo-EM structure of the
dynein tail. A) The dynein tail density from has been segmented out of the TDB
structure (EMDB accession code 2860) and coloured to highlight different domains.
The similarity between the cryo-EM map and DHC-E crystal structure shown in
Fig. 4.19D allowed the assignment of the dynein tail N-terminus and C-terminus as
well as the dimerisation domain. B) The density containing the DIC WD40 domains
were assigned by showing that a homology model could fit into the cryo-EM density.
Figure adapted from Urnavicius et al. 2015 with permission of the author.
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Figure 4.21: The DHC-E crystal structure modelled into the TDB cryo-
EM electron density map. A) The DHC-E crystal structure (PDB accession code
5AFR), which clearly displays a two-fold rotational symmetry around the dimeri-
sation domain. The cartoon model shows that in ChainA, the N-terminal part of
the elongated domain is oriented toward the top of the figure, while in Chain B,
it is oriented toward the bottom of the figure. B) The DHC-E crystal structure
after each elongated domain has been separated from the dimerisation domain and
rotated in order to fit into the TDB cryo-EM density (EMDB accession code 2860).
The cartoon model shows that now the N-termini of both elongated domains are
oriented toward the bottom of the figure and both C-termini are oriented toward
the top. Figure adapted from Urnavicius et al. 2015 with permission of the author.
2-fold rotational symmetry, with the two elongated domains positioned anti-parallel
to each other (Fig. 4.21A). On the other hand, the dynein tail observed by cryo-EM
displays a translational symmetry, with the two DHCs running parallel to each other
(Fig. 4.20A). Even when building the DHC-E model for the first time, it seemed
likely that the rotational symmetry I observed was a crystal-packing artifact; in
order for dynein to function, the two motor domains must be oriented in the same
direction so that both microtubule-binding domains can reach the same microtubule.
However, with the crystal structure alone, I could not exclude the possibility that
the DHCs might turn toward each other after the first 400 residues that I could see
in the crystal structure, providing the translational symmetry required for dynein
motility.
A comparison between the DHC-E crystal structure and the TDB cryo-EM struc-
ture revealed how the elongated domains are arranged within the context of a pro-
cessive motor. Attempts to fit the DHC-E crystal structure into the cryo-EM density
were only successful once one of the elongated domains was rotated 180°, so that it
128
Figure 4.22: The elongated domains of the DHC-E crystal structure after
being fitted into the TDB cryo-EM electron density map. A) One of the
α-helical bundles from the elongated domain of the DHC-E crystal structure (PDB
accession code 5AFR) after fitting into TDB cryo-EM density (EMDB accession
code 2860). B) The other α-helcial bundle from the elongated domain after fitting
into TDB cryo-EM density. In this case, the cryo-EM map even contained clear
density for one more α-helix, which only showed weak density in the X-ray map.
Figure adapted from Urnavicius et al. 2015 with permission of the author.
Figure 4.23: The interface between the DHC N-terminus and the Arp1
filament of dynactin. The elongated domains of the DHC N-terminus slot into
adjacent grooves within the Arp1 filament of dynactin. The translational symmetry
and distance between the elongated domains of the DHC correlates precisely with the
translational symmetry and distance between Arp1 monomers within the dynactin
filament. Figure adapted from Urnavicius et al. 2015 with permission of the author.
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would run parallel to the other one (Fig. 4.21B). Once this rotation was performed,
the cryo-EM density fit the α-helices of the DHC-E elongated domains extremely
well (Fig. 4.21B, Fig. 4.22A). This provided further evidence for the idea that the
link between the dimerisation domain and the elongated domains is flexible, and
that the elongated domains can rotate freely with respect to the dimerisation do-
main. The electron density in this portion of the cryo-EM map was so clear that we
were able to model in one α-helix that I had not yet modelled due to weak density
in the X-ray maps (Fig. 4.22B). While the dimerisation domain roughly matched
the size and shape of the globular domain observed the in the cryo-EM map, the
density was not clear enough to see individual secondary structure elements.
The most unexpected discovery we made by combining the DHC-E crystal struc-
ture and TDB cryo-EM structures was the extensive interface that exists between
the DHC N-terminus and dynactin. Before these two structures were solved, the
most important dynein/dynactin interaction was thought to occur between the DIC
and p150Glued (McKenney et al. 2011). No interactions had been mapped between
the N-terminal 500 residues of the DHC and dynactin, yet this is where we observed
the majority of the contacts between dynein and dynactin and BICD2N (Fig. 4.23).
In conclusion, the agreement between the DHC-E crystal structure and the TDB
cryo-EM structure provided a means of validating the accuracy of both structures
and provided insights that could not be made from either structure alone. It was
only by taking advantage of the DHC-E crystal structure that it was possible to
assign specific dynein subunits within the TDB cryo-EM structure. Likewise, the
cryo-EM map confirmed that the rotational symmetry observed in the DHC-E crys-
tal structure is most likely a crystal artifact, as dynein must adopt a translational
symmetry in order to bind dynactin and BICD2N. Finally, all of this taken to-
gether led to the unexpected revelation that the DHC N-terminus is responsible for
a large number of the contacts between dynein, dynactin and BICD2N in the highly
processive DDB complex.
4.3 Discussion
4.3.1 The first crystal structure within the DHC tail region
The crystal structure of DHC-E was the first to be solved for any part of the DHC N-
terminus. Previously, residues 1363-4092 in S. cerevisiae and their equivalent from
D. discoideum had been crystallised (Schmidt et al. 2012, Kon et al. 2012). But
none of the N-terminal 1362 residues (about one third) had been crystallised, leaving
the cargo-binding domain unknown. The DHC-E crystal structure only allowed me
to build a model for ∼ 400 of these residues, but even from this relatively small
fraction of the DHC some interesting features could be seen for the first time.
The most prominent feature of the DHC-E crystal structure is the intricate ∼ 180
amino acid dimerisation domain that forms at the very N-terminus of the DHC (Fig.
4.9A,B,C). This dimerisation domain was previously unknown and completely unex-
pected. Several years ago, at least one study attempted to map a homodimerisation
domain within the DHC (Habura et al. 1999). However, their chemical cross-linking
and in vitro affinity methods failed to detect any homodimerisation activity at the
very N-terminus of the DHC. They instead mapped the key homodimerisation site
to residues 627-780 in D. discoideum. According to my alignment of 13 different
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cytoplasmic DHCs (Fig. 4.12), this region is equivalent to residues 527-681 in S.
cerevisiae. This corresponds to the region of the DHC just C-terminal to what I was
able to build in the crystal structure (residues 1-412). The cryo-EM TDB structure
includes the part of the DHC that is equivalent to this reported homodimerisation
site, which may overlap with the DIC binding sites (Fig. 4.20A). From the EM
structure, the DHCs don’t appear to contact each other at all after the N-terminal
dimerisation domain, but we can’t exclude the possibility that this is only true
within the TDB complex. So the dimerisation site reported by Habura et al. 1999
may exist only when dynein is on its own.
The presence of this unexpected dimerisation domain has complicated the al-
ready poorly understood question of how dynein homodimerises, . As I discussed in
Section 3.3.1, one of the most popular models in recent years has been that the DLCs
dimerise while also binding to the DICs, which themselves are bound to the DHCs,
thus the DLCs drive the homodimerisation of the entire dynein complex. However,
as I have shown in Section 3.2.4, even complexes that lack the region of the DIC
that binds the DLCs, and therefore lack the DLCs completely, purify as soluble and
well-behaved homodimers when analysed by SEC. The presence of the DHC dimeri-
sation domain may answer the question of how dynein was able to homodimerise
in the absence of DLCs, but it raises further questions. For example, what is the
importance of the DHC dimerisation domain relative to the DLCs? What happens
when only one or the other is present? If dynein lacks both of these mechanisms,
will it still dimerise? Later in the discussion, I propose some future experiments to
try to answer these questions.
Another prominent feature that came from the crystal structure is the clear
domain boundary between the dimerisation domain and the elongated domains. The
domains appear to not make any contacts, other than through the peptide backbone
that links them together into a single peptide (Fig. 4.11D), which suggested that
these two domains may be able to rotate freely with respect to one another. This
idea became even more plausible when we realised that the elongated domains must
rotate around this flexible connection in order to fit into the cryo-EM density of the
TDB map (Fig. 4.21). It is also worth noting that the elongated domain, which
has a much higher amount of sequence conservation than the dimerisation domain
(Fig. 4.12) corresponds well with the DHC-N1 domain family predicted by the Pfam
database (Finn et al. 2013).
4.3.2 The synergistic effect of combining the DHC-E crystal
structure with the TDB cryo-EM structure
This project was yet another example of how approaching the same complex using
multiple structural techniques can have a synergistic effect, which occurs when the
strengths from one technique fill in the gaps left by another. In this case, the crystal
structure was slightly higher resolution than the cryo-EM map. But perhaps even
more important in this case was the fact that the crystal structure included a smaller
fragment of a single, subunit. This helped in the assignment of density within the
cryo-EM map, since at 8.2A˚, it was impossible to be sure where specific subunits
of the full dynein complex should have been placed in the density (Fig. 4.19).
At the same time, the cryo-EM structure helped resolve the question of rotational
symmetry versus translatinoal symmetry between the two DHC elongated domains
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(Fig. 4.21). It also provided a biological context for the DHC-E construct, and quite
unexpectedly showed that this part of the dynein complex plays a key role in the
dynein/dynactin interface.
The hybrid crystal/cryo-EM TDB structure also answered some questions that
first arose when I calculated an initial 3D model of the dynein tail complex using
negative stain EM (Section 2.2.8). First, it established the orientation of the dynein
tail more conclusively, which is actually the opposite from what I first supposed,
based on the negative stain model (Fig. 2.25). It also allowed us to assign the
correct subunits to the three distinct domains that were visible in the negative stain
2D class averages.
However, this assignment added another twist to the already perplexing DHC
dimerisation domain. As I described in Section 2.2.8, one of the three domains is
only an intact dimer in some class averages, and in others, it is separated, giving
the complex the appearance of ”fraying” at one end. I initially speculated that this
might be the C-terminus of the DHC, which was flexible due to the truncation.
However, we now know that this density corresponds to the DHC N-terminus. So
in some classes, the DHC dimerisation domain appears not to be intact, even when
the rest of the tail remains tightly associated. This may mean that neither the
DHC dimersiation domain nor the DLCs are necessary for homodimerisation and
that the dimer interface is extensive. However, the cryo-EM structure does not
seem to support this, as the two dynein monomers appear fairly separate aside
from the DHC dimerisation domain (Fig. 4.20A). In agreement with the TDB
cryo-EM map, but in contradiction to my own negative stain data, a study that
was only just published shows many negative stain 2D class averages of the full-
length dynein complex with the two DHCs completely splayed apart (Chowdhury
et al. 2015). In this conformation, the only points of contact between the two
dynein monomers appear to be at the DHC N-terminus and one of the three DLCs
(LC7/Roadblock). For now, it remains something of a mystery how all of these
results can be accounted for by a single model. It is also worth noting that these
studies all used different constructs of dynein purified from different species, and
analysed them using different techniques.
For years, one of the big questions about dynactin has been why the primary
activator of dynein, a microtubule motor, is built around an actin-like filament. The
combined knowledge gleaned from both structures finally suggests an explanation.
As the rotation of the DHC elongated domains relative to the dimerisation domain
demonstrated, the dynein tail on its own is quite flexible and capable of adopting
many different conformations. Further evidence of this was very recently provided
by the negative stain EM work done by Chowdhury et al. 2015. However, as mi-
crotubules exhibit translational symmetry both along their length and around their
circumference, it follows that the two microtubule binding domains within a single
dynein motor must also exhibit translational symmetry in order to take steps in a
single direction and make forward progress. It seems that the best mechanism the
cell has for imposing translational symmetry on a molecule is simply to bind it to
another filament. So in a sense, the requirement that dynein has translation sym-
metry in order to walk along a microtubule is satisfied by binding it to the actin-like
filament within dynactin.
Finally, the TDB structure structure shed some light on why some of the exper-
iments I describe in Chapter 3 didn’t work. In Section 3.2.5 I present my efforts
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to bind a fragment of Nip100 (the yeast homologue of p150Glued) to the dynein tail
complex. This experiment was based on the consensus at the time, which was that
the primary interface between dynein and dynactin occurs between the N-terminus
of the DIC and a coiled-coil region of p150Glued. However, as the TDB structure
revealed, there are extensive contacts between the DHC and the Arp1 filament (Fig.
4.23). Neither the p150Glued coiled-coil domains nor the DIC N-terminus were visible
in the TDB structure, so it is still possible that the two do interact. But even if they
do, that interaction now seems less likely to have an effect on the overall stability
of the dynein tail than binding the entire dynactin complex would have. Therefore,
any future experiments attempting to stabilise the dynein tail with dynactin should
probably make use of the entire complex.
4.3.3 Future directions
The most obvious next step would be to continue my efforts to improve the resolu-
tion of the DHC-E crystal structure. Many of the strategies I described in Section
4.2.7 showed promise and a more focused effort on any one of these strategies may
provide the quality of data necessary to build a complete atomic structure. Per-
haps the first priority would be to continue crystallising the SeMet derivative of the
ElongatedB construct, as the native crystals did show some diffraction spots as far
as 2.8A˚. I could also try phasing these crystals using heavy atom soaks, or even
by performing molecular replacement using the appropriate segment of the cryo-
EM electron density map as search model. Improving the model of the elongated
domains to atomic resolution would improve the refinement of the entire DHC-E
structure, which might even be enough for the density in the dimerisation domain
to reach atomic resolution as well.
It would also be worthwhile to revisit some of the other constructs I tested, or
even to design new ones. For example, the DHC-EJ and DHC-EK constructs were
capable of crystallising, but I only had time for a brief attempt at optimising the
initial crystals. Investing a little more time and effort in optimising these crystals
may yield even crystals that are even better than the original DHC-E ones. Fur-
thermore, an even finer screen around the DHC-E truncation may be useful. I have
demonstrated on two separate occasions that changing a construct by less than 5
amino acids can be the difference between crystals that diffract to better than 3.5A˚
and no diffraction (DHC-EI vs. DHC-EJ) or even no crystals (ElongatedA vs. Elon-
gatedB) at all. Therefore, a screen that tests, for example, every possible C-terminal
truncation of the DHC between amino acids 550 and 560 might produce a construct
with a significantly higher diffraction power than the original DHC-E.
Another possibility is to revisit the initial goal I set in Section 2.1 of solving
the structure of the entire yeast tail complex. The crystal structure of DHC-E
(residues 1-557 of the DHC) only accounts for a part of the DHC-NH tail construct
(residues 1-1004) described in Chapter 2. So it might be worth trying to solve
the remainder of this complex by crystallography. As the DHC-E truncation seems
to have found a clear boundary domain, it might be possible to make the inverse
truncation, expressing only residues 558-1004 of the DHC along with the full length
accessory subunits. One explanation for why the DHC-E construct crystallised
while the whole tail complex did not is that there is a flexible connection between
the DHC-E construct and the remainder of the tail complex. If separating the N-
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terminal half from the rest is what allowed the DHC-E construct to crystallise, it is
conceivable that the C-terminal half might crystallise on its own as well.
One simple, yet interesting experiment would be to try and form the TDB triple
complex using only the human equivalent of the DHC-E construct rather than the
whole tail complex. I have already purified large amounts of this construct when I
attempted to crystallise it. Since the cryo-EM structure of the TDB complex suggets
that the majority of the contacts that dynein makes with both dynactin and BICD2N
occur through the elongated domains at the DHC N-terminus, this construct may
still be able to form the TDB complex, even without any of the dynein accessory
chains. Not only would this test whether the rest of the tail complex is necessary
for complex formation, but if not, the resulting complex might be more rigid, and
therefore a more suitable sample for cryo-EM. Since the DHC C-termini and all of
the accessory chains were very flexible in the TDB map, a complex that includes
only the DHC-E construct of dynein might result in more uniform particles and a
higher resolution for the overall map.
Now that we have a better understanding of how mammalian dynein binds dyn-
actin and BICD2N to become processive, the question of how this process occurs in
yeast becomes even more complicated. There aren’t any known BICD2 homologues
in yeast, but the one known cargo, Num1, is predicted to contain a long coiled-
coil motif in its N-terminus, the same part that is responsible for dynein binding
(X. Tang et al. 2012). Therefore, one could imagine that in yeast Num1, which is
found at the cell cortex, recruits dynein and dynactin and allows them to assem-
ble into a triple complex similar to TDB. The situation is not a perfect parallel
because unlike mammalian dynein, yeast dynein is processive on its own, although
dynactin has been shown to have the effect of increasing processivity (Kardon et al.
2009). This study used endogenously expressed dynein and dynactin, purified from
yeast, meaning it is possible there was also an endogenous cargo adaptor, like Num1,
present when extra-processive dynein/dynactin complexes were formed. So it might
be revealing to reproduce these results using recombinant full-length dynein, recom-
binant dynactin, both in the presence and absence of recombinant Num1. If a yeast
dynein/dynactin complex can be formed without any adaptor, it would also be in-
teresting to solve its structure by cryo-EM for a comparison with the mammalian
version. Any differences between the two structures might answer the question of
why yeast dynein is processive on its own, whereas mammalian dynein requires
BICD2N and dynactin.
Finally, one way to test the relative importance of the DHC dimerisation domain
versus the DLCs would be to make a mutant yeast strain that lacks the first 181
residues of the DHC, and compare it to the DIC-H truncation described in Section
3.2.4, which lacks the DLC binding sites of the DIC. I would also make a strain that
combines these two mutations, to see if this prevents homodimerisation completely
or if there are even more mechanisms in place. Rescue strains could be created by
replacing the DHC dimerisation domain and the DIC N-terminus with a glutathione
S-transferase (GST) domain, or other known homodimer domain. As a background
for each of these mutant strains I would use CY286, the strain I described in Section
2.2.2, which overexpresses the full-length dynein complex. That way I would be able
to purify the mutant complexes and characterise them biochemically. After checking
whether each mutant forms a dimer or monomer by SEC-MALS, their motility could
be measured using an in vitro motility assay. The strains could also be analysed in
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vivo by testing each mutant in a spindle osciliation assay. This is a sensitive way to
detect a defective dynein phenotype by measuring how rapidly the spindle oscillates
through the bud neck of hydroxyurea arrested yeast cells (Toropova et al. 2014).
4.3.4 Conclusions
In this chapter I have presented the crystal structure of the DHC-E construct, which
constitutes the DHC N-terminus. I described each step of the structure solving
process, including purification, initial crystal screening, crystal optimisation, data
collection, experimental phasing and model building. This was the first crystal struc-
ture of any part of the DHC tail domain. It revealed that the N-terminal ∼ 180
residues of the DHC form a previously unknown dimerisation domain. Furthermore,
this crystal structure was fit into and allowed the interpretation of a cryo-EM struc-
ture of the dynein tail/dynactin/BICD2N complex. This hybrid structure provided
the unexpected insight that dynein interacts with dynactin primarily through the
DHC N-terminus. The combination of these two structures has provided a first
glimpse at how dynein adopts its processive conformation by binding dynactin and
one known adaptor, thus paving the way for future studies to probe how cytoplasmic
dynein interacts with diverse cargoes in order to carry out its myriad roles within
the cell.
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Chapter 5
Methods
5.1 Molecular Biology
5.1.1 General techniques
Polymerase chain reaction (PCR)
Genes were amplified using the Phusion High-Fidelity DNA Polymerase kit (New
England BioLabs) according to the manufacturer’s protocol. A standard 50µL reac-
tion volume contained 10µL of 5X Phusion HF buffer, 5µL of 2mM dNTPs, 0.25µL
forward primer, 0.25µL reverse primer, < 250ng of template DNA, 0.5µL of Phu-
sion polymerase and enough ddH2O to bring the total volume to 50µL. The mixture
was vortexed, centrifuged briefly and put in a thermocycler set to run the following
program with 35 cycles of denaturation, annealing and extension:
Step Temperature (°C) Time
Initial denaturation 98 30s
Denaturation 98 10s
Annealing 68 30s
Extension 72 30s/kb
Final extension 72 10min
PCR stitching was performed similarly, but with an equal amount of two tem-
plates that overlapped by ∼ 20bp.
Verification and gel extraction of PCR products
Each 50µL PCR product was mixed with 5µL of 10X DNA loading buffer (3.7M
bromphenol blue, 50mM Tris-HCl (pH = 7.6) and 60% glycerol (v/v)). Samples
were then run in a 1% agarose gel containing SYBR Safe DNA gel stain (Thermo
Fisher Scientific) at 120V for 30 to 60min. At least one lane was loaded with
10µL of the 1Kb+ DNA Ladder (Thermo Fisher Scientific) in order to confirm the
approximate length of PCR products. A blue light was used to visualise DNA
bands, which were excised using a scalpel. DNA was purified using QIAquick Gel
Extraction Kit (QIAGEN) according to the manufacturer’s protocol. Each excised
sample was added to three volumes of QG buffer and incubated at 50°C until agarose
was fully dissolved. DNA was bound to a QIAquick spin column by applying and
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centrifuging at 17, 900g for 60s. The column was washed by adding 750µL of PE
buffer and centrifuging twice more at 17, 900g for 60s each time, removing flow-
through between spins. DNA was eluted by adding 30µL of EB buffer or ddH2O to
the spin column, incubating for 60s, then placing the column in a 1.5mL centrifuge
tube and centrifuging at 17, 900g for 60s. Final DNA concentration was determined
from a 2µL sample using a NanoDrop.
Plasmid purification from bacterial stocks
Plasmids were purified from bacterial stocks using QIAprep Spin Miniprep Kit (QI-
AGEN) according to the manufacturer’s protocol. A single colony of bacteria was
used to inoculate 10mL of 2X TYE medium containing the antibiotic for which the
plasmid of interest provides resistance. This culture was incubated at 37°C with
210RPM shaking overnight. 2mL of the overnight culture was decanted into a 2mL
centrifuge tube and centrifuged at 8, 000g for 3min. The supernatant was discarded
and the pellet was resuspended in 250µL buffer P1. After adding 250µL buffer P2,
the tube was gently inverted 6 times, or until the entire solution was a homogeneous
blue. Then 350µL of buffer N3 was added and the tube was gently inverted another
6times, or until all the blue colour disappeared. The tube was centrifuged at 17, 900g
for 10min and the supernatant was recovered and applied to a QIAprep spin column,
which was then centrifuged at 17, 900g for 1min. The flow-through was discarded,
and the column was washed by adding 750µL of PE buffer and centrifuging twice
more at 17, 900g for 60s each time, removing flow-through between spins. DNA
was eluted by adding 30µL of EB buffer or ddH2O to the spin column, incubating
for 60s, then placing the column in a 1.5mL centrifuge tube and centrifuging at
17, 900g for 60s. Final DNA concentration was determined from a 2µL sample using
a NanoDrop.
Preparation of Gibson assembly mix (GA)
50mM NAD (AppliChem) was prepared by dissolving 33.2mg in 1mL MPW. Then
3mL of 1M Tris-HCl (pH = 7.4), 300µL of 1M MgCl2, 60µL of 100µM dNTPs
(Fermentas), 300µL of 1M DTT (Fermentas), 1.5g of PEG (MW = 8, 000, v/v),
600µL of 50mM NAD and enough ddH2O to bring the total volume to 6mL were
mixed together. The resulting isothermal assembly buffer (IAB) was divided into
320µL aliquots and stored at −20°C until ready for the next step. To each thawed
320µL aliquot of IAB, 1.2µ T5 exonuclease (New England BioLabs), 20µL Phusion
polymerase (New England BioLabs), 160µL Taq ligase (New England BioLabs) and
700µL MPW were added. The resulting Gibson assembly mix (GA) was divided
into 15µL aliquots and stored at −20°C.
Ligation of PCR products into vectors via Gibson assembly
Acceptor vectors were linearised either by a double digest with two site-specific
restriction enzymes or by PCR amplification. The approximate size of the linear
vector was confirmed by gel electrophoresis and purified by gel extraction as de-
scribed above. Inserts were designed to include 15 to 25bp overlap with each end
of the linear vector and created using PCR as described above. In a total volume
< 5µL, 100ng of insert and 100ng of linear vector were added to 15µL of GA mix.
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The final mixture was vortexed, centrifuged and incubated at 50°C for 30min. The
ligated product was either frozen at −20°C for storage or transformed into bacteria
immediately.
Preparation of competent bacterial cells
A single colony of the required strain was used to inoculate a 3mL culture, which
was incubated at 37°C with 210RPM shaking overnight. The overnight culture
was used to inoculate 25mL of SOB (VWR) in a 250mL polycarbonate Erlenmeyer
flask, which was incubated at 37°C with 210RPM shaking for 12 to 14hr. 2mL of
this culture was used to inoculate 250mL of SOB++ (SOB plus 10mM MgCl2 and
10mM MgSO4) in a 1L polycarbonate Erlenmeyer flask. This culture was incubated
at 20°C with 210RPM shaking until the OD600 was between 0.3 and 0.6. The flask
was then put on ice for 60min and the cells were pelleted by centrifuging in detergent
free bottles at 4, 200g and 4°C for 10min. The pellets were gently resuspended in
80mL CCMB80 buffer (10mM KOAc (pH = 7.0), 80mM CaCl2, 20mM MnCl2,
10mM MgCl2 and 10% glycerol (v/v)) and incubated on ice for 20min. The cells
were pelleted again by centrifuging at 4, 200g and 4°C for 10min and resuspended
gently in 10mL of CCMB80 buffer. The OD600 of this suspension was adjusted to
5.0 and the cells were divided into 100µL aliquots and stored at −80°C.
Bacterial transformation of GA reactions or purified plasmids
A 30µL aliquot of competent cells was thawed on ice. When the incubation was
complete, 1µL of ligated GA reaction or purified plasmid was added to the competent
cells. The tube was gently flicked and placed back on ice for 20min. Then the
bacteria were heatshocked by placing the tube in a 42°C water bath for 45s and
quickly moving it back on ice for another 2min. If the antibiotic marker being used
required a recovery step, 900µL SOC medium (2% tryptone, 0.5% yeast extract,
10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO2 and 20mM glucose) was
added and the culture was allowed to recover at 37°C for 1 to 4hr. After recovery,
the culture was briefly centrifuged to pellet cells, the supernatant was discarded, and
the pellet was resuspended in 30µL sterile ddH2O. The cells were then spread on
TYE agar plates containing the appropriate antibiotic for selection of transformed
bacteria.
Verification of new plasmids and storage as glycerol stocks
A sample of each plasmid constructed using the methods described above was sent
for Sanger sequencing at Source Bioscience (Cambridge, UK) in order to confirm
the sequence. Both forward and reverse primers were used to ensure sufficient re-
dundancy between reads. Once a plasmid’s sequence was confirmed, the remaining
8mL of the overnight culture used in the miniprep was centrifuged at 4, 000g for
5min. The supernatant was discarded and the pellet was resuspended in 900µL of
20% glycerol (v/v). This suspension was stored at −80°C and used to inoculate a
TYE agar plate for future experiments.
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Transformation of PCR products or plasmids into yeast
A single colony of the acceptor strain of yeast was used to inoculate 10mL of YEPD
media. The culture was incubated at 30°C with 200RPM shaking overnight. The
OD600 of the overnight culture was determined and the required volume was used to
inoculate 100mL of YEPD to an initial OD600 of 0.2. This culture was incubated at
30°C with 200RPM shaking until the OD600 was between 0.5 and 0.7. The cells were
pelleted by centrifuging in two 50mL tubes at 1,000g for 5min and then resuspended
in 20mL sterile ddH2O and combined. They were pelleted again and resuspended
in 1mL of LiAc TE buffer (100mM LiAc, 10mM Tris-HCl (pH = 7.5) and 1mM
EDTA). For each transformation, 100µL of cell suspension was moved to a 2mL
centrifuge tube. Either 20 to 50µL of PCR product or 1µL of purified plasmid was
added to the cells. Then 5µL of pre-boiled salmon sperm DNA (ssDNA) and 600µL
of PEG LiAc TE (LiAc TE with 40% PEG (MW = 3,350, v/v) were added. The
tube was gently inverted several times and the cells were incubated in a 30°C water
bath for 30min. 70µL of sterile DMSO was added and the tube was mixed again
by gentle inversion and incubated in a 42°C water bath for 15min. The cells were
pelleted by centrifuging at 4,000g for 5min and resuspended in 100µL sterile ddH2O.
The suspension was then spread on the appropriate selective plates and incubated
at 30°C for 3 days. Single colonies were restreaked on selective plates and incubated
at 30°C for another 3 days.
Colony PCR for verification of yeast strains and storage as glycerol stocks
After restreaking newly constructed yeast strains, single colonies were picked and
resuspended in 10µL of 10mM NaOH. The suspension was incubated at 95°C for
30min and centrifuged briefly in a tabletop centrifuge to pellet cell debris. The
supernatant was reserved as a genomic DNA template for colony PCR. Forward
and reverse primers were designed to bind ∼ 250bp to each side of successful ho-
mologous recombination sites. In this way, a ∼ 500bp fragment would be amplified
only if the transformation was successful. 25µL PCR reactions were set up using
the Quick-Load Taq 2X Master Mix kit (New England BioLabs) according to the
manufacturer’s protocol. 1µL of genomic DNA template, 0.25µL of each primer (at
100µM) and 11µL of ddH2O were added to 12.5µL of Quick-Load Taq 2X Master
Mix. The mixture was vortexed, centrifuged briefly and put in a thermocycler set to
run the following program with 30 cycles of denaturation, annealing and extension:
Step Temperature (°C) Time
Initial denaturation 95 30s
Denaturation 95 15s
Annealing 60 30s
Extension 68 1min/kb
Final extension 68 5min
10µL samples from each PCR reaction were analysed via gel electrophoresis as
described above. A colony from any strains that were positive for all intended
homologous recombination events was used to inoculate a 10mL culture, which was
incubated at 30°C with 200RPM shaking overnight. The culture was then pelleted by
centrifuging at 4, 000g for 3min and the supernatant was discarded. The pellet was
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resuspended in 900µL of 20% glycerol (v/v). This suspension was stored at −80°C
and used to inoculate the appropriate selective agar plate for future experiments.
5.1.2 Cloning for expression in S. cerevisiae
Cloning for expression from pYES2 plasmids
Dynein genes were amplified by PCR using genomic DNA from the wild type yeast
strain W303 (CY176, Fig. A.4) as a template. Inserts were assembled by combining
fragments via PCR stitching and then ligated into the linearised pYES2 vector
by Gibson assembly. The Gibson reaction products were transformed into E. coli
and plated on ampicilin containing TYE plates for selection of successfully ligated
plasmids. Bacterial colonies were used to inoculate 10mL overnight cultures, and
then minipreps were performed to isolate plasmid DNA. Plasmid sequences were
confirmed by Sanger sequencing. Successful clones were added to the Carter lab
plasmid library as glycerol stocks and documented in the database. A list of all
plasmids described in this thesis can be found in the Appendix (Figs. A.5 and A.6).
Plasmids were transformed into expression strains such as DSY-5 (CY223, Fig.
A.4) and BCY123 (CY282, Fig. A.4). Yeast was plated on Ura- selective plates
and incubated at 30°C for 3 days. Single colonies were restreaked on Ura- plates
and incubated for another 3 days at 30°C. Single colonies from this plate were used
to inoculate 10mL overnight cultures, either to make a glycerol stock of the strain
containing the plasmid, or to begin an expression immediately.
Cloning for expression from endogenous genes
The commercial strain, DSY-5 (CY223, Fig. A.4) was used as a background strain.
Linear DNA fragments were assembled using PCR to amplify individual segments
and PCR stitching to join multiple fragments together. For homologous recom-
bination, linear DNA fragments were designed to include 500bp of overlap with
the genomic sequence on both sides of the site of recombination. Auxotrophic
marker genes used for selection were amplified from closely related fungal species
other than S. cerevisiae. This was to ensure that the gene product would be func-
tional within the S. cerevisiae biosynthetic pathway, but would not have a similar
enough DNA sequence to favour homologous recombination with the endogenous
auxotrophic marker gene. For example, when using a background strain with the
common ura3-52 point mutation for selection, the functional URA3 gene from K.
lactis was included in the linear DNA fragment.
Once constructed and purified, linear DNA fragments were transformed into the
background strain and yeast was plated on auxotrophic selective plates. After three
days, plates were checked for colonies and successful clones were restreaked on a
fresh selective plate. After three more days, a single colony was picked and tested
by colony PCR and/or Sanger sequencing to verify the presence of the intended
genomic modification. Successful clones were added to the Carter lab yeast library as
glycerol stocks and documented in the database. A list of all yeast strains described
in this thesis can be found in the Appendix (Fig. A.4).
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5.1.3 Cloning for expression in Sf9 cells
Transformation of plasmids into EMBacY cells to generate bacmid
All plasmids were assembled using PCR and Gibson assembly and then verified
by Sanger sequencing. The pACEBAC1 vector was used for all baculovirus ex-
pression plasmids (Geneva Biotech). To prepare bacmids, verified plasmids were
diluted to 25ng/µL and 1µL of dilute plasmid was transformed into a 30µL aliquot
of EMBacY competent cells. Cells were recovered without antibiotics for 4 hours
and then plated on selective plates containing kanamycin (50µg/mL), gentamycin
(7µg/mL), tetracylcine (10µg/mL), Blue-Gal (100µg/mL) and IPTG (40µg/mL).
After 48 hours, white colonies were selected and grown in 3mL 2xTY media plus
kanamycin (50µg/mL), gentamycin (7µg/mL) and tetracylcine (10µg/mL) overnight
at 37°C. The next morning, an inoculating loop was used to streak a new selective
plate to ensure that only white colonies would grow before proceeding with the
bacmid.
Bacmid preparation
The bacmid prep was begun by centrifuging an overnight culture at 4000g for 5min.
The resulting pellet was resuspended in 300µL P1 buffer (Qiagen) and transferred to
a 2mL eppendorf tube. After adding 300µL P2 buffer (Qiagen), the tube was mixed
by gentle inversion and incubated at RT for 5min. 400µL P3 buffer (Qiagen) was
added and the tube was mixed again by gentle inversion and left on ice for 6min. The
tube was centrifuged at 13,000RPM for 10min to pellet the white precipitate that
formed. The supernatant was transferred to a new tube and centrifuged again to
remove residual chromatin flakes. The supernatant was moved again to a new tube
that contained 800µL isopropanol at RT. The tube was mixed by gentle inversion
and placed on ice for 10min. The tube was centrifuged at 13,000RPM for 10min at
RT before removing the supernatant and adding 500µL of RT 70% ethanol. The
tube was inverted several times to wash the DNA pellet and then centrifuged at
13,000RPM for 5min at RT. This ethanol was was repeated two more times for
a total of three washes. Then the supernatant was removed and the DNA pellet
was allowed to airdry for no longer than 1min before gently dissolving it in 50µL
sterile-filtered EB buffer (Qiagen) on ice. DNA concentration was determined by
Nanodrop and bacmids were stored at 4°C.
Transfection of bacmids into Sf9 cells to generate baculovirus
2mL of Sf9 cell suspension that was already at 5x105 cells/mL was placed into a
6-well plate. The cells were left to attach to the plate surface while bacmid DNA
mix was prepared. To prepare bacmid DNA mix, 198µL medium (SF900-II, Life
Technologies) was gently mixed with 2µL bacmid DNA (prepared at 1µg/µL). 6µL
of FuGENE HD Trasnfection Reagent (Promega) was added directly to the bacmid
DNA mixture while ensuring that no undiluted FuGENE came in direct contact with
the plastic tube. The bacmid DNA mixture was incubated at RT for 15min. 10min
into these 15min, media was removed from the attached Sf9 cells. 800µL fresh media
was added to the incubated bacmid DNA mixture, which was then added directly
to the attached Sf9 cells. The plate was incubated for 3 days at 27°C in a plastic
dish that also contained damp paper towels to maintain a high humidity. After the
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first day, 1mL fresh media was added to the cells. At the end of the three days,
2mL of media was removed, which served as the P1 virus stock. Virus stocks were
stored at 4°C.
5.1.4 Cloning for expression in E. coli
Cloning of DHC-E for expression in E. coli
A gene encoding the N-terminal 557 amino acids of the dynein heavy chain (DHC-E)
of S. cerevisiae was commercially synthesised (GeneArt, Thermo Fisher Scientific).
This synthetic gene was codon optimised for Sf9 cells, although it was ultimately
expressed in E. coli. The gene was cloned into a modified pRSET(A) plasmid, which
links a His-lipoyl domain fusion tag to the N-terminus via a TEV cleavage site (Dodd
et al. 2004). This plasmid was a generous gift from Mark Allen. The final plasmid
was verified by Sanger sequencing.
All other bacterial constructs were inserted into the same pRSET(A) vector.
Inserts used to express further E-region truncations were amplified off of existing
template sequences using PCR. Inserts used to express the DHC-E construct from
12 different species were synthesised (GeneArt, Thermo Fisher Scientific) and codon
optimised for E. coli.
5.2 Protein expression and purification
5.2.1 General techniques
SDS-PAGE analysis of protein samples
Dilute protein samples (< 3mg/mL) were prepared for SDS-PAGE by directly
adding 15µL of protein to 5µL of 4X NuPAGE LDS sample Buffer (Thermo Fisher
Scientific). More concentrated samples were first diluted with ddH2O and then
added to NuPAGE LDS sample buffer in the same way. Samples were vortexed and
centrifuged briefly in a tabletop centrifuge, then placed in a 95°C water bath for
5min. 10 to 20µL of sample were loaded into each well of precast NuPAGE Novex
4−12% Bis-Tris Protein Gels (Thermo Fisher Scientific). Gels were run in either 1X
NuPAGE MOPS SDS Running Buffer or 1X NuPAGE MES SDS Running Buffer
(both Thermo Fisher Scientific) depending on the expected distribution of protein
molecular weights in the sample. A voltage of 200V was applied for between 30 and
45 minutes, then the gels were rinsed, submerged in InstantBlue (Expedeon) and
gently shaken for > 1hr. Gels were destained in ddH2O for > 1hr and imaged using
a Gel Doc XR system with a white light conversion screen controlled by Image Lab
software (all Bio-Rad).
5.2.2 Expression in S. cerevisae
Shaker flask expression
For each litre grown, a 10mL YEPD starter culture was inoculated from a single
colony and grown overnight at 30°C with 200RPM shaking. The next evening, the
10mL culture was transferred to a 2L flask that contained 1L of 2xYEPD. This was
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grown overnight at 30°C with 200RPM shaking. The following afternoon, the culture
was monitored to determine when all the glucose had been consumed. This was
initially done by measuring the OD600 periodically to see when it no longer increased.
Later, it became possible to simply dip a urinalysis test strip (Diastix, Bayer) in
a 1mL sample of culture to determine the remaining glucose concentration. Once
glucose had been depleted, 100mL of 20% galactose was added, to induce expression.
Cells were induced overnight at 30°C and 200RPM. The following morning cells were
harvested by centrifuging in 1L bottles at 4000RPM for 5min. The supernatant was
discarded and the pellet was resuspended in ddH2O. The cells were centrifuged
again at 4000RPM for 5min and the supernatant was discarded. The cells were
resuspended in as little ddH2O as possible and then flash frozen in LN2. The frozen
pellet was ground into a fine powder using a waring blender, pre-cooled with LN2
and stored at -80°C.
120L fermentor expression
Fermentor expression was similar as in shaker flasks, aside from the scale and equip-
ment used. 6 10mL starter cultures were grown and used to inoculate 6L of YEPD.
These were grown overnight and then used to inoculate ∼ 108L of 2xYEPD. The
fermentor was kept at 30°C and the agitator was kept at 300RPM throughout the
growth. Once the glucose had been fully consumed, 6L of 40% galactose was added,
and cells were induced overnight. The cells were harvested in the same way as from
shaker flasks.
5.2.3 Purification from S. cerevisae
Small-scale protein purification from yeast
A stock of 4X lysis buffer (120mM HEPES (pH = 7.2), 200mM KC2H3O2, 8mM
MG(C2H3O2)2, 4mM EGTA, 40% glycerol (v/v)) was prepared in advance. The
day of the purification, 100mL of 4X lysis buffer was made up to 1mM DTT, 0.1mM
MgATP, 1mM PMSF and 0.8% Triton X-100. Lysis was achieved by adding 6mL
of this fresh 4X lysis buffer to 30mL of frozen yeast powder in a 50mL Falcon tube.
The tube was placed in a 37°C water bath until all the powder had just thawed, at
which point it was returned to ice. The lysate was centrifuged in a Type 70 ti rotor
at 70,000RPM and 4°C for 30min. While the lysate was spinning, 0.2mL of packed
IgG Sepharose beads (GE Healthcare) were washed into 1X lysis buffer. The lysate
supernatant was collected in a 50mL falcon tube and then the washed IgG beads
were added. The lysate was nutated at 4°C for 1hr. The lysate was poured into a
disposable column (BioRad) and the beads were washed twice with 1X lysis buffer.
The beads were then washed three times with 1X TEV buffer (20mM Tris-HCl
(pH = 8.0), 150mM KCl, 10% glycerol (v/v), 1mM DTT and 0.1mM MgATP) and
resuspended in ∼ 500µL of TEV buffer. The beads were moved to a 2mL Eppendorf
tube and the slurry was allowed to settle. Buffer was removed by pipette until the
remaining total volume was ∼ 300µL. 3µL of TEV protease was added and the tube
was gently shaken at 16°C for 1hr. The tube was spun to pellet the beads and the
supernatant was collected, and usually concentrated prior to SDS-PAGE analysis.
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Large-scale protein purification from yeast
Large-scale purification of dynein from yeast was performed in a similar way as the
small-scale purification, except after TEV cleavage, anion exchange chromatography
and size exclusion chromatography steps were added. The first part of the purifica-
tion was performed using the same buffers, and mostly the same protocol except for
scaling each step proportionally to the volume of yeast powder being used. When
purifying dynein from yeast grown in the 120L fermentor, up to 2L of yeast powder
could be feasibly purified at one time.
One difference is that the TEV digest was performed overnight at 4°C rather than
for 1hr at 16°C. After the TEV digest step, the degree of cleavage was determined
by SDS-PAGE analysis. If cleavage was sufficient, the sample was diluted into buffer
A (50mM Tris (pH = 8.0), 20mM KCl and 1mM DTT) and loaded onto a MonoQ
column. The column was then washed with 10 column volumes of buffer A to remove
unbound protein. Then, a salt gradient was applied using Buffer A as the low-salt
component and Buffer B (50mM Tris (pH = 8.0), 500mM KCl and 1mM DTT) as
the high salt component, until the protein eluted. The eluted protein’s identity was
confirmed using SDS-PAGE and then it was concentrated and loaded on a Superose6
column for size exclusion chromatography. This run exchanged the protein sample
back down into TEV buffer, which the sample was kept in for further experiments,
or for long-term storage at -80°C.
5.2.4 Expression in Sf9 cells
P2 virus amplification
50mL of Sf9 cells at 1-2x106 cells/mL was placed in a 1L disposable Erlenmeyer
flask. The cells were infected with 500µL of P1 virus and then incubated at 27°C
with 124RPM shaking for 72hr. With virus that originated from EMBacY cells, it
was possible to check fluorescence of the cells visually as a qualitative indicator of
infection and expression levels. Cells were harvested by centrifuging at 3750RPM
for 10min at RT. The supernatant was preserved in sterile conditions and stored
at 4°C in the dark as the P2 virus stock. For new constructs, the pellet from the
P2 generation was often used for a small-scale test purification. At minimum, the
crude lysate was analysed by SDS-PAGE to determine whether the construct had
expressed and was soluble or not before scaling up protein expression.
Large-scale protein expression
500mL aliquots of Sf9 cells were grown to 1-2x106 cells/mL in 3L roller bottles with
the caps left slightly loose for aeration. 5mL of P2 virus was added to each 500mL
aliquot of cells and the cells were left to grow at 27°C with 124RPM shaking for 72hr.
Cells were harvested by centrifuging at 3750RPM for 10min at 4°C. The supernatant
was discarded (unless making a P3 virus stock) and cells were resuspended in ∼
40mL of ice-cold PBS. The cells were centrifuged again at 3750RPM for 10min at
4°C. The supernatant was discarded and pellets were flash frozen in LN2 before
storing at -80°C.
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5.2.5 Purification from Sf9 cells
Dynein was purified from Sf9 cells using the same method as for purifying dynein
from yeast. The only difference was that cell lysis was achieved by resuspending the
frozen pellet in 1X lysis buffer and then using 50 strokes in a glass tissue homogeniser.
From this point on the purification was identical to a yeast one, although the yield
was much higher, so more IgG Sepharose beads had to be use for the same mass of
a cell pellet.
5.2.6 Expression in E. coli
Expression of DHC-E in E. coli
The plasmid designed for the expression of DHC-E in E. coli (described above) was
transformed into SoluBL21 cells (Genlantis), which were grown in 2XTY media,
supplemented with 7mg/L of ampicillin and 1mM MgSO4 at 37°C with 210RPM
shaking. The cultures were grown to an OD600 between 0.3 and 0.4, cooled to 16°C
and induced overnight with 1mM IPTG. The cells were pelleted by centrifuging at
8, 000g for 20min and then flash frozen in liquid nitrogen and stored at −80°C.
5.2.7 Purification from E. coli
Purification of DHC-E from E. coli
Cell pellets from 6L of bacterial culture from the expression of DHC-E were thawed
on ice in 150mL of bacterial lysis buffer (30mM Hepes-NaOH (pH = 7.4), 200mM
NaCl, 2mM MgCl2, 1mM PMSF, 10mM imidazole, 10mM BME and 0.1mM Mg-
ATP) supplemented with protease inhibitors (Complete-EDTA Free, Roche Applied
Science). This suspension was sonicated on ice at maximum amplitude for 3min with
3s on and 7s off pulses. The lysate was cleared by centrifuging in a Ti45 rotor (Beck-
man Coulter) at 40,000RPM and 4°C for 40min, syringe filtered through a 0.22µm
filter (Elkay) and loaded onto two tandem 5mL HisTrap columns (GE Healthcare)
that were pre-equilibrated in buffer NiA (30mM Hepes-KOH (pH = 7.4), 200mM
NaCl, 2mM MgCl2, 10mM imidazole, 10mM BME and 0.1mM Mg-ATP). Unbound
proteins were washed off the columns with 50mL of buffer NiA. The protein of in-
terest was eluted in a single 15mL fraction with buffer NiB (30mM Hepes-KOH (pH
= 7.4), 200mM NaCl, 2mM MgCl2, 500mM imidazole, 10mM BME and 0.1mM Mg-
ATP). This fraction was exchanged back into buffer NiA by concentrating (30kDa
molecular weight cut-off concentrator, Amicon Ultracel, Merck-Millipore) to ∼ 1mL
and diluting with 15mL of buffer NiA twice. Subsequently, the sample was incu-
bated with 1mL of TEV protease (3.7mg/mL) and incubated on a roller at 4°C
overnight. After TEV cleavage (confirmed by SDS-PAGE), the sample was run
back through two tandem 5mL HisTrap columns (GE Healthcare), pre-equilibrated
in buffer NiA. The flow-through was collected, concentrated to approximately 5mL
and run through a HiLoad 26/600 Superdex200 column (GE Healthcare) that had
been pre-equilibrated in GF buffer (30mM Hepes-NaOH (pH = 7.4), 200mM NaCl,
2mM MgCl2, 10mM BME and 0.1mM Mg-ATP). This run resulted in two distinct
peaks (Fig. 4.3), one near the void volume and the other at the expected elution
volume for a dimer of DHC-E. The dimer peak was pooled, concentrated to ∼ 5mL
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and run back through the same column, which was now equilibrated in crystallisa-
tion buffer (20mM Tris-NaOH (pH = 8.0, 150mM KCl, 10% glycerol (v/v), 1mM
DTT and 0.1mM Mg-ATP). This run resulted in a single peak of dimerised DHC,
which was pooled, concentrated to ∼ 5mg/mL, aliquoted and flash frozen in liquid
nitrogen before storing at −80°C.
5.3 Crystallography
5.3.1 Crystallisation of DHC-E
The DHC-E purified as described above was crystallised using the hanging drop
method in EasyXtal 15-well plates (QIAGEN). Frozen protein was thawed on ice
and 1µL was applied to the screw cap followed by either 0.75µL or 1µL of reservoir
solution (0.1M Tris-NaOH (pH = 8.5), 0.2M Li2SO4 and 10− 12.5% PEG (MW =
8, 000, v/v)). Before screwing the cap back on the well, 500µL of Al’s oil (Hampton
Research) was applied on top of the 500µL of reservoir solution already in the
well. Crystals grew overnight at 18°C to a maximum size of 500µm x 80µm x
80µm. When harvesting, individual crystals were briefly soaked in a cryo-protectant
solution (0.1M Tris-NaOH (pH = 8.5), 0.2M Li2SO4, 10−12.5% PEG (MW = 8, 000,
v/v) and 30% ethylene glycol (v/v)) before being flash frozen in liquid nitrogen.
5.3.2 Selenomethionine derivative of DHC-E
Since no homology models were available for phasing via molecular replacement, we
prepared a selenometionine (SeMet) derivative of DHC-E for experimental phasing.
The same plasmid described above was transformed into B834 (DE3) cells (No-
vagen), which were grown in M9 media supplemented with 2mM MgSO4,0.4% glu-
cose (w/v), 25mg/L FeSO4·7H2O, 7mg/L ampicillin, 1mg/L each of riboflavin, niaci-
namide, pyridoxine monohydrochloride and thiamine, 40mg/L each of L-alanine,
L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L-glutamine,
L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L-proline,
L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine and seleno-L-methionine.
Cells were incubated at 30°C with shaking at 210RPM until OD600 reached between
0.8 and 1.0. They were induced with 0.3M IPTG and grown at 16°C for another
12hr and harvested as above. SeMet protein was purified in the same way as native
protein except to minimise oxidation, all buffers were made with double the amount
of BME or DTT and were thoroughly degassed before use. SeMet crystals were
obtained and harvested in the same was as native crystals.
5.3.3 Data collection, phasing and model building
All data were collected at beamline i03 of Diamond Light Source (Didcot, UK). The
data were integrated using IMOSFLM (Battye et al. 2011) and scaled using AIM-
LESS (Evans & Murshudov 2013). Experimental phase information was obtained
employing the MIRAS approach (multiple isomorphous replacement with anomalous
scattering) in autoSHARP (Vonrhein et al. 2007) with a native data set and three
SeMet data sets as derivatives (Table 4.8). All data sets were cut at 5A˚ because
including higher resolution data did not improve map quality. The resulting 5A˚ map
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revealed density for two protein molecules in the asymmetric unit. The map was
of sufficient quality to resolve α-helices, a β-sheet and several loops, which allowed
an initial model to be constructed in COOT (Emsley et al. 2010). Model building
was aided by an anomalous difference map calculated in the CCP4 program FFT
(K. Cowtan 1994) using experimental phases and the amplitudes from the SeMet
peak data set.
5.4 Electron microscopy
5.4.1 Negative stain EM of the NH dynein tail complex
Negative stain was performed on the NH dynein tail complex at ∼ 20nM in TEV
buffer. The sample was applied to plasma-cleaned carbonfilm on 400-square-mesh
copper grids (Electron Microscopy Sciences) and stained with 2% (w/v) uranyl
acetate. ∼ 200 electron micrographs were recorded on a Gatan Ultrascan 1,000
XPCCD fitted to a FEI Tecnai G2 Spirit transmission electron micro-scope operat-
ing at 120 kV with a 26,000× nominal magnification (4 A˚/pix, 30e/A˚) at 1.5 µm
underfocus. ∼ 10, 000 particles were picked manually. Image analysis and 2D clas-
sification was performed using RELION (Scheres 2012). The initial 3D model was
calculated using EMAN2 (G. Tang et al. 2007).
5.4.2 Fitting the DHC-E crystal structure into EM density
To fit the DHC-E crystal structure into the TDB EM density map, the full crystal
structure was divided into three fragments: the dimerisation domain (residues 1
to 179 from both chains A and B) and the two elongated domains (chain A and
chain B). All three fragments were fitted into the EM helices in the density indepen-
dently using the ”jiggle” command in COOT (Emsley et al. 2010). The positions of
individual helices in the elongated domains were fitted by minor adjustments.
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Appendix A
Supplemental figures and tables
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Figure A.1: Secondary structure prediction of DHC N-terminus: Part 1
164
Figure A.2: Secondary structure prediction of DHC N-terminus: Part 2
165
Figure A.3: An alignment of the DHC ”N region” from thirteen dif-
ferent species. Full-length DHCs from thirteen different species were aligned
using ClustalX. The alignment was visualised with Jalview 2 using the ”per-
centage identity” colour scheme (darker purple indicates higher conservation).
Only the region preceding and including the DHC-NH truncation are included.
The red arrow indicates residues S1004 of S. cerevisiae, which was used to
make a human equivalent of the tail complex truncation. Ag=Ashbya gossypii,
Ce=Caenorhabditis elegans, Ct=Chaetomium thermophilum, Dd=Dictyostelium
discoideum, Dm=Drosophila melanogaster, Dr=Danio rerio, Gg=Gallus gallus,
Hs=Homo sapiens, Kl=Kluyveromyces lactis, Mm=Mus musculus, Nc=Neurospora
crassa, Sc=Saccharomyces cerevisiae, Tt=Tetrahymena thermophila.
166
Figure A.4: Yeast strains used in and created for the work described in
the thesis.
167
Figure A.5: Plasmids used in and created for the work described in the
thesis: Part 1.
168
Figure A.6: Plasmids used in and created for the work described in the
thesis: Part 2.
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Nativecomb PeakA InflectionA RemoteA
Diffraction data
Space group P212121 P212121 P212121 P212121
Unit cell (A˚) a = 71.9 a = 72.0 a = 72.1 a = 72.1
b = 148.9 b = 149.0 b = 148.9 b = 149.2
c = 179.6 c = 179.4 c = 179.5 c = 178.8
Unit cell (°) α = 90.0 α = 90.0 α = 90.0 α = 90.0
β = 90.0 β = 90.0 β = 90.0 β = 90.0
γ = 90.0 γ = 90.0 γ = 90.0 γ = 90.0
Resolution (A˚) 52.6 - 5.0 64.9 - 5.0 61.0 - 5.0 64.9 - 5.0
RSym
1 7.7 (28.7)* 9.9 (58.2) 7.5 (41.5) 7.5 (37.1)
<I>/< σI> 15.8 (9.7) 12.9 (4.3) 14.7 (4.9) 14.5 (5.5)
Completeness (%) 99.9 (100.0) 99.8 (99.3) 99.8 (99.3) 99.8 (99.3)
Redundancy 11.4 (11.8) 9.9 (9.9) 9.8 (9.9) 9.6 (9.6)
No. reflections 101,399 (29,169) 87,406 (24,417) 87,249 (24,362) 84,886 (23,558)
No. unique reflections 8,866 (2,463) 8,870 (2,455) 8,870 (2,455) 8,871 (2,455)
Wavelength (A˚) 0.9763 0.9795 0.9797 0.9393
CCanom=0.5 cutoff (A˚) - 6.7 - -
Phasing statistics
FOM2 0.36 - - -
Table A.1: Data collection and phasing statistics for the four datasets used
to solve the SeMet DHC-E structure cut to 5.0A˚. *Values in parentheses refer
to the highest resolution shell. 1RSym (I) = (ΣhklΣi |I hkl,i - <I hkl> |) / ΣhklΣiI hkl,i for
n independent reflections and i observations of a given reflection. 2FOM = mean
figure of merit.
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